{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;}
{\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;}
{\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;}
{\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;}
{\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;}
{\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;}
{\s6\tqc\lang1033\sbasedon0\snext6 footer;}
{\*\cs16 \additive\super\sbasedon10 footnote reference;}
{\*\cs18 \additive\sbasedon10 page number;}}
{\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}}
{\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;\red70\green83\blue97;\red160\green50\blue69;\red153\green153\blue153;\red204\green238\blue255;}
{\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs13\b\qc As filed with the Securities and Exchange Commission on February 9, 2011\par\pard\plain\cf10\f51\fs13\b\qr Registration No.\~333-170594\par\pard\plain\cf1\f51\fs3\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\sb22\cf10\f51\fs24\b\qc UNITED STATES\par\pard\plain\cf10\f51\fs24\b\qc SECURITIES AND EXCHANGE COMMISSION\par\pard\plain\cf10\f51\fs16\b\qc Washington, D.C. 20549\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs24\b\qc AMENDMENT NO. 5\par\pard\plain\cf10\f51\fs24\b\qc TO\par\pard\plain\cf10\f51\fs24\b\qc FORM S-1\par\pard\plain\cf10\f51\fs24\b\qc REGISTRATION STATEMENT\par\pard\plain\cf10\f51\fs16\b\i\qc UNDER\par\pard\plain\cf10\f51\fs16\b\i\qc THE SECURITIES ACT OF\~1933\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs28\b\qc ACELRX PHARMACEUTICALS, INC.\par\pard\plain\cf10\f51\fs16\b\qc (Exact name of registrant as specified in its charter)\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3671\clvertalb\cellx3778\clvertalc\cellx7234\clvertalb\cellx7341\clvertalc\cellx10797\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3671\clvertalb\cellx3778\clvertalc\cellx7234\clvertalb\cellx7341\clvertalc\cellx10797\trrh-66\row}}}
{\trowd\cellx3671\clvertalb\cellx3778\cellx7234\clvertalb\cellx7341\cellx10797\trrh172
\pard\plain\intbl\cf10\f51\fs13\b\qc Delaware\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2834\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 41-2193603\cell{
{\trowd\cellx3671\clvertalb\cellx3778\cellx7234\clvertalb\cellx7341\cellx10797\trrh172\row}}}
{\trowd\cellx3671\clvertalb\cellx3778\cellx7234\clvertalb\cellx7341\cellx10797\trrh361
\pard\plain\intbl\cf10\f51\fs13\b\qc (State or other jurisdiction of\par\pard\plain\intbl\cf10\f51\fs13\b\qc incorporation or organization)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Primary Standard Industrial\par\pard\plain\intbl\cf10\f51\fs13\b\qc Classification Code Number)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (I.R.S. Employer\par\pard\plain\intbl\cf10\f51\fs13\b\qc Identification Number)\cell{
{\trowd\cellx3671\clvertalb\cellx3778\cellx7234\clvertalb\cellx7341\cellx10797\trrh361\row}}}\pard\plain\sb88\cf10\f51\fs13\b\qc 575 Chesapeake Drive\par\pard\plain\cf10\f51\fs13\b\qc Redwood City, CA 94063\par\pard\plain\cf10\f51\fs13\b\qc (650) 216-3500\par\pard\plain\cf10\f51\fs13\b\qc (Address, including zip code, and telephone number, including area code, of registrant\u8217?s principal executive offices)\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs13\b\qc Richard King\par\pard\plain\cf10\f51\fs13\b\qc President and Chief Executive Officer\par\pard\plain\cf10\f51\fs13\b\qc 575 Chesapeake Drive\par\pard\plain\cf10\f51\fs13\b\qc Redwood City, CA 94063\par\pard\plain\cf10\f51\fs13\b\qc (650) 216-3500\par\pard\plain\cf10\f51\fs13\b\qc (Name, address, including zip code, and telephone number, including area code, of agent for service)\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs13\b\i\qc Copies to:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5400\clvertalb\cellx5615\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5400\clvertalb\cellx5615\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\cellx5400\clvertalb\cellx5615\cellx10799\trrh1220
\pard\plain\intbl\cf10\f51\fs13\b\qc Mark B. Weeks\par\pard\plain\intbl\cf10\f51\fs13\b\qc Chadwick L. Mills\par\pard\plain\intbl\cf10\f51\fs13\b\qc Cooley LLP\par\pard\plain\intbl\cf10\f51\fs13\b\qc Five Palo Alto Square\par\pard\plain\intbl\cf10\f51\fs13\b\qc 3000 El Camino Real\par\pard\plain\intbl\cf10\f51\fs13\b\qc Palo Alto, CA 94306-2155\par\pard\plain\intbl\cf10\f51\fs13\b\qc (650) 843-5000\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc David W. Pollak\par\pard\plain\intbl\cf10\f51\fs13\b\qc Morgan, Lewis & Bockius LLP\par\pard\plain\intbl\cf10\f51\fs13\b\qc 101 Park Avenue\par\pard\plain\intbl\cf10\f51\fs13\b\qc New York, NY 10178\par\pard\plain\intbl\cf10\f51\fs13\b\qc (212) 309-6058\cell{
{\trowd\cellx5400\clvertalb\cellx5615\cellx10799\trrh1220\row}}}\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs13\b\ql Approximate date of commencement of proposed sale to the public:\plain\cf10\f51\fs13\ql As soon as practicable after the effective date of this registration statement.\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs13\ql If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule\~415 under the Securities Act of 1933, check the following\plain\cf10\f51\fs13\ql box.\~\~\plain\cf10\f54\fs13\ql ¨\par\pard\plain\sb88\cf10\f51\fs13\ql If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration\plain\cf10\f51\fs13\ql statement number of the earlier effective registration statement for the same offering.\~\~\plain\cf10\f54\fs13\ql ¨\par\pard\plain\sb88\cf10\f51\fs13\ql If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of\plain\cf10\f51\fs13\ql the earlier effective registration statement for the same offering.\~\~\plain\cf10\f54\fs13\ql ¨\par\pard\plain\sb88\cf10\f51\fs13\ql If this form is a post-effective amendment filed pursuant to Rule\~462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier\plain\cf10\f51\fs13\ql effective registration statement for the same offering.\~\~\plain\cf10\f54\fs13\ql ¨\par\pard\plain\sb88\cf10\f51\fs13\ql Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of\plain\cf10\f51\fs13\ql \u8220?large accelerated filer,\u8221? \u8220?accelerated filer\u8221? and \u8220?smaller reporting company\u8221? in Rule 12b-2 of the Exchange Act.\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1510\clvertalb\cellx1617\clvertalc\cellx8497\clvertalb\cellx8604\clvertalc\cellx10545\clvertalb\cellx10652\clvertalc\cellx10795\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx1510\clvertalb\cellx1617\clvertalc\cellx8497\clvertalb\cellx8604\clvertalc\cellx10545\clvertalb\cellx10652\clvertalc\cellx10795\trrh-66\row}}}
{\trowd\clvertalb\cellx1510\clvertalb\cellx1617\clvertalb\cellx8497\clvertalb\cellx8604\clvertalb\cellx10545\clvertalb\cellx10652\clvertalb\cellx10795\trrh172
\pard\plain\intbl\cf10\f51\fs13\ql Large\~accelerated\~filer\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f54\fs13\ql ¨\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql Accelerated\~filer\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f54\fs13\ql ¨\cell{
{\trowd\clvertalb\cellx1510\clvertalb\cellx1617\clvertalb\cellx8497\clvertalb\cellx8604\clvertalb\cellx10545\clvertalb\cellx10652\clvertalb\cellx10795\trrh172\row}}}
{\trowd\clvertalb\cellx1510\clvertalb\cellx1617\clvertalb\cellx8497\clvertalb\cellx8604\clvertalb\cellx10545\clvertalb\cellx10652\clvertalb\cellx10795\trrh172
\pard\plain\intbl\cf10\f51\fs13\ql Non-accelerated filer\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f54\fs13\ql þ\plain\intbl\cf10\f51\fs13\ql \~\~(Do not check if a smaller reporting company)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql Smaller\~reporting\~company\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f54\fs13\ql ¨\cell{
{\trowd\clvertalb\cellx1510\clvertalb\cellx1617\clvertalb\cellx8497\clvertalb\cellx8604\clvertalb\cellx10545\clvertalb\cellx10652\clvertalb\cellx10795\trrh172\row}}}\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}\par\pard\plain\sb88\cf10\f51\fs13\b\qc CALCULATION OF REGISTRATION FEE\par\pard\plain\cf1\f51\fs6\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx7343\clvertalb\cellx7450\clvertalc\cellx9070\clvertalb\cellx9177\clvertalc\cellx10797\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx7343\clvertalb\cellx7450\clvertalc\cellx9070\clvertalb\cellx9177\clvertalc\cellx10797\trrh-66\row}}}
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29
\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29\row}}}
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx7343\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx7450\clbrdrt\brdrs\brdrcf10\clvertalb\cellx9070\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx9177\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10797\trrh549
\pard\plain\intbl\cf10\f51\fs13\b\qc Title of Each Class of Securities\par\pard\plain\intbl\cf10\f51\fs13\b\qc to be Registered\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Proposed\~Maximum
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Aggregate\~Offering\par\pard\plain\intbl\cf10\f51\fs13\b\qc Price\plain\intbl\cf10\f51\fs11\b\qc\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Amount of
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Registration\~Fee\plain\intbl\cf10\f51\fs11\b\qc\super (2)(3)\cell{
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx7343\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx7450\clbrdrt\brdrs\brdrcf10\clvertalb\cellx9070\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx9177\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10797\trrh549\row}}}
{\trowd\clbrdrt\brdrs\brdrcf10\cellx7343\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx7450\clbrdrt\brdrs\brdrcf10\clvertalb\cellx9070\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx9177\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10797\trrh189
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Common Stock, $0.001 par value\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qc $46,000,000\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qc $5,340.60\cell{
{\trowd\clbrdrt\brdrs\brdrcf10\cellx7343\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx7450\clbrdrt\brdrs\brdrcf10\clvertalb\cellx9070\clbrdrt\brdrs\brdrcf10\clbrdrl\brdrs\brdrcf10\clvertalb\cellx9177\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10797\trrh189\row}}}
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29
\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29\row}}}
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29
\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clbrdrt\brdrs\brdrcf10\clvertalb\cellx10800\trrh29\row}}}
\pard\plain
{\trowd\cellx154\cellx10673\trrh172
\pard\plain\intbl\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf10\f51\fs13\ql Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule\~457(o) of the Securities Act of 1933, as amended.\cell{
{\trowd\cellx154\cellx10673\trrh172\row}}}
\pard\plain
{\trowd\cellx154\cellx9135\trrh172
\pard\plain\intbl\cf10\f51\fs11\ql\super (2)\cell\pard\plain\intbl\cf10\f51\fs13\ql Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.\cell{
{\trowd\cellx154\cellx9135\trrh172\row}}}
\pard\plain
{\trowd\cellx154\cellx10799\trrh344
\pard\plain\intbl\cf10\f51\fs11\ql\super (3)\cell\pard\plain\intbl\cf10\f51\fs13\ql The registrant previously paid a registration fee of $6,149.63 in connection with the initial filing of this registration statement and paid an additional $771.72 in connection with the\plain\intbl\cf10\f51\fs13\ql filing of the Amendment No.\~3. to Form\~S-1.\cell{
{\trowd\cellx154\cellx10799\trrh344\row}}}\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\sb88\cf10\f51\fs13\b\ql The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further\plain\cf10\f51\fs13\b\ql amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section\~8(a)\~of the Securities Act of 1933, as amended,\plain\cf10\f51\fs13\b\ql or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section\~8(a), may determine.\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs1\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf11\f51\fs16\b\ql The information in this prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange\plain\cf11\f51\fs16\b\ql Commission declares our registration statement effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to\plain\cf11\f51\fs16\b\ql buy these securities in any state where the offer or sale is not permitted.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf11\f51\fs16\b\qc Subject to completion, dated February\~9, 2011\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\sb264\cf10\f51\fs28\b\ql 8,000,000 Shares\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5508\clvertalb\cellx5723\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5508\clvertalb\cellx5723\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clvertalc\cellx5508\clvertalb\cellx5723\cellx10799\trrh1198
\pard\plain\intbl\cf10\f51\fs28\b\ql ACELRX PHARMACEUTICALS, INC.\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\intbl\qr{\*\shppict{\pict\jpegblip\picw268\pich71\picscalex75\picscaley75\bliptag-7110467716
{\*\blipuid 9028345a90a4d62d49cd33752ced7e5f}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}}
\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5508\clvertalb\cellx5723\cellx10799\trrh1198\row}}}\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\sb198\cf10\f51\fs28\b\ql Common Stock\par\pard\plain\sb198\cf10\f51\fs24\b\ql $\~\~\~\~\~\~\~\~\~\~\~\~\~per share\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5723\clvertalb\cellx6047\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5723\clvertalb\cellx6047\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\cellx5723\clvertalb\cellx6047\cellx10799\trrh1271
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql \u8226?AcelRx Pharmaceuticals, Inc. is offering 8,000,000 shares.\par\pard\plain\intbl\cf1\f51\fs18\ql \~\par\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql \u8226?We anticipate that the initial public offering price will be $5.00 per share.\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql \u8226?This is our initial public offering and no public market\plain\intbl\li176\cf10\f51\fs16\ql currently exists for our shares.\par\pard\plain\intbl\cf1\f51\fs18\ql \~\par\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql \u8226?Our common stock has been approved for listing on the\plain\intbl\li176\cf10\f51\fs16\ql NASDAQ Global Market under the symbol\plain\intbl\li176\cf10\f51\fs16\ql \u8220?ACRX\u8221?.\cell{
{\trowd\cellx5723\clvertalb\cellx6047\cellx10799\trrh1271\row}}}\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\sb88\cf10\f51\fs16\b\ql This investment involves risk. See \u8220?\pard\plain\sb88\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_2" }{\*\fldrslt\cf3\f51\fs16\b\ql Risk Factors}}\plain\cf10\f51\fs16\b\ql \u8221? beginning on page 13.\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx8317\clvertalb\cellx8729\clvertalc\cellx9034\clvertalc\cellx9554\clvertalc\cellx9677\clvertalb\cellx9987\clvertalc\cellx10155\clvertalc\cellx10674\clvertalc\cellx10797\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8317\clvertalb\cellx8729\clvertalc\cellx9034\clvertalc\cellx9554\clvertalc\cellx9677\clvertalb\cellx9987\clvertalc\cellx10155\clvertalc\cellx10674\clvertalc\cellx10797\trrh-66\row}}}
{\trowd\clvertalc\cellx8317\clvertalc\cellx9677\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8317\clvertalc\cellx9677\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clvertalb\cellx8317\clvertalb\cellx8729\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9554\clvertalb\cellx9677\clvertalb\cellx9987\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Per\~Share\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Total\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx8317\clvertalb\cellx8729\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9554\clvertalb\cellx9677\clvertalb\cellx9987\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8317\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8729\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9034\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9554\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9987\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10797\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Public offering price\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\~\~\~\~\~\~\~\~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\~\~\~\~\~\~\~\~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8317\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8729\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9034\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9554\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9987\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10797\trrh206\row}}}
{\trowd\cellx8317\clvertalb\cellx8729\clvertalb\cellx9034\clvertalb\cellx9554\clvertalb\cellx9677\clvertalb\cellx9987\clvertalb\cellx10155\clvertalb\cellx10674\clvertalb\cellx10797\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Underwriting discount\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx8317\clvertalb\cellx8729\clvertalb\cellx9034\clvertalb\cellx9554\clvertalb\cellx9677\clvertalb\cellx9987\clvertalb\cellx10155\clvertalb\cellx10674\clvertalb\cellx10797\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8317\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8729\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9034\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9554\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9987\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10797\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Proceeds, before expenses, to AcelRx Pharmaceuticals, Inc.\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8317\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8729\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9034\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9554\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9987\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10797\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\sb198\cf10\f51\fs16\i\ql The underwriters have a 30-day option to purchase up to 1,200,000 additional shares of common stock from us to cover over-allotments, if any.\par\pard\plain\sb198\cf10\f51\fs16\ql Entities affiliated with certain of our current stockholders have indicated an interest in purchasing an aggregate of $24.0 million of shares of common\plain\cf10\f51\fs16\ql stock in this offering at the price offered to the public. However, because indications of interest are not binding agreements or commitments to purchase,\plain\cf10\f51\fs16\ql the underwriters may determine to sell more, less or no shares in this offering to any of these entities, or any of these entities may determine to purchase\plain\cf10\f51\fs16\ql more, less or no shares in this offering. The underwriters will receive an underwriting discount of $\~\~\~\~ per share on any sales of shares to these entities.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Neither the Securities and Exchange Commission nor any state securities commission has approved of anyone\u8217?s investment in these\plain\cf10\f51\fs16\b\ql securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.\par\pard\plain\sb396\cf10\f51\fs28\b\qc Piper Jaffray\par\pard\plain\cf1\f51\fs27\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3564\clvertalb\cellx3887\clvertalc\cellx7235\clvertalb\cellx8099\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3564\clvertalb\cellx3887\clvertalc\cellx7235\clvertalb\cellx8099\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clvertalb\cellx3564\clvertalb\cellx3887\clvertalb\cellx7235\clvertalb\cellx8099\clvertalb\cellx10799\trrh248
\pard\plain\intbl\cf10\f51\fs20\b\qc Canaccord Genuity\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs20\b\qc \~Cowen and Company\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs20\b\qr JMP\~Securities\cell{
{\trowd\clvertalb\cellx3564\clvertalb\cellx3887\clvertalb\cellx7235\clvertalb\cellx8099\clvertalb\cellx10799\trrh248\row}}}\pard\plain\sb198\cf10\f51\fs16\b\qc The date of this prospectus is \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~, 2011
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\qc{\*\shppict{\pict\jpegblip\picw622\pich810\picscalex75\picscaley75\bliptag-7110467716
{\*\blipuid 9028345a90a4d62d49cd33752ced7e5f}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}}
\par\pard\plain\cf10\f51\fs13\qc This product candidate has not been approved by the FDA. We have not generated any revenue from the sale of any of our product candidates.
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart toc}{\*\bkmkend toc}\par\pard\plain\sb88\cf10\f51\fs16\b\qc TABLE OF CONTENTS\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\trqc\clvertalc\cellx7634\clvertalb\cellx8053\clvertalc\cellx8205\clvertalc\cellx8515\clvertalc\cellx8638\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalb\cellx8053\clvertalc\cellx8205\clvertalc\cellx8515\clvertalc\cellx8638\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx7634\clvertalb\cellx8053\clbrdrb\brdrs\brdrcf10\clvertalb\cellx8515\clvertalb\cellx8638\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Page\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\cellx7634\clvertalb\cellx8053\clbrdrb\brdrs\brdrcf10\clvertalb\cellx8515\clvertalb\cellx8638\trrh172\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_1" }{\*\fldrslt\cf3\f51\fs16\ql Prospectus Summary}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_2" }{\*\fldrslt\cf3\f51\fs16\ql Risk Factors}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 13\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_3" }{\*\fldrslt\cf3\f51\fs16\ql Special Note Regarding Forward-Looking Statements}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_4" }{\*\fldrslt\cf3\f51\fs16\ql Use of Proceeds}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 39\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_5" }{\*\fldrslt\cf3\f51\fs16\ql Dividend Policy}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 39\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_6" }{\*\fldrslt\cf3\f51\fs16\ql Capitalization}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 40\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_7" }{\*\fldrslt\cf3\f51\fs16\ql Dilution}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 43\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_8" }{\*\fldrslt\cf3\f51\fs16\ql Selected Financial Data}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 46\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_9" }{\*\fldrslt\cf3\f51\fs16\ql Management\u8217?s Discussion and Analysis of Financial Condition and Results of Operations}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 48\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_10" }{\*\fldrslt\cf3\f51\fs16\ql Business}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 68\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_11" }{\*\fldrslt\cf3\f51\fs16\ql Management}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 99\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_12" }{\*\fldrslt\cf3\f51\fs16\ql Executive Compensation}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 108\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_13" }{\*\fldrslt\cf3\f51\fs16\ql Certain Relationships and Related Party Transactions}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 140\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_14" }{\*\fldrslt\cf3\f51\fs16\ql Principal Stockholders}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 144\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_15" }{\*\fldrslt\cf3\f51\fs16\ql Description of Capital Stock}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 148\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_16" }{\*\fldrslt\cf3\f51\fs16\ql Shares Eligible For Future Sale}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 153\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_17" }{\*\fldrslt\cf3\f51\fs16\ql Material U.S. Federal Income and Estate Tax Consequences to Non-U.S. Holders}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 156\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_18" }{\*\fldrslt\cf3\f51\fs16\ql Underwriting}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 160\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_19" }{\*\fldrslt\cf3\f51\fs16\ql Legal Matters}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 164\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_20" }{\*\fldrslt\cf3\f51\fs16\ql Experts}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 164\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_21" }{\*\fldrslt\cf3\f51\fs16\ql Where You Can Find Additional Information}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 164\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx7634\clvertalc\cellx8639\trrh-66\row}}}
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206
\pard\plain\intbl\li374\ul{\field{\*\fldinst HYPERLINK \\l "toc113475_22" }{\*\fldrslt\cf3\f51\fs16\ql Index to Financial Statements}}\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr F-1\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx7634\clvertalb\cellx8053\clvertalb\cellx8205\clvertalb\cellx8515\clvertalb\cellx8638\trrh206\row}}}\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\cf1\f51\fs9\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs18\ql \~\par\pard\plain\sb88\cf10\f51\fs16\ql You should rely only on the information contained in this prospectus or any related free writing prospectus we may authorize to be delivered to you. We\plain\cf10\f51\fs16\ql have not, and the underwriters have not, authorized anyone to provide you with information different from, or in addition to, that contained in this\plain\cf10\f51\fs16\ql prospectus or any related free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We are\plain\cf10\f51\fs16\ql offering to sell, and are seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information\plain\cf10\f51\fs16\ql contained in this prospectus or any related free writing prospectus is accurate only as of its date, regardless of its time of delivery, or of any sale of the\plain\cf10\f51\fs16\ql common stock. Our business, financial condition, results of operations and prospects may have changed since that date.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc i
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\ql Until and including\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~ , 2011 (25 days after the date of this prospectus), all dealers that buy, sell or trade our common stock, whether or\plain\cf10\f51\fs16\b\ql not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to\plain\cf10\f51\fs16\b\ql deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.\par\pard\plain\sb198\cf10\f51\fs16\ql For investors outside of the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or\plain\cf10\f51\fs16\ql distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform\plain\cf10\f51\fs16\ql yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.\par\pard\plain\sb198\cf10\f51\fs16\ql Unless the context indicates otherwise, as used in this prospectus, the terms \u8220?AcelRx,\u8221? \u8220?AcelRx Pharmaceuticals,\u8221?\plain\cf10\f51\fs16\ql \u8220?we,\u8221? \u8220?us\u8221? and \u8220?our\u8221? refer to AcelRx Pharmaceuticals, Inc. The name \u8220?ACELRX\u8221? is our trademark.\plain\cf10\f51\fs16\ql We have a trademark application pending for the term, \u8220?NANOTAB\u8221? and for our tagline, \u8220?ACCELERATE, INNOVATE,\plain\cf10\f51\fs16\ql ALLEVIATE\u8221? in Class 5, in the United States. This prospectus also contains trademarks and trade names that are the property of their respective\plain\cf10\f51\fs16\ql owners.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc ii
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~{\*\bkmkstart item_1_3_1}{\*\bkmkend item_1_3_1}{\*\bkmkstart toc113475_1}{\*\bkmkend toc113475_1}\par\pard\plain\cf10\f51\fs16\b\qc PROSPECTUS SUMMARY\par\pard\plain\sb198\cf10\f51\fs16\i\ql The items in the following summary are described in more detail later in this prospectus. This summary provides an overview of selected information and\plain\cf10\f51\fs16\i\ql does not contain all the information you should consider. Before you decide to invest in our common stock, you should read the entire prospectus\plain\cf10\f51\fs16\i\ql carefully, including the \u8220?Risk Factors\u8221? and the financial statements and related notes included in this prospectus.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Overview\par\pard\plain\sb88\cf10\f51\fs16\ql We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and\plain\cf10\f51\fs16\ql breakthrough pain. We were founded to solve the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. Although\plain\cf10\f51\fs16\ql widely used, IV PCA has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of\plain\cf10\f51\fs16\ql delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. We are preparing to initiate two\plain\cf10\f51\fs16\ql Phase\~3 clinical trials for our lead product candidate, the Sufentanil NanoTab PCA System, or ARX-01. The system is designed to address these problems\plain\cf10\f51\fs16\ql by utilizing:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql sufentanil, a high therapeutic index opioid;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql NanoTabs, our proprietary, non-invasive sublingual dosage form; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our novel handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the\plain\intbl\cf10\f51\fs16\ql risk of programming errors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\ql We have completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02,\plain\cf10\f51\fs16\ql for the treatment of cancer breakthrough pain, or BTP, and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety\plain\cf10\f51\fs16\ql reduction and pain relief for patients undergoing painful procedures in a physician\u8217?s office.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Sufentanil NanoTabs\par\pard\plain\sb88\cf10\f51\fs16\ql All of our product candidates utilize sufentanil in our proprietary, non-invasive NanoTab sublingual dosage form.\par\pard\plain\sb198\cf10\f51\fs16\ql Sufentanil has many pharmacological advantages over other opioids.\~Sufentanil has a high therapeutic index, or the ratio of the toxic dose to the\plain\cf10\f51\fs16\ql therapeutic dose of a drug, which is used as a measure of the relative safety of a drug for a particular treatment.\~Published studies demonstrate that\plain\cf10\f51\fs16\ql sufentanil produces less respiratory depressive effects relative to its analgesic effects compared to other opioids, which correlates well with preclinical\plain\cf10\f51\fs16\ql studies demonstrating sufentanil\u8217?s high therapeutic index.\~The molecular attributes of sufentanil allow rapid cell membrane penetration and onset of\plain\cf10\f51\fs16\ql action, which we believe make sufentanil an attractive opioid for the treatment of both acute and breakthrough pain.\~Although the analgesic efficacy and\plain\cf10\f51\fs16\ql tolerability of sufentanil has been well established, its use has been limited due to a short duration of action when delivered intravenously and low\plain\cf10\f51\fs16\ql gastrointestinal uptake when delivered orally.\par\pard\plain\sb198\cf10\f51\fs16\ql We have demonstrated that sublingual delivery of sufentanil avoids the high peak plasma levels and short duration of action of IV administration, enabling\plain\cf10\f51\fs16\ql potential for broader use. Our proprietary NanoTab dosage form is a very small disc-shaped tablet with a bioadhesive excipient, or inactive ingredient,\plain\cf10\f51\fs16\ql that enables the NanoTab to adhere to mucosal tissues. This allows sublingual delivery of sufentanil from the NanoTab by adherence to the sublingual\plain\cf10\f51\fs16\ql mucosa, or tissues under the tongue. The NanoTab adheres within seconds after administration and full disintegration occurs within minutes. The small\plain\cf10\f51\fs16\ql size of the NanoTab is designed to minimize the saliva response and amount of sufentanil swallowed, resulting in high oral transmucosal uptake, whereby\plain\cf10\f51\fs16\ql a majority of the drug is absorbed through the oral tissues directly into the bloodstream, and consistent pharmacokinetics.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 1
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\sb198\cf10\f51\fs16\ql Our portfolio of product candidates leverages the inherent advantages of sufentanil that are underutilized in medical practice. We believe our non-invasive,\plain\cf10\f51\fs16\ql proprietary NanoTab sublingual dosage form overcomes the limitations of the current treatment options available for both acute and breakthrough pain.\par\pard\plain\sb198\cf10\f51\fs16\ql We have established and continue to build proprietary positions for our product candidates in the United\~States and internationally. We seek patent\plain\cf10\f51\fs16\ql protection for compositions of matter related to NanoTabs, our formulations, our devices, the combination of our drugs and devices, and methods of\plain\cf10\f51\fs16\ql treatment using these compositions. We have filed patent applications in the United States and internationally and have one issued patent in Europe. Our\plain\cf10\f51\fs16\ql issued European patent, though granted, may be opposed by third parties during a nine-month opposition period that ends on April\~21, 2011. If issued, we\plain\cf10\f51\fs16\ql expect our patents will expire between 2027 and 2030.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Our Product Candidates\par\pard\plain\sb88\cf10\f51\fs16\ql The following table summarizes key information about our existing product candidates. We currently hold worldwide commercialization rights to all of\plain\cf10\f51\fs16\ql our product candidates.\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1835\clvertalb\cellx1943\clvertalc\cellx4361\clvertalb\cellx4468\clvertalc\cellx6693\clvertalb\cellx6800\clvertalc\cellx10795\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx1835\clvertalb\cellx1943\clvertalc\cellx4361\clvertalb\cellx4468\clvertalc\cellx6693\clvertalb\cellx6800\clvertalc\cellx10795\trrh-66\row}}}
{\trowd\clvertalb\cellx1835\clvertalb\cellx1943\clvertalb\cellx4361\clvertalb\cellx4468\clvertalb\cellx6693\clvertalb\cellx6800\clvertalb\cellx10795\trrh211
\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Product Candidate\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Description\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Target\~Indication\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Development Status\cell{
{\trowd\clvertalb\cellx1835\clvertalb\cellx1943\clvertalb\cellx4361\clvertalb\cellx4468\clvertalb\cellx6693\clvertalb\cellx6800\clvertalb\cellx10795\trrh211\row}}}
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh1329
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-01\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Sufentanil\~NanoTab
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql PCA System\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Acute\~post-operative
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql pain\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~Three Phase 2 clinical trials and End of Phase\plain\intbl\li374\cf10\f51\fs16\ql 2 meeting successfully completed\par\pard\plain\intbl\cf1\f51\fs6\ql \~\par\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~Two efficacy trials and one open label safety\plain\intbl\li374\cf10\f51\fs16\ql trial planned in Phase 3; the first efficacy trial and\plain\intbl\li374\cf10\f51\fs16\ql the open label safety trial are anticipated to begin\plain\intbl\li374\cf10\f51\fs16\ql in the second half of 2011\cell{
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh1329\row}}}
{\trowd\clvertalc\cellx1835\clvertalc\cellx4361\clvertalc\cellx6694\clvertalc\cellx10797\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx1835\clvertalc\cellx4361\clvertalc\cellx6694\clvertalc\cellx10797\trrh-66\row}}}
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh916
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-02\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Sufentanil\~NanoTab\~BTP
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql Management System\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Cancer\~breakthrough
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql pain\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~Phase 2 clinical trial and End of Phase 2\plain\intbl\li374\cf10\f51\fs16\ql meeting successfully completed\par\pard\plain\intbl\cf1\f51\fs6\ql \~\par\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~One efficacy trial and two open label safety\plain\intbl\li374\cf10\f51\fs16\ql trials planned in Phase 3\cell{
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh916\row}}}
{\trowd\clvertalc\cellx1835\clvertalc\cellx4361\clvertalc\cellx6694\clvertalc\cellx10797\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx1835\clvertalc\cellx4361\clvertalc\cellx6694\clvertalc\cellx10797\trrh-66\row}}}
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh710
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-03\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Sufentanil/Triazolam
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql NanoTab\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Mild sedation for
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql painful procedures in
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs16\ql a physician\u8217?s office\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~Phase 2 clinical trial and End of Phase 2\plain\intbl\li374\cf10\f51\fs16\ql meeting successfully completed\par\pard\plain\intbl\cf1\f51\fs6\ql \~\par\pard\plain\intbl\li374\fi-286\cf10\f51\fs16\ql \u8226?\~\~\~Two efficacy trials planned in Phase 3\cell{
{\trowd\cellx1835\clvertalb\cellx1943\cellx4361\clvertalb\cellx4468\cellx6693\clvertalb\cellx6800\cellx10795\trrh710\row}}}\pard\plain\sb198\cf10\f51\fs16\b\ql The Market Opportunity for Our Product Candidates\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql Acute Post-Operative Pain\par\pard\plain\sb88\cf10\f51\fs16\ql The post-operative pain market in the United States, Europe and Japan is growing steadily and is expected to reach $6.5 billion by 2018. Despite its size,\plain\cf10\f51\fs16\ql this market remains underserved. Studies report that up to 75% of patients experience inadequate pain relief after surgery. Inadequate pain relief can lead\plain\cf10\f51\fs16\ql to decreased mobility, which increases the risks of other medical complications, including deep vein thrombosis and partial lung collapse, and can result in\plain\cf10\f51\fs16\ql extended hospital stays.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 2
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\sb198\cf10\f51\fs16\ql In the post-operative environment, the most common method for the treatment of acute pain is through IV PCA, in which patients self-dose by pushing a\plain\cf10\f51\fs16\ql button to administer morphine via a programmable intravenous pump. Despite the common use of IV PCA, there are many deficiencies associated with\plain\cf10\f51\fs16\ql this treatment that create a significant unmet medical need, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Drug-Related Side Effects\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~Morphine, the most commonly used opioid for post-operative pain control, can produce many side\plain\intbl\cf10\f51\fs16\ql effects, such as excessive somnolence, delirium, oxygen desaturation and respiratory depression. Morphine has active metabolites, the\plain\intbl\cf10\f51\fs16\ql compounds that are produced when the body breaks down, or metabolizes, morphine, which amplify these side effects.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Complications Associated with IV Delivery\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~IV PCA poses infection risk and creates opportunities for analgesic gaps due to\plain\intbl\cf10\f51\fs16\ql dislodged catheters. Peripheral venous catheters have been associated with phlebitis and bacteremia. Catheter tubing tethering the\plain\intbl\cf10\f51\fs16\ql patient to the PCA pump also hinders early post-operative mobility that can lead to increased post-operative complications.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh2062
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Medication Delivery Errors\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~The complexity associated with ordering, dispensing, preparing, programming and administering the IV\plain\intbl\cf10\f51\fs16\ql PCA pump results in many analgesia related errors. Human factors, such as programming the PCA pump, or administering the wrong\plain\intbl\cf10\f51\fs16\ql dose, are among the most common and serious type of errors. According to published literature, the estimated annual error rate is 407\plain\intbl\cf10\f51\fs16\ql errors per 10,000 people treated with IV PCA in the United States. Published analysis of a national medication error-reporting\plain\intbl\cf10\f51\fs16\ql program, or Medmarx, from 2000 to 2005 reveals that IV PCA errors represent a four-fold higher relative risk of harm compared to\plain\intbl\cf10\f51\fs16\ql all other medication errors. The most recent published analysis of the FDA Manufacturer and User Facility Device Experience, or\plain\intbl\cf10\f51\fs16\ql MAUDE, database reports that 5% of IV PCA operator errors reported during a two-year index period, from 2002 to 2003, resulted\plain\intbl\cf10\f51\fs16\ql in patient deaths. Recently, the risks associated with the use of infusion pumps, such as those used in IV PCA, have been the subject\plain\intbl\cf10\f51\fs16\ql of scrutiny by the FDA, resulting in a new initiative to address the safety problems associated with infusion pumps and the\plain\intbl\cf10\f51\fs16\ql underreporting of errors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh2062\row}}}\pard\plain\sb198\cf10\f51\fs16\b\i\ql Cancer Breakthrough Pain\par\pard\plain\sb88\cf10\f51\fs16\ql Breakthrough pain is a common component of chronic pain and is characterized by its rapid onset, intensity and relatively short duration, which breaks\plain\cf10\f51\fs16\ql through the analgesic effect of chronic pain medication. According to published data, in 2006 more than 700,000 cancer patients in the United States\plain\cf10\f51\fs16\ql experienced breakthrough pain. Fentanyl-based products are the only medications indicated to treat cancer breakthrough pain and account for less than\plain\cf10\f51\fs16\ql 20,000 prescriptions per month. We believe this demonstrates a need for additional and improved cancer breakthrough pain medications.\par\pard\plain\sb198\cf10\f51\fs16\ql Currently available fentanyl-based cancer breakthrough pain products have limited ability to provide effective and focused pain relief because their\plain\cf10\f51\fs16\ql average half-lives extend to 6 to 14 hours, which is significantly longer than the average 15 to 60 minute duration of a cancer breakthrough pain episode.\plain\cf10\f51\fs16\ql Oral transmucosal fentanyl, unlike sufentanil, is swallowed and absorbed extensively through the gastrointestinal tract in addition to the oral mucosal\plain\cf10\f51\fs16\ql tissue, leading to erratic and delayed timing to peak plasma levels, ranging from 20 to 240 minutes. In addition, we believe none of the currently\plain\cf10\f51\fs16\ql approved cancer breakthrough pain products have effective deterrent features to address the problem of abuse and misuse of pain medication.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Mild Sedation for Painful Procedures in a Physician\u8217?s Office\par\pard\plain\sb88\cf10\f51\fs16\ql Each year in the United States, more than 100\~million procedures take place in a physician\u8217?s office. A substantial subset of these procedures are\plain\cf10\f51\fs16\ql painful and anxiety inducing. Many practitioners do not\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 3
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\ql provide any sedation or analgesic medications to their patients prior to or during short duration procedures, and instead rely solely on local anesthetic\plain\cf10\f51\fs16\ql injections, which are often insufficient to provide effective pain relief and do not address patient anxiety.\par\pard\plain\sb198\cf10\f51\fs16\b\ql ARX-01\u8212?Sufentanil NanoTab PCA System\par\pard\plain\sb88\cf10\f51\fs16\ql ARX-01 is designed to avoid many of the limitations of IV PCA by delivering sufentanil, a high therapeutic index opioid, using our proprietary NanoTab\plain\cf10\f51\fs16\ql sublingual tablet via a non-invasive, pre-programmed, handheld PCA device.\par\pard\plain\sb198\cf10\f51\fs16\ql Sufentanil has one of the highest therapeutic indices of all commercially available opioids, making it an attractive candidate for the management of\plain\cf10\f51\fs16\ql post-operative pain. Formulated in our proprietary sublingual NanoTab dosage form, sufentanil has relatively high bioavailability, with lower peak drug\plain\cf10\f51\fs16\ql levels and a longer duration of action compared to IV delivery. Our novel handheld PCA device enables simple patient-controlled delivery of NanoTabs\plain\cf10\f51\fs16\ql in the hospital setting. ARX-01 has the potential to address many of the key disadvantages of IV PCA by:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7075\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql reducing the incidence of drug related side effects;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7075\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9955\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql eliminating the risk of IV PCA related infections, reducing analgesic gaps and enhancing mobility; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9955\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6859\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql eliminating the risk of programming errors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6859\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql We believe that ARX-01 will provide a favorable safety, efficacy and tolerability profile, enabling ARX-01 to become the new standard of care for\plain\cf10\f51\fs16\ql patient-controlled analgesia.\par\pard\plain\sb198\cf10\f51\fs16\ql We have completed three successful Phase 2 clinical trials of sufentanil NanoTabs in 212 patients in the post-operative setting and have completed an\plain\cf10\f51\fs16\ql End of Phase 2 meeting with the FDA. Our Phase 2 studies for ARX-01 demonstrated analgesic efficacy, a low adverse event profile and excellent\plain\cf10\f51\fs16\ql device functionality. Across all studies, the average time interval between doses was approximately 80 minutes, which compares favorably to typical\plain\cf10\f51\fs16\ql redosing intervals for IV PCA, which have an average period between dosing of 20 to 40 minutes. The FDA stated that the demonstration of efficacy\plain\cf10\f51\fs16\ql versus placebo in two Phase 3 studies with a total safety database of at least 600 patients exposed to the active drug, should suffice to support a new drug\plain\cf10\f51\fs16\ql application, or NDA, for the treatment of acute post-operative pain.\par\pard\plain\sb198\cf10\f51\fs16\ql We plan to conduct one Phase\~3 trial to evaluate the efficacy of ARX-01 and one Phase 3 open-label active comparator study. Manufacturing scale up\plain\cf10\f51\fs16\ql activities and Phase 3 clinical trial planning are ongoing to enable initiation and patient enrollment in our first two Phase 3 trials in the second half of\plain\cf10\f51\fs16\ql 2011. We expect to receive top-line data from these two trials in the first half of 2012. Contingent on our ability to secure additional funding, we plan to\plain\cf10\f51\fs16\ql begin a second Phase\~3 efficacy study in the second half of 2012 and submit an NDA in 2013 if the results from these studies are positive.\par\pard\plain\sb198\cf10\f51\fs16\b\ql ARX-02\u8212?Sufentanil NanoTab BTP Management System\par\pard\plain\sb88\cf10\f51\fs16\ql ARX-02 is a potential new treatment option for cancer patients who suffer from breakthrough pain. ARX-02 is designed to avoid many of the limitations\plain\cf10\f51\fs16\ql of currently available cancer breakthrough pain medications by combining the rapid onset and appropriate offset of sufentanil with abuse-deterrent\plain\cf10\f51\fs16\ql packaging. The ARX-02 system consists of a magazine containing 30 single dose applicators. Each single dose applicator includes a sufentanil NanoTab\plain\cf10\f51\fs16\ql that a patient can self-administer under their tongue for rapid transmucosal absorption.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 4
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\sb198\cf10\f51\fs16\ql We have completed a Phase 2 study of the analgesic efficacy of the sufentanil NanoTab in adult cancer patients who are opioid tolerant and suffering\plain\cf10\f51\fs16\ql from breakthrough pain events and have completed an End of Phase 2 meeting with the FDA. Our Phase 2 study for ARX-02 demonstrated analgesic\plain\cf10\f51\fs16\ql efficacy versus placebo and a low adverse event profile. The FDA stated that the demonstration of efficacy versus placebo in a single Phase 3 study with\plain\cf10\f51\fs16\ql a total safety database of 300 to 500 patients exposed to the active drug, with at least 100 patients treated for a minimum of three months, may support\plain\cf10\f51\fs16\ql an indication for the treatment of breakthrough pain in cancer patients with underlying chronic pain.\par\pard\plain\sb198\cf10\f51\fs16\ql Based on the availability of additional financial resources subsequent to this offering, we plan to conduct one Phase 3 efficacy study for ARX-02 and two\plain\cf10\f51\fs16\ql open-label studies to demonstrate long term safety.\par\pard\plain\sb198\cf10\f51\fs16\b\ql ARX-03\u8212?Sufentanil/Triazolam NanoTab\par\pard\plain\sb88\cf10\f51\fs16\ql ARX-03 is a single, fixed-dose sublingual product candidate designed to provide non-invasive sedation, anxiety reduction and pain relief for patients\plain\cf10\f51\fs16\ql prior to a painful procedure in a physician\u8217?s office. ARX-03 is designed to eliminate the need for specialized personnel and requires only minimal\plain\cf10\f51\fs16\ql monitoring equipment. We have completed a successful Phase 2 clinical trial of ARX-03 demonstrating rapid onset of mild sedation and reduction in\plain\cf10\f51\fs16\ql anxiety in 15 to 30 minutes. We have preliminary guidance as to a clinical development path for this product as a result of completion of an End of\plain\cf10\f51\fs16\ql Phase 2 meeting with the FDA.\par\pard\plain\sb198\cf10\f51\fs16\ql Further development of ARX-03 will depend on the identification of a partner to support this effort.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Our Strategy\par\pard\plain\sb88\cf10\f51\fs16\ql Our strategy is to develop and commercialize a portfolio of sufentanil NanoTab-based products in specialty markets. We have designed and are\plain\cf10\f51\fs16\ql developing product candidates which have clearly defined clinical development programs, target large commercial market opportunities, and require modest\plain\cf10\f51\fs16\ql commercial organizations in the United States. We selectively utilize third party contractors in order to maximize the capital efficiency of our development\plain\cf10\f51\fs16\ql and commercialization efforts. We plan to enter into partnerships to market our product candidates outside the United States.\par\pard\plain\sb198\cf10\f51\fs16\ql We intend to advance ARX-01 into two Phase 3 trials, and contingent on our ability to secure additional funding, we plan to complete the third ARX-01\plain\cf10\f51\fs16\ql Phase 3 clinical trial, submit an NDA and, if approved, to commercialize ARX-01 ourselves in the United States. Based on the availability of additional\plain\cf10\f51\fs16\ql financial resources, we plan to advance ARX-02 into Phase 3 trials, submit an NDA and, if approved, commercialize ARX-02 ourselves or with a partner\plain\cf10\f51\fs16\ql in the United States. Further development of ARX-03 will depend on the identification of a partner to support this effort.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Associated with Our Business\par\pard\plain\sb88\cf10\f51\fs16\ql Our business is subject to numerous risks, as more fully described in the section entitled \u8220?Risk Factors\u8221? immediately following this\plain\cf10\f51\fs16\ql prospectus summary, beginning on page 13. You should read these risks before you invest in our common stock. We may be unable, for many reasons,\plain\cf10\f51\fs16\ql including those that are beyond our control, to implement our business strategy. In particular, our risks include:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the\plain\intbl\cf10\f51\fs16\ql foreseeable future.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8043\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql We have never generated any revenue and may never be profitable.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8043\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql If we fail to obtain additional financing, we would be forced to delay, reduce or eliminate our product development programs.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql We depend substantially on the success of our product candidate ARX-01, which is still under clinical development and may not\plain\intbl\cf10\f51\fs16\ql receive regulatory approval or be successfully commercialized.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 5
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql We depend substantially on the successful completion of Phase 3 clinical trials for our product candidates. The positive clinical results\plain\intbl\cf10\f51\fs16\ql obtained for our product candidates in Phase 2 clinical studies may not be repeated in Phase 3.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or\plain\intbl\cf10\f51\fs16\ql delay our ability to obtain regulatory approval and commence product sales.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or\plain\intbl\cf10\f51\fs16\ql limit the scope of any approved label or market acceptance.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Our designs for the device components of our product candidates for Phase 3 clinical trials may not be fully functional or\plain\intbl\cf10\f51\fs16\ql commercially viable.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql The commercial success of ARX-01 and our other product candidates will depend upon the acceptance of these products by the\plain\intbl\cf10\f51\fs16\ql medical community, including physicians, patients and health care payors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10798\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql We have numerous pending patent applications, but no issued patents in the United States, and the degree of future protection for our\plain\intbl\cf10\f51\fs16\ql proprietary rights is uncertain.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10798\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\b\ql Corporate Information\par\pard\plain\sb88\cf10\f51\fs16\ql We were originally incorporated as SuRx Pharmaceuticals, Inc. in Delaware on July\~13, 2005. We subsequently changed our name to AcelRx\plain\cf10\f51\fs16\ql Pharmaceuticals, Inc. on August\~13, 2006. Our principal executive offices are located at 575 Chesapeake Drive, Redwood City, California 94063, and our\plain\cf10\f51\fs16\ql telephone number is (650)\~216-3500. Our website address is www.acelrx.com. The information contained in or that can be accessed through our website\plain\cf10\f51\fs16\ql is not part of this prospectus.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 6
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\b\qc THE OFFERING\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx8417\trrh223
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql Common stock offered\cell\pard\plain\intbl\cf10\f51\fs16\ql 8,000,000 shares\cell{
{\trowd\cellx4144\cellx8417\trrh223\row}}}\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx10800\trrh412
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql Over-allotment option\cell\pard\plain\intbl\cf10\f51\fs16\ql We have granted the underwriters an option for a period of 30 days to purchase up to\plain\intbl\cf10\f51\fs16\ql 1,200,000 additional shares of common stock.\cell{
{\trowd\cellx4144\cellx10800\trrh412\row}}}\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx8501\trrh223
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql Common stock outstanding after the offering\cell\pard\plain\intbl\cf10\f51\fs16\ql 19,371,750 shares\cell{
{\trowd\cellx4144\cellx8501\trrh223\row}}}\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx10800\trrh825
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql Use of proceeds\cell\pard\plain\intbl\cf10\f51\fs16\ql We intend to use the net proceeds from this offering of approximately $35.6 million, based on\plain\intbl\cf10\f51\fs16\ql the expected initial public offering price of $5.00 per share, to fund two of our three planned\plain\intbl\cf10\f51\fs16\ql ARX-01 Phase 3 clinical trials, and for working capital and other general corporate purposes.\plain\intbl\cf10\f51\fs16\ql See \u8220?Use of Proceeds\u8221? on page\~39.\cell{
{\trowd\cellx4144\cellx10800\trrh825\row}}}\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx7965\trrh223
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql NASDAQ Global Market symbol\cell\pard\plain\intbl\cf10\f51\fs16\ql ACRX\cell{
{\trowd\cellx4144\cellx7965\trrh223\row}}}\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\cellx4144\cellx10800\trrh619
\pard\plain\intbl\li44\cf10\f51\fs16\b\ql Risk factors\cell\pard\plain\intbl\cf10\f51\fs16\ql You should read the \u8220?Risk Factors\u8221? section of, and all of the other information\plain\intbl\cf10\f51\fs16\ql set forth in, this prospectus for a discussion of factors to consider carefully before deciding to\plain\intbl\cf10\f51\fs16\ql invest in shares of our common stock.\cell{
{\trowd\cellx4144\cellx10800\trrh619\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The number of shares of common stock outstanding immediately after this offering is based\~on 11,371,750 shares of common stock outstanding as of\plain\cf10\f51\fs16\ql September\~30, 2010. This number excludes:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,892,860 shares of common stock issuable upon the exercise of stock options outstanding as of September\~30, 2010 under our 2006\plain\intbl\cf10\f51\fs16\ql Stock Plan having a weighted average exercise price at September\~30, 2010 of $1.88 per share (or $2.77 per share assuming that the\plain\intbl\cf10\f51\fs16\ql December 2010 stock option modification described under \u8220?Management\u8217?s Discussion and Analysis of Financial\plain\intbl\cf10\f51\fs16\ql Condition and Results of Operations\u8212?Critical Accounting Policies and Estimates\u8212?Stock-Based Compensation\u8221? had\plain\intbl\cf10\f51\fs16\ql occurred as of September 30, 2010);\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 167,630 shares of common stock reserved for future issuance under our 2006 Stock Plan as of September\~30, 2010, which share\plain\intbl\cf10\f51\fs16\ql reserve will become available for issuance under our 2011 Equity Incentive Plan upon the execution and delivery of the underwriting\plain\intbl\cf10\f51\fs16\ql agreement for this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 231,678 shares of common stock issuable upon the exercise of warrants outstanding as of September\~30, 2010 having a weighted\plain\intbl\cf10\f51\fs16\ql average exercise price of $3.94 per share, which warrants are expected to remain outstanding upon completion of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,875,000 shares of common stock (which will include the shares then reserved for issuance under our 2006 Stock Plan at the time of\plain\intbl\cf10\f51\fs16\ql the execution and delivery of the underwriting agreement for this offering) reserved for future issuance under our 2011 Equity\plain\intbl\cf10\f51\fs16\ql Incentive Plan, which will become effective immediately upon the execution and delivery of the underwriting agreement for this\plain\intbl\cf10\f51\fs16\ql offering, as well as any future increases in the number of shares of common stock reserved for issuance under this plan; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 250,000 shares of common stock reserved for future issuance under our 2011 Employee Stock Purchase Plan, which will\plain\intbl\cf10\f51\fs16\ql become effective immediately upon the execution and delivery of the underwriting agreement for this offering, as well as\plain\intbl\cf10\f51\fs16\ql any future increases in the number of shares of common stock reserved for issuance under this plan.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 7
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\sb198\cf10\f51\fs16\ql Unless otherwise indicated, all information in this prospectus assumes or gives effect to:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10559\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql a 1-for-4 reverse stock split of our common stock and preferred stock that became effective on January 28, 2011;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10559\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,555,713 shares of common\plain\intbl\cf10\f51\fs16\ql stock upon completion of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the exercise, on a net issuance basis, of warrants outstanding as of September 30, 2010 that we issued in connection with a bridge\plain\intbl\cf10\f51\fs16\ql loan financing in September 2010, or the 2010 warrants, which will be exercisable for shares of our Series C convertible preferred\plain\intbl\cf10\f51\fs16\ql stock immediately prior to this offering, and the concomitant conversion of the shares of Series C convertible preferred stock acquired\plain\intbl\cf10\f51\fs16\ql upon exercise into 107,246 shares of common stock upon completion of this offering, based on the expected initial public offering\plain\intbl\cf10\f51\fs16\ql price of $5.00 per share;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of our remaining warrants to purchase convertible preferred stock, which warrants are expected to remain\plain\intbl\cf10\f51\fs16\ql outstanding upon completion of this offering, into warrants to purchase an aggregate of 231,678 shares of common stock upon\plain\intbl\cf10\f51\fs16\ql completion of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of the principal and accrued interest outstanding under our $8.0 million in aggregate principal amount of\plain\intbl\cf10\f51\fs16\ql convertible promissory notes into 2,034,438 shares of common stock immediately prior to the closing of this offering at a conversion\plain\intbl\cf10\f51\fs16\ql price equal to 80% of the initial public offering price, based on the expected initial public offering price of $5.00 per share and\plain\intbl\cf10\f51\fs16\ql assuming the conversion occurs on February\~16, 2011, the expected closing date of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the filing of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of this\plain\intbl\cf10\f51\fs16\ql offering; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8199\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql no exercise of the underwriters\u8217? over-allotment option.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8199\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Because the number of shares that will be issued upon exercise of the 2010 warrants and conversion of the 2010 notes depends upon the actual initial\plain\cf10\f51\fs16\ql public offering price per share in this offering and, in the case of the 2010 notes, the closing date of this offering, the actual number of shares issuable\plain\cf10\f51\fs16\ql upon such exercise and conversion may differ from the respective number of shares set forth above.\par\pard\plain\sb198\cf10\f51\fs16\ql A $1.00 increase in the assumed initial public offering price of $5.00 per share would decrease the number of shares of our common stock issued on\plain\cf10\f51\fs16\ql conversion of the 2010 notes (and therefore the number of shares to be outstanding after this offering) by 339,075 shares, assuming that the closing date\plain\cf10\f51\fs16\ql of this offering (and therefore the conversion date of the 2010 notes) is February\~16, 2011. A $1.00 decrease in the expected initial public offering price\plain\cf10\f51\fs16\ql of $5.00 per share would increase the number of shares of our common stock issued on conversion of the 2010 notes (and therefore the number of shares\plain\cf10\f51\fs16\ql to be outstanding after this offering) by 508,609 shares, assuming that the closing date of this offering (and therefore the conversion date of the 2010\plain\cf10\f51\fs16\ql notes) is February\~16, 2011. To the extent the closing date of this offering occurs after February\~16, 2011, the 2010 notes will continue to accrue interest\plain\cf10\f51\fs16\ql at a rate of 4.0%\~per annum and additional shares of our common stock will be issued upon conversion of this additional accrued interest. Likewise, if the\plain\cf10\f51\fs16\ql closing date occurs prior to February\~16, 2011, fewer shares will be issued upon conversion of the 2010 notes.\par\pard\plain\sb198\cf10\f51\fs16\ql A $1.00 increase in the expected initial public offering price of $5.00 per share would increase the number of shares of our common stock issued upon\plain\cf10\f51\fs16\ql the net exercise of the 2010 warrants (and therefore the\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 8
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\ql number of shares to be outstanding after this offering) by 66,665 shares. A $1.00 decrease in the expected initial public offering price of $5.00 per share\plain\cf10\f51\fs16\ql would decrease the number of shares of our common stock issued upon the net exercise of the 2010 warrants (and therefore the number of shares to be\plain\cf10\f51\fs16\ql outstanding after this offering) by 100,000 shares.\par\pard\plain\sb198\cf10\f51\fs16\ql Entities affiliated with Three Arch Partners, Skyline Venture Partners, Alta Partners and Kaiser Foundation Hospitals, each of which is a current\plain\cf10\f51\fs16\ql stockholder, have indicated an interest in purchasing an aggregate of $24.0 million of shares of common stock in this offering, at the price offered to the\plain\cf10\f51\fs16\ql public. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more,\plain\cf10\f51\fs16\ql less or no shares in this offering to any of these entities, or any of these entities may determine to purchase more, less or no shares in this offering. The\plain\cf10\f51\fs16\ql underwriters will receive an underwriting discount of $\~\~\~\~\~\~\~\~ per share on any sales of shares to these entities.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 9
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\b\qc SUMMARY FINANCIAL DATA\par\pard\plain\sb198\cf10\f51\fs16\ql The following table summarizes our financial data. We have derived the following summary statement of operations data for the years ended\plain\cf10\f51\fs16\ql December\~31, 2007, 2008 and 2009 from our audited financial statements included elsewhere in this prospectus. The summary statement of operations data\plain\cf10\f51\fs16\ql for the nine months ended September\~30, 2009 and 2010 and the balance sheet data as of September\~30, 2010 have been derived from our unaudited\plain\cf10\f51\fs16\ql interim financial statements included elsewhere in this prospectus. The unaudited interim financial results have been prepared on the same basis as the\plain\cf10\f51\fs16\ql audited financial statements and reflect all adjustments necessary to fairly reflect our financial position as of September\~30, 2010 and results of operations\plain\cf10\f51\fs16\ql for the nine months ended September\~30, 2009 and 2010. Our historical results are not necessarily indicative of the results that may be expected in the\plain\cf10\f51\fs16\ql future. The following summary financial data should be read in conjunction with \u8220?Management\u8217?s Discussion and Analysis of Financial\plain\cf10\f51\fs16\ql Condition and Results of Operations\u8221? and our financial statements and related notes included elsewhere in this prospectus.\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx4329\clvertalb\cellx4675\clvertalc\cellx4823\clvertalc\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clvertalc\cellx6094\clvertalc\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clvertalc\cellx7365\clvertalc\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalc\cellx8674\clvertalc\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clvertalc\cellx9966\clvertalc\cellx10652\clvertalc\cellx10789\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4329\clvertalb\cellx4675\clvertalc\cellx4823\clvertalc\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clvertalc\cellx6094\clvertalc\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clvertalc\cellx7365\clvertalc\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalc\cellx8674\clvertalc\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clvertalc\cellx9966\clvertalc\cellx10652\clvertalc\cellx10789\trrh-66\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8056\clvertalb\cellx8193\clvertalb\cellx8531\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10661\clvertalb\cellx10798\trrh419
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year Ended December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine\~Months Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8056\clvertalb\cellx8193\clvertalb\cellx8531\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10661\clvertalb\cellx10798\trrh419\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5464\clvertalb\cellx5601\clvertalb\cellx5947\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6736\clvertalb\cellx6873\clvertalb\cellx7219\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8054\clvertalb\cellx8191\clvertalb\cellx8529\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9318\clvertalb\cellx9462\clvertalb\cellx9822\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10657\clvertalb\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2007\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2008\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5464\clvertalb\cellx5601\clvertalb\cellx5947\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6736\clvertalb\cellx6873\clvertalb\cellx7219\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8054\clvertalb\cellx8191\clvertalb\cellx8529\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9318\clvertalb\cellx9462\clvertalb\cellx9822\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10657\clvertalb\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx5464\clvertalb\cellx5601\clvertalb\cellx5947\clvertalb\cellx6736\clvertalb\cellx6873\clvertalb\cellx7219\clvertalb\cellx8054\clvertalb\cellx8191\clvertalb\cellx8529\clvertalb\cellx10659\clvertalb\cellx10796\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx5464\clvertalb\cellx5601\clvertalb\cellx5947\clvertalb\cellx6736\clvertalb\cellx6873\clvertalb\cellx7219\clvertalb\cellx8054\clvertalb\cellx8191\clvertalb\cellx8529\clvertalb\cellx10659\clvertalb\cellx10796\trrh172\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx10661\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands, except share and per share data)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx10661\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\b\ql Statement of Operations Data:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Operating Expenses:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,209\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 18,325\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 15,502\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 13,180\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,309\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,365\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 3,529\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,510\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 3,033\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total operating expenses\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,291\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 20,690\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 19,031\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 15,690\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,342\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Loss from operations\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (10,291\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (20,690\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (19,031\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (15,690\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (9,342\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest income\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 687\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 484\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 33\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest expense\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (25\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (404\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,242\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (965\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (656\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (52\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 121\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 196\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (825\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Loss before provision for income taxes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (9,630\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (20,662\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (20,119\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (16,422\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (10,821\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Provision for income taxes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh29\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (9,630\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (20,662\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (20,119\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (16,422\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (10,821)\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Net loss per share of common stock, basic and diluted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (26.45\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (43.69\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (34.93\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (29.09\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (16.63\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh413
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Shares used in computing net loss per share of common\plain\intbl\li176\cf10\f51\fs16\ql stock, basic and diluted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 364,039\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 472,914\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 576,021\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 564,571\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 650,774\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh413\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4823\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5463\clvertalc\cellx5600\clvertalb\cellx5946\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6094\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6734\clvertalc\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8674\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9314\clvertalc\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh413
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Pro forma net loss per share of common stock, basic and\plain\intbl\li176\cf10\f51\fs16\ql diluted (unaudited)\plain\intbl\li176\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (3.51\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (1.09\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4329\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4675\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4823\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5463\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5600\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5946\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6094\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6734\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6871\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7365\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8051\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8188\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8526\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8674\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9314\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9818\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9966\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10652\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh413\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63\row}}}
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh413
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Shares used in computing pro forma net loss per share of\plain\intbl\li176\cf10\f51\fs16\ql common stock, basic and diluted (unaudited)\plain\intbl\li176\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,746,372\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,204,999\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clvertalb\cellx7365\clvertalb\cellx8051\clvertalb\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clvertalb\cellx9966\clvertalb\cellx10652\clvertalb\cellx10789\trrh413\row}}}
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx4329\clvertalb\cellx4675\clvertalb\cellx4823\clvertalb\cellx5463\clvertalb\cellx5600\clvertalb\cellx5946\clvertalb\cellx6094\clvertalb\cellx6734\clvertalb\cellx6871\clvertalb\cellx7217\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7365\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8051\clvertalc\cellx8188\clvertalb\cellx8526\clvertalb\cellx8674\clvertalb\cellx9314\clvertalb\cellx9458\clvertalb\cellx9818\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9966\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10652\clvertalc\cellx10789\trrh63\row}}}\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx154\cellx10799\trrh344
\pard\plain\intbl\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf10\f51\fs13\ql See Note 11 of the audited financial statements included elsewhere in this prospectus for a discussion regarding the calculations for the net loss per share and the pro forma net loss\plain\intbl\cf10\f51\fs13\ql per share and the shares used in these calculations.\cell{
{\trowd\cellx154\cellx10799\trrh344\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 10
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5805\clvertalb\cellx6449\clvertalc\cellx6665\clvertalc\cellx7198\clvertalc\cellx7335\clvertalb\cellx7878\clvertalc\cellx8310\clvertalc\cellx8950\clvertalc\cellx9073\clvertalb\cellx9616\clvertalc\cellx10031\clvertalc\cellx10671\clvertalc\cellx10794\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5805\clvertalb\cellx6449\clvertalc\cellx6665\clvertalc\cellx7198\clvertalc\cellx7335\clvertalb\cellx7878\clvertalc\cellx8310\clvertalc\cellx8950\clvertalc\cellx9073\clvertalb\cellx9616\clvertalc\cellx10031\clvertalc\cellx10671\clvertalc\cellx10794\trrh-66\row}}}
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc As of September\~30, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10672\clvertalb\cellx10795\trrh344
\pard\plain\intbl\cf1\f51\fs20\ql \~\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Actual\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Pro Forma\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Pro\~Forma\~as
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Adjusted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10672\clvertalb\cellx10795\trrh344\row}}}
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clvertalb\cellx10672\clvertalb\cellx10795\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clvertalb\cellx10672\clvertalb\cellx10795\trrh172\row}}}
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clvertalb\cellx10672\clvertalb\cellx10795\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in\~thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5805\clvertalb\cellx6449\clvertalb\cellx7199\clvertalb\cellx7336\clvertalb\cellx7879\clvertalb\cellx8951\clvertalb\cellx9074\clvertalb\cellx9617\clvertalb\cellx10672\clvertalb\cellx10795\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6665\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\b\ql Balance Sheet Data:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6665\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Cash, cash equivalents and short-term investments\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr $8,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 43,722\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Working capital (deficit)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,894\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,709\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 38,349\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total assets\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,786\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,786\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 45,426\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total debt, including convertible notes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,985\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,382\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,382\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock warrant liability\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,219\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 55,941\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5805\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6449\clshdng100\clcfpat13\clcbpat13\cellx6665\clshdng100\clcfpat13\clcbpat13\cellx7198\clshdng100\clcfpat13\clcbpat13\cellx7335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7878\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8310\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9073\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9616\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total stockholders\u8217? equity (deficit)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (60,986\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,253\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37,893\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx5805\clvertalb\cellx6449\cellx6665\cellx7198\cellx7335\clvertalb\cellx7878\clvertalb\cellx8310\clvertalb\cellx8950\clvertalb\cellx9073\clvertalb\cellx9616\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The pro forma column in the balance sheet data above gives effect to the following transactions and adjustments as if they had occurred as of September\plain\cf10\f51\fs16\ql 30, 2010:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (1)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,555,713 shares of common stock\plain\intbl\cf10\f51\fs16\ql upon completion of this offering;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (2)\cell\pard\plain\intbl\cf10\f51\fs16\ql the exercise, on a net issuance basis, of warrants outstanding as of September 30, 2010 that we issued in connection with a bridge loan\plain\intbl\cf10\f51\fs16\ql financing in September 2010, or the 2010 warrants, which will be exercisable for shares of our Series C convertible preferred stock\plain\intbl\cf10\f51\fs16\ql immediately prior to this offering, and the concomitant conversion of the shares of Series C convertible preferred stock acquired upon\plain\intbl\cf10\f51\fs16\ql exercise into 107,246 shares of common stock upon completion of this offering, based on the expected initial public offering price of $5.00\plain\intbl\cf10\f51\fs16\ql per share;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (3)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of our remaining warrants to purchase convertible preferred stock, which warrants are expected to remain\plain\intbl\cf10\f51\fs16\ql outstanding upon the completion of this offering, into warrants to purchase an aggregate of 231,678 shares of common stock upon completion\plain\intbl\cf10\f51\fs16\ql of this offering;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (4)\cell\pard\plain\intbl\cf10\f51\fs16\ql the reclassification of the liability associated with the warrants to purchase convertible preferred stock to additional paid-in capital; and\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (5)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of the principal and accrued interest outstanding under our $8.0\~million in aggregate principal amount of convertible\plain\intbl\cf10\f51\fs16\ql promissory notes, or the 2010 notes, into 2,034,438 shares of common stock immediately prior to the closing of this offering at a conversion\plain\intbl\cf10\f51\fs16\ql price equal to 80% of the initial public offering price, based on the expected initial public offering price of $5.00 per share and assuming the\plain\intbl\cf10\f51\fs16\ql conversion occurs on February\~16, 2011, and the reclassification of the convertible note liability to common stock and additional paid-in\plain\intbl\cf10\f51\fs16\ql capital in connection with the conversion.\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The pro forma as adjusted column in the balance sheet data above gives further effect to the sale of 8,000,000 shares of common stock in this offering at\plain\cf10\f51\fs16\ql the expected initial public offering price of $5.00 per share, after deducting estimated underwriting discounts and commissions and estimated offering\plain\cf10\f51\fs16\ql expenses payable by us, as if the sale of the shares in this offering had occurred as of September 30, 2010.\par\pard\plain\sb198\cf10\f51\fs16\ql Because the number of shares of common stock that will be issued upon exercise of the 2010 warrants and conversion of the 2010 notes depends upon\plain\cf10\f51\fs16\ql the actual initial public offering price per share in this\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 11
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\ql offering and, in the case of the 2010 notes, the closing date of this offering, the actual number of shares issuable upon such exercise and conversion may\plain\cf10\f51\fs16\ql differ from the respective number of shares set forth above. See \u8220?Prospectus Summary \u8211? The Offering.\u8221?\par\pard\plain\sb198\cf10\f51\fs16\ql Each $1.00 increase (decrease) in the expected initial public offering price of $5.00 per share would increase (decrease) each of cash, cash equivalents and\plain\cf10\f51\fs16\ql short-term investments, working capital, total assets and total stockholders\u8217? equity (deficit) by $7.4 million, assuming that the number of shares\plain\cf10\f51\fs16\ql offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions\plain\cf10\f51\fs16\ql and estimated offering expenses payable by us. Each increase (decrease) of 1.0\~million shares in the number of shares of common stock offered by us\plain\cf10\f51\fs16\ql would increase (decrease) each of cash, cash equivalents and short-term investments, working capital, total assets and total stockholders\u8217? equity\plain\cf10\f51\fs16\ql (deficit) by approximately $4.7 million, assuming that the expected initial public offering price, as set forth on the cover page of this prospectus, remains\plain\cf10\f51\fs16\ql the same. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and\plain\cf10\f51\fs16\ql other terms of this offering.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\cf1\f51\fs6\ql \~\par\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 12
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart item_1_3_2}{\*\bkmkend item_1_3_2}{\*\bkmkstart toc113475_2}{\*\bkmkend toc113475_2}\par\pard\plain\cf10\f51\fs16\b\qc RISK FACTORS\par\pard\plain\sb198\cf10\f51\fs16\i\ql Before you decide to invest in our common stock, you should consider carefully the risks described below, together with the other information contained\plain\cf10\f51\fs16\i\ql in this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks\plain\cf10\f51\fs16\i\ql comes to fruition, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In\plain\cf10\f51\fs16\i\ql these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Our Financial Condition and Need for Additional Capital\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.\par\pard\plain\sb88\cf10\f51\fs16\ql We are a development stage company with limited operating history. To date, we have focused primarily on developing our lead product candidate, the\plain\cf10\f51\fs16\ql Sufentanil NanoTab PCA System, or ARX-01. We have two additional product candidates, the Sufentanil NanoTab BTP Management System, or\plain\cf10\f51\fs16\ql ARX-02, and the Sufentanil/Triazolam NanoTab, or ARX-03. We have incurred significant net losses in each year since our inception in July 2005,\plain\cf10\f51\fs16\ql including net losses of approximately $9.6\~million, $20.7\~million, $20.1\~million and $10.8 million for fiscal years 2007, 2008, 2009 and for the nine\plain\cf10\f51\fs16\ql months ended September\~30, 2010, respectively. As of September\~30, 2010, we had an accumulated deficit of $65.0 million.\par\pard\plain\sb198\cf10\f51\fs16\ql We have devoted most of our financial resources to research and development, including our non-clinical development activities and clinical trials. To\plain\cf10\f51\fs16\ql date, we have financed our operations exclusively through the sale of equity securities and debt. The size of our future net losses will depend, in part, on\plain\cf10\f51\fs16\ql the rate of future expenditures and our ability to generate revenues. To date, none of our product candidates have been commercialized, and if our product\plain\cf10\f51\fs16\ql candidates are not successfully developed or commercialized, or if revenues are insufficient following marketing approval, we will not achieve profitability\plain\cf10\f51\fs16\ql and our business may fail. Even if we successfully obtain regulatory approval to market our product candidates in the United States, our revenues are also\plain\cf10\f51\fs16\ql dependent upon the size of the markets outside of the United States, as well as our ability to obtain market approval and achieve commercial success.\par\pard\plain\sb198\cf10\f51\fs16\ql We expect to continue to incur substantial and increased expenses as we expand our research and development activities and advance our clinical\plain\cf10\f51\fs16\ql programs. We also expect an increase in our expenses associated with preparing for the potential commercialization of ARX-01 and creating additional\plain\cf10\f51\fs16\ql infrastructure to support operations as a public company. As a result of the foregoing, we expect to continue to incur significant and increasing losses and\plain\cf10\f51\fs16\ql negative cash flows for the foreseeable future.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We have never generated any revenue and may never be profitable.\par\pard\plain\sb88\cf10\f51\fs16\ql Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development,\plain\cf10\f51\fs16\ql obtain the necessary regulatory approvals and commercialize our product candidates. We do not anticipate generating revenues from sales of our product\plain\cf10\f51\fs16\ql candidates for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql completing the clinical development of ARX-01, initially for the treatment of post-operative pain in the hospital setting;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6678\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql obtaining regulatory approval for ARX-01;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6678\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql launching and commercializing ARX-01, including building a hospital-directed sales force and collaborating with third parties; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql completing the clinical development, obtaining regulatory approval, launching and commercializing ARX-02 and ARX-03, which will\plain\intbl\cf10\f51\fs16\ql require additional funding.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 13
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of\plain\cf10\f51\fs16\ql increased expenses, when, or if, we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we\plain\cf10\f51\fs16\ql are required by the FDA to perform studies in addition to those that we currently anticipate.\par\pard\plain\sb198\cf10\f51\fs16\ql Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing\plain\cf10\f51\fs16\ql any approved product candidate. Even if we are able to generate revenues from the sale of our products, we may not become profitable and may need to\plain\cf10\f51\fs16\ql obtain additional funding to continue operations.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We have a limited operating history which may make it difficult to predict our future performance or evaluate our business and prospects.\par\pard\plain\sb88\cf10\f51\fs16\ql We were incorporated in 2005. Since inception, our operations have been primarily limited to organizing and staffing our company, developing our\plain\cf10\f51\fs16\ql technology and undertaking preclinical studies and clinical trials for our product candidates. We have not yet obtained regulatory approval for any of our\plain\cf10\f51\fs16\ql product candidates. Consequently, any predictions you make about our future success or viability or evaluation of our business and prospects may not be\plain\cf10\f51\fs16\ql accurate.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql If we fail to obtain additional financing, we would be forced to delay, reduce or eliminate our product development programs.\par\pard\plain\sb88\cf10\f51\fs16\ql Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development\plain\cf10\f51\fs16\ql expenses to substantially increase in connection with our ongoing activities, particularly as we advance our clinical programs. As of September\~30, 2010,\plain\cf10\f51\fs16\ql we had negative working capital of approximately $1.9 million, and our audit report in our 2009 financial statements contains an explanatory paragraph\plain\cf10\f51\fs16\ql stating that our recurring losses from operations and cash used in operating activities raise substantial doubt about our ability to continue as a going\plain\cf10\f51\fs16\ql concern. If we are unable to successfully complete this offering, we will need to seek alternative financing or operational plans to continue as a going\plain\cf10\f51\fs16\ql concern. Even if the offering is successful, we will need to raise additional funds to support our operations, and such funding may not be available to us\plain\cf10\f51\fs16\ql on acceptable terms, or at all.\par\pard\plain\sb198\cf10\f51\fs16\ql We estimate that the net proceeds from this offering will be approximately $35.6 million, based on the expected initial public offering price of $5.00 per\plain\cf10\f51\fs16\ql share, after deducting estimated underwriting discounts and commissions and offering expenses payable by us. We expect that the net proceeds from this\plain\cf10\f51\fs16\ql offering and our existing cash and cash equivalents, together with interest, will be sufficient to fund our current operations through the second quarter of\plain\cf10\f51\fs16\ql 2012. However, changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate. For example, our\plain\cf10\f51\fs16\ql clinical trials may encounter technical, enrollment or other difficulties that could increase our development costs more than we expected. We will need to\plain\cf10\f51\fs16\ql raise additional funding or otherwise enter into collaborations to complete the third ARX-01 Phase\~3 clinical trial required to file our NDA and, if we\plain\cf10\f51\fs16\ql choose, to initiate clinical trials for our product candidates other than ARX-01. In any event, we will require additional capital to obtain regulatory\plain\cf10\f51\fs16\ql approval for, and to commercialize, our product candidates. Raising funds in the current economic environment, when the capital markets have been\plain\cf10\f51\fs16\ql affected by the global recession, may present additional challenges.\par\pard\plain\sb198\cf10\f51\fs16\ql Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and\plain\cf10\f51\fs16\ql commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable\plain\cf10\f51\fs16\ql to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10724\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql significantly delay, scale back or discontinue the development or commercialization of our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10724\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 14
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql seek corporate partners for ARX-01 at an earlier stage than otherwise would be desirable or on terms that are less favorable than\plain\intbl\cf10\f51\fs16\ql might otherwise be available; or\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop\plain\intbl\cf10\f51\fs16\ql or commercialize ourselves.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\sb198\cf10\f51\fs16\ql If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and\plain\cf10\f51\fs16\ql commercialization efforts, including completing the third ARX-01 Phase\~3 clinical trial required to file our NDA, which will have a material adverse\plain\cf10\f51\fs16\ql effect on our business, operating results and prospects.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We might be unable to service our current debt due to a lack of cash flow and might be subject to default.\par\pard\plain\sb88\cf10\f51\fs16\ql Pursuant to the loan agreement with Pinnacle Ventures L.L.C., or Pinnacle, we granted to Pinnacle a first priority security interest in substantially all of\plain\cf10\f51\fs16\ql our assets, with the exception of our intellectual property, where the security interest is limited to proceeds of intellectual property. As of September\~30,\plain\cf10\f51\fs16\ql 2010, we had $6.4 million of outstanding debt under the Pinnacle loan agreement. Under the terms of this agreement, we are required to make monthly\plain\cf10\f51\fs16\ql payments of approximately $442,000 on the first day of each month through November 1, 2011, the maturity date of the loan, with an additional final\plain\cf10\f51\fs16\ql interest payment of $600,000 due on November 1, 2011. The loan carries an 8.5% annual interest rate. If we do not make the required payments when\plain\cf10\f51\fs16\ql due, either at maturity, or at applicable installment payment dates, if we breach the agreement or become insolvent, Pinnacle could elect to declare all\plain\cf10\f51\fs16\ql amounts outstanding, together with accrued and unpaid interest and penalty, to be immediately due and payable. Even if we were able to prepay the full\plain\cf10\f51\fs16\ql amount in cash, any such repayment could leave us with little or no working capital for our business. If we are unable to repay those amounts, Pinnacle\plain\cf10\f51\fs16\ql will have a first claim on our assets pledged under the loan agreement. If Pinnacle should attempt to foreclose on the collateral, it is unlikely that there\plain\cf10\f51\fs16\ql would be any assets remaining after repayment in full of such secured indebtedness. Any default under the loan agreement and resulting foreclosure would\plain\cf10\f51\fs16\ql have a material adverse effect on our financial condition and our ability to continue our operations.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on\plain\cf10\f51\fs16\b\i\ql our business.\par\pard\plain\sb88\cf10\f51\fs16\ql In order to raise additional funds to support our operations, we may sell additional equity or debt securities, which would result in dilution to all of our\plain\cf10\f51\fs16\ql stockholders or impose restrictive covenants that adversely impact our business. The sale of additional equity or convertible debt securities would result in\plain\cf10\f51\fs16\ql the issuance of additional shares of our capital stock and dilution to all of our stockholders. The incurrence of indebtedness would result in increased fixed\plain\cf10\f51\fs16\ql payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our\plain\cf10\f51\fs16\ql ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.\plain\cf10\f51\fs16\ql If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations\plain\cf10\f51\fs16\ql could be materially adversely affected and we may not be able to meet our debt service obligations.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Clinical Development and Regulatory Approval\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql We depend substantially on the success of our product candidate, ARX-01, which is still under clinical development, and may not obtain regulatory\plain\cf10\f51\fs16\b\i\ql approval or be successfully commercialized.\par\pard\plain\sb88\cf10\f51\fs16\ql We have not marketed, distributed or sold any products. The success of our business depends primarily upon our ability to develop and commercialize\plain\cf10\f51\fs16\ql ARX-01, which has completed Phase 2 clinical trials for the treatment of post-operative pain. We expect to initiate two of the three planned Phase 3\plain\cf10\f51\fs16\ql clinical trials for ARX-01 in the second half of 2011. Contingent on our ability to secure additional funding, we plan\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 15
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql to begin a third Phase 3 clinical trial in the second half of 2012. We intend to use these trials as a basis to submit an NDA for ARX-01. There is no\plain\cf10\f51\fs16\ql guarantee that our Phase 3 clinical trials will be completed, or if completed, will be successful.\par\pard\plain\sb198\cf10\f51\fs16\ql Any delay in obtaining, or inability to obtain, regulatory approval would prevent us from commercializing ARX-01, generating revenues and achieving\plain\cf10\f51\fs16\ql profitability. If any of these events occur, we may be forced to abandon our development efforts for ARX-01, which would have a material adverse effect\plain\cf10\f51\fs16\ql on our business and could potentially cause us to cease operations.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We depend substantially on the successful completion of Phase 3 clinical trials for our product candidates. The positive clinical results obtained for\plain\cf10\f51\fs16\b\i\ql our product candidates in Phase 2 clinical studies may not be repeated in Phase 3.\par\pard\plain\sb88\cf10\f51\fs16\ql We have completed Phase 2 clinical studies and participated in an End of Phase 2 meeting for each of our three product candidates. However, we have\plain\cf10\f51\fs16\ql never conducted a Phase 3 clinical trial. Our product candidates are subject to the risks of failure inherent in pharmaceutical and medical device\plain\cf10\f51\fs16\ql development. Before obtaining regulatory approval for the commercial sale of any product candidate, we must successfully complete Phase 3 clinical\plain\cf10\f51\fs16\ql trials. Negative or inconclusive results of a Phase 3 clinical study could cause the FDA to require that we repeat it or conduct additional clinical studies.\plain\cf10\f51\fs16\ql Furthermore, while we have obtained positive safety and efficacy results for our sufentanil-based product candidates during our prior clinical trials, we\plain\cf10\f51\fs16\ql cannot be certain that these results will be duplicated when our product candidates are tested in a larger number of patients in our Phase 3 clinical trials.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to\plain\cf10\f51\fs16\b\i\ql obtain regulatory approval and commence product sales.\par\pard\plain\sb88\cf10\f51\fs16\ql We may experience delays in clinical trials of our product candidates. We expect to initiate two of the three planned Phase 3 clinical trials of ARX-01 in\plain\cf10\f51\fs16\ql the second half of 2011. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, or be\plain\cf10\f51\fs16\ql completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql inability to raise funding necessary to initiate or continue a trial, including the inability to secure additional funding to complete the\plain\intbl\cf10\f51\fs16\ql third ARX-01 Phase 3 clinical trial required to file our NDA;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8434\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in pharmacokinetic studies required prior to Phase 3 initiation;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8434\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7657\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in obtaining regulatory approval to commence a trial;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7657\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7898\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in reaching agreement with the FDA on final trial design;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7898\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory\plain\intbl\cf10\f51\fs16\ql authorities;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8558\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in obtaining required institutional review board approval at each site;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8558\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7629\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in recruiting suitable patients to participate in a trial;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7629\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10690\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in the testing, validation, manufacturing and delivery of the device components of our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10690\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9849\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays in having patients complete participation in a trial or return for post-treatment follow-up;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9849\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8078\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql clinical sites dropping out of a trial to the detriment of enrollment;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8078\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 16
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6555\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql time required to add new clinical sites; or\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6555\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10153\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10153\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql If initiation or completion of the Phase 3 trials are delayed for our product candidates for any of the above reasons, our development costs may increase,\plain\cf10\f51\fs16\ql our approval process could be delayed and our ability to commercialize and commence sales of our product candidates could be materially harmed, which\plain\cf10\f51\fs16\ql could have a material adverse effect on our business.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of\plain\cf10\f51\fs16\b\i\ql any approved label or market acceptance.\par\pard\plain\sb88\cf10\f51\fs16\ql Adverse events, or AEs, caused by our product candidates could cause us, other reviewing entities, clinical study sites or regulatory authorities to\plain\cf10\f51\fs16\ql interrupt, delay or halt clinical studies and could result in the denial of regulatory approval. Phase 2 clinical studies conducted by us with our product\plain\cf10\f51\fs16\ql candidates have generated some AEs, but no serious adverse events, or SAEs. For example, in ARX-01 clinical studies completed to date, 11% of the\plain\cf10\f51\fs16\ql patients experienced vomiting and 8% experienced itching for 10 mcg and 15 mcg treated groups, as compared to the placebo treated subjects, of which\plain\cf10\f51\fs16\ql 6% experienced vomiting and none experienced itching. If SAEs are observed in any of our clinical studies, our ability to obtain regulatory approval for\plain\cf10\f51\fs16\ql our product candidates may be adversely impacted.\par\pard\plain\sb198\cf10\f51\fs16\ql Further, if our products cause serious or unexpected side effects after receiving market approval, a number of potentially significant negative consequences\plain\cf10\f51\fs16\ql could result, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a modified\plain\intbl\cf10\f51\fs16\ql Risk Evaluation and Mitigation Strategy, or REMS;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10578\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10578\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10203\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql we may be required to change the way the product is administered or conduct additional clinical studies;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10203\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7931\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql we could be sued and held liable for harm caused to patients;\~or\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7931\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5758\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our reputation may suffer.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5758\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase\plain\cf10\f51\fs16\ql the costs of commercializing our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Additional time may be required to obtain regulatory approval for our ARX-01 product candidate because it is a drug/device combination.\par\pard\plain\sb88\cf10\f51\fs16\ql ARX-01 is a drug/device combination. We have filed an IND for ARX-01. Based on our discussions with the FDA, we believe that ARX-01 will be\plain\cf10\f51\fs16\ql reviewed as a combination product, with both drug and device components submitted in the IND, and both components will eventually be part of an\plain\cf10\f51\fs16\ql NDA. There are very few examples of the FDA approval process for drug/device combination products such as ARX-01. As a result, we may experience\plain\cf10\f51\fs16\ql delays in regulatory approval for ARX-01 due to uncertainties in the approval process, in particular as it relates to device approval under an NDA.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql After the completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize ARX-01 and we\plain\cf10\f51\fs16\b\i\ql cannot, therefore, predict the timing of any future revenue from ARX-01.\par\pard\plain\sb88\cf10\f51\fs16\ql We cannot commercialize ARX-01 until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The\plain\cf10\f51\fs16\ql regulatory agencies may not complete their review\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 17
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql processes in a timely manner, or we may not be able to obtain regulatory approval for ARX-01. Additional delays may result if ARX-01 is taken before\plain\cf10\f51\fs16\ql an FDA Advisory Committee which may recommend restrictions on approval or recommend non-approval. In addition, we may experience delays or\plain\cf10\f51\fs16\ql rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the\plain\cf10\f51\fs16\ql period of product development, clinical studies and the review process.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Even if we obtain regulatory approval for ARX-01 and our other product candidates, we will still face extensive regulatory requirements and our\plain\cf10\f51\fs16\b\i\ql products may face future development and regulatory difficulties.\par\pard\plain\sb88\cf10\f51\fs16\ql Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our\plain\cf10\f51\fs16\ql product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the labeling\plain\cf10\f51\fs16\ql ultimately approved for ARX-01 and our other product candidates will likely include restrictions on use due to the opiate nature of sufentanil. ARX-01\plain\cf10\f51\fs16\ql and our other product candidates will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety\plain\cf10\f51\fs16\ql surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is\plain\cf10\f51\fs16\ql obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also\plain\cf10\f51\fs16\ql submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process.\plain\cf10\f51\fs16\ql Advertising and promotional materials must comply with FDA rules and are subject to FDA review,\~in addition to other potentially applicable federal and\plain\cf10\f51\fs16\ql state laws.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the\plain\cf10\f51\fs16\ql FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the\plain\cf10\f51\fs16\ql NDA. If we, or a regulatory agency discovers previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or\plain\cf10\f51\fs16\ql problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing\plain\cf10\f51\fs16\ql facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.\par\pard\plain\sb198\cf10\f51\fs16\ql If we fail to comply with applicable regulatory requirements following approval of our product candidate, a regulatory agency may:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7951\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql issue a warning letter asserting that we are in violation of the law;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7951\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8390\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql seek an injunction or impose civil or criminal penalties or monetary fines;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8390\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6579\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql suspend or withdraw regulatory approval;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6579\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6156\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql suspend any ongoing clinical trials;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6156\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8790\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql refuse to approve a pending NDA or supplements to an NDA submitted by us;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8790\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5165\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql seize product; or\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5165\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8827\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql refuse to allow us to enter into supply contracts, including government contracts.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8827\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate\plain\cf10\f51\fs16\ql negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenues.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 18
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Even if we obtain FDA approval for ARX-01 in the United States, we may never obtain approval for or commercialize our products outside of the\plain\cf10\f51\fs16\b\i\ql United States, which would limit our ability to realize their full market potential.\par\pard\plain\sb88\cf10\f51\fs16\ql In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other\plain\cf10\f51\fs16\ql countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and\plain\cf10\f51\fs16\ql regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among\plain\cf10\f51\fs16\ql countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could\plain\cf10\f51\fs16\ql result in difficulties and costs for us and require additional non-clinical studies or clinical trials which could be costly and time consuming. Regulatory\plain\cf10\f51\fs16\ql requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any\plain\cf10\f51\fs16\ql product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval\plain\cf10\f51\fs16\ql in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if\plain\cf10\f51\fs16\ql regulatory approval in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our\plain\cf10\f51\fs16\ql products will be harmed.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql ARX-01 and our other product candidates will require Risk Evaluation and Mitigation Strategies.\par\pard\plain\sb88\cf10\f51\fs16\ql The FDA Amendments Act of 2007 implemented safety-related changes to product labeling and require the adoption of REMS. Our product candidates\plain\cf10\f51\fs16\ql will require REMS. The REMS may include requirements for special labeling or medication guides for patients, special communication plans to health\plain\cf10\f51\fs16\ql care professionals and restrictions on distribution and use. While we have received information from the FDA regarding certain aspects of the required\plain\cf10\f51\fs16\ql REMS for ARX-01, we cannot predict the specific REMS to be required as part of the FDA\u8217?s approval of ARX-01. Depending on the extent of\plain\cf10\f51\fs16\ql the REMS requirements, our costs to commercialize ARX-01 may increase significantly. ARX-02 and ARX-03, if approved, will also require REMS\plain\cf10\f51\fs16\ql programs that may increase our costs to commercialize these product candidates. Furthermore, risks of sufentanil that are not adequately addressed through\plain\cf10\f51\fs16\ql proposed REMS for our product candidates may also prevent or delay their approval for commercialization.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Our Reliance on Third Parties\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql We rely on third party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce\plain\cf10\f51\fs16\b\i\ql commercial supplies of any approved product candidates.\par\pard\plain\sb88\cf10\f51\fs16\ql Reliance on third party manufacturers entails risks to which we would not be subject if we manufactured the pharmaceutical, device and drug cartridge\plain\cf10\f51\fs16\ql aspects of our product candidates ourselves, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9113\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the inability to meet our product specifications and quality requirements consistently;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9113\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8641\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql a delay or inability to procure or expand sufficient manufacturing capacity;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8641\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8858\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql manufacturing and product quality issues related to scale-up of manufacturing;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8858\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8420\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql costs and validation of new equipment and facilities required for scale-up;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8420\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7712\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql a failure to comply with cGMP and similar foreign standards;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7712\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10353\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10353\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 19
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to\plain\intbl\cf10\f51\fs16\ql secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely\plain\intbl\cf10\f51\fs16\ql fashion, in sufficient quantities or under acceptable terms;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql operations of our third party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations,\plain\intbl\cf10\f51\fs16\ql including the bankruptcy of the manufacturer or supplier;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8176\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql carrier disruptions or increased costs that are beyond our control; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8176\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9431\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the failure to deliver our products under specified storage conditions and in a timely manner.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9431\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Any of these events could lead to clinical study delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our\plain\cf10\f51\fs16\ql products. Some of these events could be the basis for FDA action, including injunction, recall, seizure, or total or partial suspension of production.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We rely on limited sources of supply for the drug component of our product candidates and any disruption in the chain of supply may cause delay in\plain\cf10\f51\fs16\b\i\ql developing and commercializing our product candidates.\par\pard\plain\sb88\cf10\f51\fs16\ql Currently we use two established suppliers of sufentanil citrate for our NanoTabs, Covidien plc and Johnson Matthey plc. For each product candidate,\plain\cf10\f51\fs16\ql only one of the two suppliers will be qualified as a vendor with the FDA. If supply from the approved vendor is interrupted, there could be a significant\plain\cf10\f51\fs16\ql disruption in commercial supply. The alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The\plain\cf10\f51\fs16\ql FDA or other regulatory agencies outside of the United States may also require additional studies if a new sufentanil supplier is relied upon for\plain\cf10\f51\fs16\ql commercial production. In addition, the Drug Enforcement Administration, or the DEA, may reduce, delay or refuse our quota for sufentanil, which would\plain\cf10\f51\fs16\ql disrupt our supply of sufentanil citrate and cause delay in the development and commercialization of our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\ql Currently, we use one supplier of triazolam for our ARX-03 NanoTabs. Switching triazolam suppliers may involve substantial cost and is a likely to\plain\cf10\f51\fs16\ql result in a delay in our desired clinical and commercial timelines.\par\pard\plain\sb198\cf10\f51\fs16\ql These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us\plain\cf10\f51\fs16\ql to incur higher costs and prevent us from commercializing them successfully. Furthermore, if our suppliers fail to deliver the required commercial\plain\cf10\f51\fs16\ql quantities of active pharmaceutical ingredient on a timely basis and at commercially reasonable prices, and we are unable to secure one or more\plain\cf10\f51\fs16\ql replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Manufacture of sufentanil NanoTabs requires specialized equipment and expertise.\par\pard\plain\sb88\cf10\f51\fs16\ql Ethanol, which is used in the manufacturing process, is flammable, which necessitates the use of specialized equipment and facilities for manufacture of\plain\cf10\f51\fs16\ql sufentanil NanoTabs. There are a limited number of facilities that can accommodate our manufacturing process and we need to use dedicated equipment\plain\cf10\f51\fs16\ql throughout development and commercial manufacturing to avoid the possibility of cross-contamination. If our equipment breaks down or needs to be\plain\cf10\f51\fs16\ql repaired or replaced, it may cause significant disruption in clinical or commercial supply, which could result in delay in the process of obtaining approval\plain\cf10\f51\fs16\ql for or sale of our products. Furthermore, we are using one facility to manufacture our sufentanil NanoTabs and have not identified a back up facility to\plain\cf10\f51\fs16\ql date. Any problems with our existing facility or equipment may delay or impair our ability to complete our clinical trials or commercialize our product\plain\cf10\f51\fs16\ql candidates and increase our cost.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 20
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.\par\pard\plain\sb88\cf10\f51\fs16\ql As we scale up manufacturing of our product candidates and conduct required stability testing, product, packaging, equipment and process-related issues\plain\cf10\f51\fs16\ql may require refinement or resolution in order to proceed with our planned clinical trials and obtain regulatory approval for commercial marketing. In the\plain\cf10\f51\fs16\ql past we have identified impurities in the drug substance or excipients that comprise the sufentanil or sufentanil/triazolam NanoTab products. In the future\plain\cf10\f51\fs16\ql we may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical program and regulatory\plain\cf10\f51\fs16\ql approval, increases in our operating expenses, or failure to obtain or maintain approval for our products.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Our designs for the device components of our product candidates for Phase 3 clinical trials may not be fully functional or commercially viable.\par\pard\plain\sb88\cf10\f51\fs16\ql The ARX-01 device we plan to use in Phase 3 clinical trials and commercially, or Phase 3 device, has more features than the device used in Phase 2,\plain\cf10\f51\fs16\ql including additional software and functionality. Although we have conducted multiple human factor and usability studies, the design of the ARX-01 Phase\plain\cf10\f51\fs16\ql 3 device is still under development. We plan to complete an additional user testing study prior to release of the device for Phase 3 clinical trials.\plain\cf10\f51\fs16\ql However, we cannot predict if the Phase 3 device will be fully functional or acceptable for commercial use. If we need to modify the Phase 3 device after\plain\cf10\f51\fs16\ql the completion of the Phase 3 studies, we may incur higher costs and experience delay in regulatory approval and commercialization of ARX-01.\plain\cf10\f51\fs16\ql Furthermore, if the changes to the device are substantial, we may need to conduct further clinical studies in order to have the commercial device approved\plain\cf10\f51\fs16\ql by the FDA.\par\pard\plain\sb198\cf10\f51\fs16\ql The dispensing components of ARX-02 and ARX-03 are still under development. We cannot be certain that the dispensing components of ARX-02 and\plain\cf10\f51\fs16\ql ARX-03 will be fully functional or acceptable for commercial use or that we will be able to effectively scale up the manufacturing process. Failure to do\plain\cf10\f51\fs16\ql so may delay or prevent regulatory approval or commercialization of ARX-02 and ARX-03.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We have no experience manufacturing the ARX-01 Phase 3 device on a clinical or commercial scale and do not own or operate a manufacturing\plain\cf10\f51\fs16\b\i\ql facility.\par\pard\plain\sb88\cf10\f51\fs16\ql We have relied on contract manufacturers, component fabricators and secondary service providers to produce ARX-01 devices for Phase 2 clinical trials.\plain\cf10\f51\fs16\ql We currently outsource manufacturing and packaging of the controller, dispenser and cartridge components of the ARX-01 device to third parties and\plain\cf10\f51\fs16\ql intend to continue to do so. We may encounter unanticipated problems in the scale-up and automation process that will result in delays in the\plain\cf10\f51\fs16\ql manufacturing of the ARX-01 cartridge, dispenser or controller.\par\pard\plain\sb198\cf10\f51\fs16\ql We do not currently have any agreements with third party manufacturers for the manufacture of the Phase 3 device. We may not be able to enter into\plain\cf10\f51\fs16\ql agreements for commercial supply of ARX-01 with third party manufacturers, or may be unable to do so on acceptable terms.\par\pard\plain\sb198\cf10\f51\fs16\ql We may not be able to establish additional sources of supply for device manufacture. Such suppliers are subject to FDA regulations requiring that\plain\cf10\f51\fs16\ql materials be produced under cGMPs, or Quality System Regulations, or QSR, and subject to ongoing inspections by regulatory agencies. Failure by any of\plain\cf10\f51\fs16\ql our suppliers to comply with applicable regulations may result in delays and interruptions to our product candidate supply while we seek to secure another\plain\cf10\f51\fs16\ql supplier that meets all regulatory requirements.\par\pard\plain\sb198\cf10\f51\fs16\ql Reliance on third party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including the\plain\cf10\f51\fs16\ql possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and the possibility of termination or\plain\cf10\f51\fs16\ql nonrenewal of the agreements by the third parties because of our breach of the manufacturing agreement or based on their own business priorities.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 21
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may\plain\cf10\f51\fs16\b\i\ql harm our business.\par\pard\plain\sb88\cf10\f51\fs16\ql We rely on clinical research organizations, or CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have\plain\cf10\f51\fs16\ql agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CROs to\plain\cf10\f51\fs16\ql monitor and manage data for our ongoing clinical programs for ARX-01 and our other product candidates, as well as the execution of nonclinical studies.\plain\cf10\f51\fs16\ql We control only certain aspects of our CROs\u8217? activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in\plain\cf10\f51\fs16\ql accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory\plain\cf10\f51\fs16\ql responsibilities.\par\pard\plain\sb198\cf10\f51\fs16\ql Since our drug products are controlled substances, all of our contract manufacturing organizations, or CMOs, and CROs must follow proper DEA rules\plain\cf10\f51\fs16\ql and procedures or comparable rules and procedures in other countries. Failure to properly follow these rules and procedures could results in DEA action,\plain\cf10\f51\fs16\ql up to and including losing their license to work with controlled substances. This would result in a major delay in our clinical studies and/or NDA\plain\cf10\f51\fs16\ql submission.\par\pard\plain\sb198\cf10\f51\fs16\ql We and our CROs are required to comply with the FDA\u8217?s current good clinical practices, or cGCPs, which are regulations and guidelines enforced\plain\cf10\f51\fs16\ql by the FDA for all of our product candidates in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors,\plain\cf10\f51\fs16\ql principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials\plain\cf10\f51\fs16\ql may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. Upon inspection,\plain\cf10\f51\fs16\ql the FDA may determine that our Phase 3 clinical trials do not comply with cGCPs. In addition, our Phase 3 clinical trials will require a sufficiently large\plain\cf10\f51\fs16\ql number of test subjects to evaluate the safety and effectiveness of ARX-01. Accordingly, if our CROs fail to comply with these regulations or fail to\plain\cf10\f51\fs16\ql recruit a sufficient number of patients, we may be required to repeat the Phase 3 clinical trials, which would delay the regulatory approval process.\par\pard\plain\sb198\cf10\f51\fs16\ql Our CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical\plain\cf10\f51\fs16\ql programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting\plain\cf10\f51\fs16\ql clinical studies, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or\plain\cf10\f51\fs16\ql misappropriation of our intellectual property by CROs, which may allow our potential competitors to access our proprietary technology. If our CROs do\plain\cf10\f51\fs16\ql not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they\plain\cf10\f51\fs16\ql obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be\plain\cf10\f51\fs16\ql extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize ARX-01, or our other product\plain\cf10\f51\fs16\ql candidates. As a result, our financial results and the commercial prospects for ARX-01 and any future product candidates that we develop would be\plain\cf10\f51\fs16\ql harmed, our costs could increase, and our ability to generate revenues could be delayed.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Commercialization of Our Product Candidates\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql The commercial success of ARX-01 and our other product candidates will depend upon the acceptance of these products by the medical community,\plain\cf10\f51\fs16\b\i\ql including physicians, patients and health care payors.\par\pard\plain\sb88\cf10\f51\fs16\ql The degree of market acceptance of any of our product candidates will depend on a number of factors, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8457\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql demonstration of clinical safety and efficacy compared to other products;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8457\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10524\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the relative convenience, ease of administration and acceptance by physicians, patients and health care payors;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10524\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 22
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6569\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the prevalence and severity of any AEs;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6569\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9437\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql overcoming the perception of sufentanil as a potentially unsafe drug due to its high potency;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9437\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8694\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql limitations or warnings contained in the FDA-approved label for ARX-01;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8694\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6345\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql availability of alternative treatments;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6345\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6431\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql pricing and cost-effectiveness;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6431\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9736\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the effectiveness of our or any future collaborators\u8217? sales and marketing strategies;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9736\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6987\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to obtain hospital formulary approval;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6987\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9374\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to obtain and maintain sufficient third party coverage or reimbursement; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9374\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9346\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the willingness of patients to pay out-of-pocket in the absence of third party coverage.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9346\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql If ARX-01 is approved, but does not achieve an adequate level of acceptance by physicians, patients and health care payors, we may not generate\plain\cf10\f51\fs16\ql sufficient revenue from ARX-01 and we may not become or remain profitable.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we\plain\cf10\f51\fs16\b\i\ql may be unable to generate any revenue.\par\pard\plain\sb88\cf10\f51\fs16\ql We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining\plain\cf10\f51\fs16\ql such an organization may exceed the cost- effectiveness of doing so. In order to market any products that may be approved, we must build our sales,\plain\cf10\f51\fs16\ql marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We intend to enter into\plain\cf10\f51\fs16\ql strategic partnerships with third parties to commercialize our product candidates outside of the United States. We will also consider the option to enter\plain\cf10\f51\fs16\ql into strategic partnerships for our product candidates in the United States.\par\pard\plain\sb198\cf10\f51\fs16\ql To date, we have not entered into any strategic partnerships for any of our product candidates. We face significant competition in seeking appropriate\plain\cf10\f51\fs16\ql strategic partners, and these strategic partnerships can be intricate and time consuming to negotiate and document. We may not be able to negotiate\plain\cf10\f51\fs16\ql strategic partnerships on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any strategic partnerships because of the\plain\cf10\f51\fs16\ql numerous risks and uncertainties associated with establishing strategic partnerships. Our strategy for ARX-01 is to develop a hospital-directed sales force\plain\cf10\f51\fs16\ql and/or collaborate with third parties to promote the product to healthcare professionals and third party payors in the United States. Our future collaboration\plain\cf10\f51\fs16\ql partners, if any, may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization\plain\cf10\f51\fs16\ql due to factors beyond our control. If we are unable to establish effective collaborations to enable the sale of our product candidates to healthcare\plain\cf10\f51\fs16\ql professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential\plain\cf10\f51\fs16\ql future collaboration partners do not successfully commercialize our product candidates, our ability to generate revenues from product sales will be\plain\cf10\f51\fs16\ql adversely affected.\par\pard\plain\sb198\cf10\f51\fs16\ql If we are unable to negotiate a strategic partnership or obtain additional financial resources for ARX-02 or ARX-03, we may be forced to curtail the\plain\cf10\f51\fs16\ql development of ARX-02 or ARX-03, delay potential commercialization, reduce the scope of our sales or marketing activities or undertake development\plain\cf10\f51\fs16\ql or commercialization activities at our own expense. In addition, without a partnership, we will bear all the risk related to the development of ARX-02 or\plain\cf10\f51\fs16\ql ARX-03. If we elect to increase our expenditures to fund development or commercialization activities ourselves, we will need to obtain additional capital,\plain\cf10\f51\fs16\ql which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring ARX-02 or ARX-03 to\plain\cf10\f51\fs16\ql market or generate product revenue.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 23
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to\plain\cf10\f51\fs16\ql generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and\plain\cf10\f51\fs16\ql well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be\plain\cf10\f51\fs16\ql unable to compete successfully against these more established companies.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql If we obtain approval to commercialize our products outside of the United States, a variety of risks associated with international operations could\plain\cf10\f51\fs16\b\i\ql materially adversely affect our business.\par\pard\plain\sb88\cf10\f51\fs16\ql If our product candidates are approved for commercialization, we intend to enter into agreements with third parties to market ARX-01 outside the United\plain\cf10\f51\fs16\ql States. We expect that we will be subject to additional risks related to entering into international business relationships, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8407\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql different regulatory requirements for drug approvals in foreign countries;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8407\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7064\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql reduced protection for intellectual property rights;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7064\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8445\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql unexpected changes in tariffs, trade barriers and regulatory requirements;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8445\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10145\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql economic weakness, including inflation, or political instability in particular foreign economies and markets;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10145\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10127\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10127\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7303\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql foreign taxes, including withholding of payroll taxes;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7303\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident\plain\intbl\cf10\f51\fs16\ql to doing business in another country;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9691\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql workforce uncertainty in countries where labor unrest is more common than in the United States;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9691\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes,\plain\intbl\cf10\f51\fs16\ql typhoons, floods and fires.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\b\i\ql If we are unable to compete effectively, our product candidates may not reach their commercial potential.\par\pard\plain\sb88\cf10\f51\fs16\ql The market for our product candidates is characterized by intense competition and rapid technological advances. If our product candidates obtain FDA\plain\cf10\f51\fs16\ql approval, they will compete with a number of existing and future pharmaceuticals and drug delivery devices developed, manufactured and marketed by\plain\cf10\f51\fs16\ql others. We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical\plain\cf10\f51\fs16\ql companies, academic institutions, government agencies and other public and private research organizations.\par\pard\plain\sb198\cf10\f51\fs16\ql The primary competition for ARX-01 is the IV PCA pump, which is widely used in the post-operative setting. Leading manufacturers of IV PCA pumps\plain\cf10\f51\fs16\ql include Hospira Inc., CareFusion Corporation, Baxter International Inc., Curlin Medical, Inc. and Smiths Medical. The most common opioids used to treat\plain\cf10\f51\fs16\ql post-operative pain are morphine, hydromorphone and fentanyl, all of which are available as generics. Also available on the market is the Avancen\plain\cf10\f51\fs16\ql Medication on Demand, or MOD, Oral PCA Device developed by Avancen MOD Corporation.\par\pard\plain\sb198\cf10\f51\fs16\ql Additional potential competitors for ARX-01 include products in development, including the fentanyl iontophoretic transdermal system, IONSYS,\plain\cf10\f51\fs16\ql originally developed by ALZA Corporation and Ortho-\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 24
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql McNeil Pharmaceutical, Inc., both Johnson\~& Johnson subsidiaries, and currently under development by Incline Therapeutics, Inc.; and Rylomine, an\plain\cf10\f51\fs16\ql intranasal morphine product developed by Javelin Pharmaceuticals, Inc.\par\pard\plain\sb198\cf10\f51\fs16\ql Our potential competitors for ARX-02 include products approved in the United States for cancer breakthrough pain, including: ACTIQ and FENTORA,\plain\cf10\f51\fs16\ql currently manufactured by Cephalon Inc.; Onsolis, currently manufactured by BioDelivery Sciences International, Inc.; and Abstral, currently manufactured\plain\cf10\f51\fs16\ql by ProStrakan Group plc; as well as products approved in Europe, including: Instanyl, currently manufactured by Nycomed International Management\plain\cf10\f51\fs16\ql GmbH. The active ingredient in all approved products for cancer breakthrough pain is fentanyl. Additional potential competitors for ARX-02 include\plain\cf10\f51\fs16\ql products in late stage development for cancer breakthrough pain, such as PecFent, currently manufactured by Archimedes Pharma Limited; Fentanyl\plain\cf10\f51\fs16\ql TAIFUN, currently manufactured by Akela Pharma, Inc. and SL Spray, currently manufactured by Insys Therapeutics, Inc.\par\pard\plain\sb198\cf10\f51\fs16\ql It is possible that any of these competitors could develop or improve technologies or products that would render our product candidates obsolete or\plain\cf10\f51\fs16\ql non-competitive, which could adversely affect our revenue potential. Key competitive factors affecting the commercial success of our product candidates\plain\cf10\f51\fs16\ql are likely to be efficacy, safety profile, reliability, convenience of dosing, price and reimbursement.\par\pard\plain\sb198\cf10\f51\fs16\ql Many of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in\plain\cf10\f51\fs16\ql the discovery and development of drug candidates, obtaining FDA and other regulatory approval of products and the commercialization of those products.\plain\cf10\f51\fs16\ql Accordingly, our competitors may be more successful than we are in obtaining FDA approval for drugs and achieving widespread market acceptance. Our\plain\cf10\f51\fs16\ql competitors\u8217? drugs or drug delivery systems may be more effective, have fewer adverse effects, be less expensive to develop and manufacture, or\plain\cf10\f51\fs16\ql be more effectively marketed and sold than any product candidate we may commercialize. This may render our product candidates obsolete or\plain\cf10\f51\fs16\ql non-competitive before we can recover our loses. We anticipate that we will face intense and increasing competition as new drugs enter the market and\plain\cf10\f51\fs16\ql additional technologies become available. These entities may also establish collaborative or licensing relationships with our competitors, which may\plain\cf10\f51\fs16\ql adversely affect our competitive position. Finally, the development of different methods for the treatment of post-operative pain or breakthrough pain\plain\cf10\f51\fs16\ql could render ARX-01 and ARX-02, respectively, non-competitive or obsolete. These and other risks may materially adversely affect our ability to attain\plain\cf10\f51\fs16\ql or sustain profitable operations.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Hospital formulary approval and reimbursement may not be available for ARX-01 and our other product candidates, which could make it difficult for\plain\cf10\f51\fs16\b\i\ql us to sell our products profitably.\par\pard\plain\sb88\cf10\f51\fs16\ql Obtaining formulary approval can be an expensive and time consuming process. We cannot be certain if and when we will obtain formulary approval to\plain\cf10\f51\fs16\ql allow us to sell our products into our target markets. Failure to obtain timely formulary approval will limit our commercial success.\par\pard\plain\sb198\cf10\f51\fs16\ql Furthermore, market acceptance and sales of ARX-01, or any future product candidates that we develop, will depend on reimbursement policies and may\plain\cf10\f51\fs16\ql be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, hospitals and health\plain\cf10\f51\fs16\ql maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that reimbursement will be\plain\cf10\f51\fs16\ql available for ARX-01, or any future product candidates. Also, reimbursement amounts may reduce the demand for, or the price of, our products. If\plain\cf10\f51\fs16\ql reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize ARX-01, or any future product\plain\cf10\f51\fs16\ql candidates that we develop.\par\pard\plain\sb198\cf10\f51\fs16\ql There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions\plain\cf10\f51\fs16\ql that could affect our ability to sell our products\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 25
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for our products, following approval. The availability of\plain\cf10\f51\fs16\ql numerous generic pain medications may also substantially reduce the likelihood of reimbursement for ARX-01. The potential application of user fees to\plain\cf10\f51\fs16\ql generic drug products may expedite the approval of additional pain medication generic drugs. We expect to experience pricing pressures in connection\plain\cf10\f51\fs16\ql with the sale of ARX-01 and any other products that we develop, due to the trend toward managed healthcare, the increasing influence of health\plain\cf10\f51\fs16\ql maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our products or\plain\cf10\f51\fs16\ql are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our business will be harmed.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Our Business Operations and Industry\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql Failure to comply with the Drug Enforcement Administration regulations, or the cost of compliance with these regulations, may adversely affect our\plain\cf10\f51\fs16\b\i\ql business.\par\pard\plain\sb88\cf10\f51\fs16\ql Our sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Sufentanil is a Schedule II opioid,\plain\cf10\f51\fs16\ql considered to present the highest risk of abuse. The manufacture, shipment, storage, sale and use of controlled substances are subject to a high degree of\plain\cf10\f51\fs16\ql regulation, including security, record-keeping and reporting obligations enforced by the DEA. This high degree of regulation can result in significant costs\plain\cf10\f51\fs16\ql in order to comply with the required regulations, which may have an adverse effect on the development and commercialization of our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\ql The DEA limits the availability and production of all Schedule\~II substances, including sufentanil, through a quota system. The DEA requires substantial\plain\cf10\f51\fs16\ql evidence and documentation of expected legitimate medical and scientific needs before assigning quotas to manufacturers. At present, our contract\plain\cf10\f51\fs16\ql manufacturers have applied for a quota on our behalf which allocates a sufficient quantity of sufentanil to meet our planned clinical and pre-clinical needs\plain\cf10\f51\fs16\ql during 2011. In future years, we may need greater amounts of sufentanil to sustain and complete our Phase 3 development program for ARX-01, and we\plain\cf10\f51\fs16\ql will need significantly greater amounts of sufentanil to implement our commercialization plans if the FDA approves ARX-01. Any delay or refusal by the\plain\cf10\f51\fs16\ql DEA in establishing the procurement quota or a reduction in our quota for sufentanil or a failure to increase it over time as we anticipate could delay or\plain\cf10\f51\fs16\ql stop the clinical development or commercial sale of ARX-01. This could have a material adverse effect on our business, results of operations, financial\plain\cf10\f51\fs16\ql condition and prospects.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition, we purchase sufentanil in the United States and ship it to our third party manufacturer, Patheon Inc. in Toronto, Canada, where much of our\plain\cf10\f51\fs16\ql clinical trial manufacturing has been completed to date. Shipping across international borders is a bureaucratic process that takes a minimum of three\plain\cf10\f51\fs16\ql months and requires permits to export drug out of the United States and import NanoTabs into the United States. If we fail to comply with applicable\plain\cf10\f51\fs16\ql regulatory requirements or fail to submit permit applications in a timely manner, the government could refuse to permit sufentanil to be exported from or\plain\cf10\f51\fs16\ql imported into the United States. Our failure to comply with these requirements could result in increased costs, delayed shipments, the loss of DEA\plain\cf10\f51\fs16\ql registration for one of our suppliers, significant restrictions on ARX-01, civil penalties or criminal prosecution and delays in conducting our clinical trials.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Drug Enforcement Administration regulations require that sufentanil be manufactured in the United States if sufentanil-based products are to be\plain\cf10\f51\fs16\b\i\ql marketed in the United States, and there is no guarantee that we will secure a commercial supply agreement with a manufacturer based in the United\plain\cf10\f51\fs16\b\i\ql States.\par\pard\plain\sb88\cf10\f51\fs16\ql A substantial portion of our clinical trial manufacturing to date has been completed at Patheon Inc. in Toronto, Canada. However, we cannot rely on the\plain\cf10\f51\fs16\ql Patheon facility located in Toronto for commercial manufacturing of sufentanil because the DEA requires that sufentanil be manufactured in the United\plain\cf10\f51\fs16\ql States if our product candidates are marketed in the United States.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 26
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql We have identified potential commercial manufacturers for ARX-01 in the United States. However, we do not yet have a commercial supply contract in\plain\cf10\f51\fs16\ql place. If we cannot establish a supply contract on commercially reasonable terms, or if facility modifications, equipment manufacture or modification do\plain\cf10\f51\fs16\ql not meet expected deadlines, we may not be able to successfully commercialize our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\ql Switching or adding commercial manufacturing capability can involve substantial cost and require extensive management time and focus, as well as\plain\cf10\f51\fs16\ql additional regulatory filings. In addition, there is a natural transition period when a new manufacturing facility commences work. As a result, delays may\plain\cf10\f51\fs16\ql occur, which can materially impact our ability to meet our desired commercial timelines, thereby increasing our costs and reducing our ability to generate\plain\cf10\f51\fs16\ql revenue.\par\pard\plain\sb198\cf10\f51\fs16\ql The facilities of any of our future manufacturers of sufentanil-containing NanoTabs must be approved by the FDA after we submit our NDA and before\plain\cf10\f51\fs16\ql approval of ARX-01 and our other product candidates. We do not control the manufacturing process of sufentanil NanoTabs and are completely\plain\cf10\f51\fs16\ql dependent on these third party manufacturing partners for compliance with the FDA\u8217?s requirements for manufacture. In addition, although our third\plain\cf10\f51\fs16\ql party manufacturers are well established commercial manufacturers, we are dependent on their continued adherence to cGMP manufacturing and\plain\cf10\f51\fs16\ql acceptable changes to their process. If our manufacturers cannot successfully produce material that conforms to our specifications and the FDA\u8217?s\plain\cf10\f51\fs16\ql strict regulatory requirements, they will not be able to secure FDA approval for their manufacturing facilities. If the FDA does not approve these facilities\plain\cf10\f51\fs16\ql for the commercial manufacture of sufentanil NanoTabs, we will need to find alternative suppliers, which would result in significant delays in obtaining\plain\cf10\f51\fs16\ql FDA approval for ARX-01. These challenges may have a material adverse impact on our business, results of operations, financial condition and prospects.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Business interruptions could delay us in the process of developing our products and could disrupt our sales.\par\pard\plain\sb88\cf10\f51\fs16\ql Our headquarters is located in the San Francisco Bay Area, near known earthquake fault zones and is vulnerable to significant damage from earthquakes.\plain\cf10\f51\fs16\ql We are also vulnerable to other types of natural disasters and other events that could disrupt our operations. We do not carry insurance for earthquakes or\plain\cf10\f51\fs16\ql other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages\plain\cf10\f51\fs16\ql we incur could have a material adverse effect on our business operations.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.\par\pard\plain\sb88\cf10\f51\fs16\ql We are highly dependent on principal members of our executive team listed under \u8220?Management\u8221? on page 99 of this prospectus, the loss of\plain\cf10\f51\fs16\ql whose services may adversely impact the achievement of our objectives. While we have entered into offer letters with each of our executive officers, any\plain\cf10\f51\fs16\ql of them could leave our employment at any time, as all of our employees are \u8220?at will\u8221? employees. Recruiting and retaining other qualified\plain\cf10\f51\fs16\ql employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled\plain\cf10\f51\fs16\ql executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may\plain\cf10\f51\fs16\ql not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with\plain\cf10\f51\fs16\ql similar skill sets. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to\plain\cf10\f51\fs16\ql recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization\plain\cf10\f51\fs16\ql objectives.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.\par\pard\plain\sb88\cf10\f51\fs16\ql As of December\~31, 2010, we had 19 full-time employees. As our company matures, we expect to expand our employee base to increase our managerial,\plain\cf10\f51\fs16\ql scientific and engineering, operational, sales,\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 27
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql marketing, financial and other resources and to hire more consultants and contractors. Future growth would impose significant additional responsibilities\plain\cf10\f51\fs16\ql on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our\plain\cf10\f51\fs16\ql management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to\plain\cf10\f51\fs16\ql managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our\plain\cf10\f51\fs16\ql infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.\plain\cf10\f51\fs16\ql Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of\plain\cf10\f51\fs16\ql additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability\plain\cf10\f51\fs16\ql to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our\plain\cf10\f51\fs16\ql ability to commercialize ARX-01 and our other product candidates and compete effectively will depend, in part, on our ability to effectively manage any\plain\cf10\f51\fs16\ql future growth.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.\par\pard\plain\sb88\cf10\f51\fs16\ql The use of our product candidates in clinical studies and the sale of any products for which we obtain marketing approval exposes us to the risk of\plain\cf10\f51\fs16\ql product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others\plain\cf10\f51\fs16\ql selling or otherwise coming into contact with our products. If we cannot successfully defend against product liability claims, we could incur substantial\plain\cf10\f51\fs16\ql liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6455\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql impairment of our business reputation;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6455\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6642\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql withdrawal of clinical study participants;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6642\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5941\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql costs due to related litigation;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5941\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8798\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql distraction of management\u8217?s attention from our primary business;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8798\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7520\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql substantial monetary awards to patients or other claimants;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7520\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7722\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the inability to commercialize our product candidates;\~and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7722\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8703\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql decreased demand for our product candidates, if approved for commercial sale.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8703\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance\plain\cf10\f51\fs16\ql coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient\plain\cf10\f51\fs16\ql amounts to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we intend to expand our\plain\cf10\f51\fs16\ql insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially\plain\cf10\f51\fs16\ql reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated\plain\cf10\f51\fs16\ql adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed\plain\cf10\f51\fs16\ql our insurance coverage, could adversely affect our results of operations and business.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 28
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to Our Intellectual Property\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql We have numerous pending patent applications in the United States, but no issued patents. Our only patent, which is issued in Europe, is currently in\plain\cf10\f51\fs16\b\i\ql the opposition period. If our pending patent applications fail to issue or if our issued European patent is successfully opposed, our business will be\plain\cf10\f51\fs16\b\i\ql adversely affected.\par\pard\plain\sb88\cf10\f51\fs16\ql Our commercial success will depend in part on obtaining and maintaining patent protection for our product candidates, as well as successfully defending\plain\cf10\f51\fs16\ql our current and future patents against third party challenges. To protect our proprietary technology, we rely on patents as well as other intellectual\plain\cf10\f51\fs16\ql property protections, including trade secrets, nondisclosure agreements and confidentiality provisions.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition, there can be no assurance that our pending patent applications will result in issued patents. As of December\~31, 2010, we are the owner of\plain\cf10\f51\fs16\ql record and are pursuing 15 U.S. non-provisional patent applications, three pending international Patent Cooperation Treaty applications and 39 foreign\plain\cf10\f51\fs16\ql national and ten European regional counterpart patent applications directed to our product candidates. The patent applications that we have filed and have\plain\cf10\f51\fs16\ql not yet been granted may fail to result in issued patents in the United States or in foreign countries. Even if the patents do successfully issue, third parties\plain\cf10\f51\fs16\ql may challenge the patents.\par\pard\plain\sb198\cf10\f51\fs16\ql Our European patent, though granted, may be opposed by third parties during a nine-month opposition period that ends on April\~21, 2011. If a third party\plain\cf10\f51\fs16\ql opposes our European patent, we will need to spend considerable time and resources to defend our granted patent claims. European opposition proceedings\plain\cf10\f51\fs16\ql may fail and, even if successful, may result in substantial costs and distract our management.\par\pard\plain\sb198\cf10\f51\fs16\ql The patent positions of pharmaceutical companies, including us, can be highly uncertain and involve complex and evolving legal and factual questions. No\plain\cf10\f51\fs16\ql consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States. Legal developments may\plain\cf10\f51\fs16\ql preclude or limit the scope of available patent protection.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Litigation involving patents, patent applications and other proprietary rights is expensive and time consuming. If we are involved in such litigation, it\plain\cf10\f51\fs16\b\i\ql could cause delays in bringing our product candidates to market and interfere with our business.\par\pard\plain\sb88\cf10\f51\fs16\ql Our commercial success depends in part on not infringing patents and proprietary rights of third parties. Although we are not currently aware of litigation\plain\cf10\f51\fs16\ql or other proceedings or third party claims of intellectual property infringement related to our product candidates, the pharmaceutical industry is\plain\cf10\f51\fs16\ql characterized by extensive litigation regarding patents and other intellectual property rights.\par\pard\plain\sb198\cf10\f51\fs16\ql As we enter our markets, it is possible that competitors or other third parties will claim that our products and/or processes infringe their intellectual\plain\cf10\f51\fs16\ql property rights. These third parties may have obtained and may in the future obtain patents covering products or processes that are similar to, or may\plain\cf10\f51\fs16\ql include compositions or methods that encompass our technology, allowing them to claim that the use of our technologies infringes these patents.\par\pard\plain\sb198\cf10\f51\fs16\ql In a patent infringement claim against us, we may assert, as a defense, that we do not infringe the relevant patent claims, that the patent is invalid or\plain\cf10\f51\fs16\ql both. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents.\plain\cf10\f51\fs16\ql However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense. In the United States, issued patents enjoy a\plain\cf10\f51\fs16\ql presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high\plain\cf10\f51\fs16\ql burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 29
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql If we were found by a court to have infringed a valid patent claim, we could be prevented from using the patented technology or be required to pay the\plain\cf10\f51\fs16\ql owner of the patent for the right to license the patented technology. If we decide to pursue a license to one or more of these patents, we may not be able\plain\cf10\f51\fs16\ql to obtain a license on commercially reasonable terms, if at all, or the license we obtain may require us to pay substantial royalties or grant cross licenses\plain\cf10\f51\fs16\ql to our patent rights. For example, if the relevant patent is owned by a competitor, that competitor may choose not to license patent rights to us. If we\plain\cf10\f51\fs16\ql decide to develop alternative technology, we may not be able to do so in a timely or cost-effective manner, if at all.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition, because patent applications can take years to issue and are often afforded confidentiality for some period of time there may currently be\plain\cf10\f51\fs16\ql pending applications, unknown to us, that later result in issued patents that could cover one or more of our products.\par\pard\plain\sb198\cf10\f51\fs16\ql It is possible that we may in the future receive, particularly as a public company, communications from competitors and other companies alleging that we\plain\cf10\f51\fs16\ql may be infringing their patents, trade secrets or other intellectual property rights, offering licenses to such intellectual property or threatening litigation. In\plain\cf10\f51\fs16\ql addition to patent infringement claims, third parties may assert copyright, trademark or other proprietary rights against us. We may need to expend\plain\cf10\f51\fs16\ql considerable resources to counter such claims and may not be able to successful in our defense. Our business may suffer if a finding of infringement is\plain\cf10\f51\fs16\ql established.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.\par\pard\plain\sb88\cf10\f51\fs16\ql The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal\plain\cf10\f51\fs16\ql principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United\plain\cf10\f51\fs16\ql States. The pharmaceutical patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of\plain\cf10\f51\fs16\ql patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of\plain\cf10\f51\fs16\ql claims that may be allowed or enforced in the patents that may be issued from the applications we currently or may in the future own or license from\plain\cf10\f51\fs16\ql third parties. Further, if any patents license we obtain is deemed invalid and/or unenforceable, it could impact our ability to commercialize or partner our\plain\cf10\f51\fs16\ql technology.\par\pard\plain\sb198\cf10\f51\fs16\ql The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9565\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql we were the first to make the inventions covered by each of our pending patent applications;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9565\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7947\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql we were the first to file patent applications for these inventions;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7947\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10476\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql others will not independently develop similar or alternative technologies or duplicate any of our technologies;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10476\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any\plain\intbl\cf10\f51\fs16\ql competitive advantages or will not be challenged by third parties; or\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8083\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the patents of others will not have an adverse effect on our business.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8083\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql If we do not adequately protect our proprietary rights, competitors may be able to use our technologies and erode or negate any competitive advantage we\plain\cf10\f51\fs16\ql may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our product\plain\cf10\f51\fs16\ql candidates and delay or render impossible our achievement of profitability.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.\par\pard\plain\sb88\cf10\f51\fs16\ql We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is\plain\cf10\f51\fs16\ql appropriate or obtainable. However, trade secrets are\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 30
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers\plain\cf10\f51\fs16\ql and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential\plain\cf10\f51\fs16\ql information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may\plain\cf10\f51\fs16\ql independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine\plain\cf10\f51\fs16\ql the scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to\plain\cf10\f51\fs16\ql develop products that compete with our products or cause additional, material adverse effects upon our competitive business position.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the\plain\cf10\f51\fs16\b\i\ql United States Patent and Trademark Office and various foreign governmental patent agencies in several stages over the lifetime of the patents and/or\plain\cf10\f51\fs16\b\i\ql applications.\par\pard\plain\sb88\cf10\f51\fs16\ql We have systems in place to remind us to pay periodic maintenance fees, renewal fees, annuity fees and various other patent and application fees, and we\plain\cf10\f51\fs16\ql employ an outside firm, McDonnell Boehnen Hulbert Berghoff LLP, or MBHB, in Chicago, Illinois, to pay these fees. The United States Patent and\plain\cf10\f51\fs16\ql Trademark Office, or the USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee\plain\cf10\f51\fs16\ql payment and other similar provisions during the patent application process. We employ MBHB and other professionals to help us comply, and in many\plain\cf10\f51\fs16\ql cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations\plain\cf10\f51\fs16\ql in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the\plain\cf10\f51\fs16\ql relevant jurisdiction. If this occurs, our competitors might be able to enter the market, which would have a material adverse effect on our business.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We may not be able to enforce our intellectual property rights throughout the world.\par\pard\plain\sb88\cf10\f51\fs16\ql The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have\plain\cf10\f51\fs16\ql encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some\plain\cf10\f51\fs16\ql countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to\plain\cf10\f51\fs16\ql life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights.\plain\cf10\f51\fs16\ql For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many\plain\cf10\f51\fs16\ql countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may\plain\cf10\f51\fs16\ql provide limited or no benefit.\par\pard\plain\sb198\cf10\f51\fs16\ql Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of\plain\cf10\f51\fs16\ql our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and\plain\cf10\f51\fs16\ql legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the\plain\cf10\f51\fs16\ql enforcement of intellectual property.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.\par\pard\plain\sb88\cf10\f51\fs16\ql We have registered our ACELRX mark in Class 5, \u8220?Pharmaceutical preparations for treating pain; pharmaceutical preparations for treating\plain\cf10\f51\fs16\ql anxiety,\u8221? and Class 10, \u8220?Drug delivery systems; medical device, namely, a mechanical and electronic device used to administer medications,\plain\cf10\f51\fs16\ql perform timed medication delivery, and to provide secure access to and delivery of medications,\u8221? in the United States. Our ACELRX mark has also\plain\cf10\f51\fs16\ql been registered in the European Community and in Canada, and is pending in India. We\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 31
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql have\~filed a trademark application for our NANOTAB mark and our tagline, ACCELERATE, INNOVATE, ALLEVIATE in Class 5, in the United States.\plain\cf10\f51\fs16\ql Although we are not currently aware of any oppositions to or cancellations of our registered trademarks or pending applications, it is possible that one or\plain\cf10\f51\fs16\ql more of the applications could be subject to opposition or cancellation after the marks are registered.\~The registrations will be subject to use and\plain\cf10\f51\fs16\ql maintenance requirements.\~It is also possible that we have not yet registered all of our trademarks in all of our potential markets, and that there are names\plain\cf10\f51\fs16\ql or symbols\~other than \u8220?ACELRX\u8221? that may be protectable marks for which we have not sought registration, and failure to secure those\plain\cf10\f51\fs16\ql registrations could adversely affect our business.\~Opposition or cancellation proceedings may be filed against our trademarks and our trademarks may not\plain\cf10\f51\fs16\ql survive such proceedings.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Risks Related to this Offering and Ownership of Our Common Stock\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the initial public offering\plain\cf10\f51\fs16\b\i\ql price.\par\pard\plain\sb88\cf10\f51\fs16\ql Prior to this offering, there has not been a public market for our common stock. An active trading market for our common stock may not develop\plain\cf10\f51\fs16\ql following this offering. You may not be able to sell your shares quickly or at the market price if trading in our common stock is not active. The initial\plain\cf10\f51\fs16\ql public offering price for the shares will be determined by negotiations between us and representatives of the underwriters and may not be indicative of\plain\cf10\f51\fs16\ql prices that will prevail in the trading market.\par\pard\plain\sb198\cf10\f51\fs16\ql The trading price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors,\plain\cf10\f51\fs16\ql including the following:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6473\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql adverse results or delays in clinical trials;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6473\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql inability to obtain additional funding, including funding necessary to complete the third ARX-01 Phase 3 clinical trial required to file\plain\intbl\cf10\f51\fs16\ql our NDA;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql any delay in filing an NDA for any of our product candidates and any adverse development or perceived adverse development with\plain\intbl\cf10\f51\fs16\ql respect to the FDA\u8217?s review of that NDA;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8539\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql failure to successfully develop and commercialize our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8539\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7533\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql changes in laws or regulations applicable to our products;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7533\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10714\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10714\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5887\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql adverse regulatory decisions;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5887\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8479\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql introduction of new products, services or technologies by our competitors;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8479\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8320\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql failure to meet or exceed financial projections we provide to the public;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8320\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9076\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql failure to meet or exceed the estimates and projections of the investment community;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9076\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10795\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10795\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent\plain\intbl\cf10\f51\fs16\ql protection for our technologies;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8074\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql additions or departures of key scientific or management personnel;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8074\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7726\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql significant lawsuits, including patent or stockholder litigation;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7726\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7388\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql changes in the market valuations of similar companies;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7388\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 32
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8401\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql sales of our common stock by us or our stockholders in the future; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8401\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6332\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql trading volume of our common stock.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6332\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql In addition, the stock market in general, and the NASDAQ Global Market in particular, have experienced extreme price and volume fluctuations that have\plain\cf10\f51\fs16\ql often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the\plain\cf10\f51\fs16\ql market price of our common stock, regardless of our actual operating performance.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters\plain\cf10\f51\fs16\b\i\ql subject to stockholder approval.\par\pard\plain\sb88\cf10\f51\fs16\ql Our executive officers, directors, 5% stockholders and their affiliates beneficially own approximately 98% of our voting stock and, upon completion of\plain\cf10\f51\fs16\ql this offering, that same group will beneficially own approximately 57% of our outstanding voting stock, assuming such persons do not purchase any\plain\cf10\f51\fs16\ql shares of our common stock in this offering. However, certain of our current stockholders have indicated an interest in purchasing an aggregate of\plain\cf10\f51\fs16\ql $24.0\~million of shares of common stock in this offering at the expected initial public offering price of $5.00 per share. If such current stockholders\plain\cf10\f51\fs16\ql purchase $24.0\~million of shares of common stock in this offering, our executive officers, directors and stockholders who beneficially owned more than\plain\cf10\f51\fs16\ql 5% of our outstanding common stock before this offering would beneficially own shares representing 80% of our common stock after this offering.\plain\cf10\f51\fs16\ql Therefore, even after this offering these stockholders will have the ability to influence us through this ownership position. These stockholders may be able\plain\cf10\f51\fs16\ql to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors,\plain\cf10\f51\fs16\ql amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or\plain\cf10\f51\fs16\ql discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time\plain\cf10\f51\fs16\b\i\ql to new compliance initiatives.\par\pard\plain\sb88\cf10\f51\fs16\ql As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the\plain\cf10\f51\fs16\ql Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange\plain\cf10\f51\fs16\ql Commission, or SEC, and the NASDAQ Global Market have imposed various requirements on public companies. Our management and other personnel\plain\cf10\f51\fs16\ql will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial\plain\cf10\f51\fs16\ql compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more\plain\cf10\f51\fs16\ql difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our\plain\cf10\f51\fs16\ql current levels of such coverage.\par\pard\plain\sb198\cf10\f51\fs16\ql As a public company, we will be subject to the requirements of Section\~404 of the Sarbanes-Oxley Act. If we are unable to comply with Section\~404 in a\plain\cf10\f51\fs16\ql timely manner, it may affect the reliability of our internal control over financial reporting. Assessing our staffing and training procedures to improve our\plain\cf10\f51\fs16\ql internal control over financial reporting is an ongoing process. We are not currently required to comply with Section\~404 of the Sarbanes-Oxley Act and\plain\cf10\f51\fs16\ql are therefore not required to make an assessment of the effectiveness of our internal control over financial reporting. Further, our independent registered\plain\cf10\f51\fs16\ql public accounting firm has not been engaged to express, nor have they expressed, an opinion on the effectiveness of our internal control over financial\plain\cf10\f51\fs16\ql reporting.\par\pard\plain\sb198\cf10\f51\fs16\ql We plan to continue to assess our internal controls and procedures and intend to take further action as necessary or appropriate to address any other\plain\cf10\f51\fs16\ql matters we identify. For the year ending December\~31, 2011, pursuant to Section\~404 of the Sarbanes-Oxley Act, our management will be required to\plain\cf10\f51\fs16\ql deliver a report that assesses the effectiveness of our internal control over financial reporting. In addition, our\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 33
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql independent registered public accounting firm will also be required to deliver an attestation report on the operating effectiveness of our internal control\plain\cf10\f51\fs16\ql over financial reporting beginning with the year ending December\~31, 2012, unless we qualify for an exemption as a non-accelerated filer under the\plain\cf10\f51\fs16\ql applicable SEC rules and regulations.\par\pard\plain\sb198\cf10\f51\fs16\ql We have been and will continue to be involved in a substantial effort to implement appropriate processes, document the system of internal control over\plain\cf10\f51\fs16\ql key processes, assess their design, remediate any deficiencies identified and test their operation. We cannot be certain at this time whether our measures to\plain\cf10\f51\fs16\ql improve internal controls will be successful, that we will be able to successfully complete the procedures, certification and attestation requirements of\plain\cf10\f51\fs16\ql Section\~404 or that we or our independent registered public accounting firm will not identify material weaknesses in our internal control over financial\plain\cf10\f51\fs16\ql reporting. If we fail to comply with the requirements of Section\~404, it may affect the reliability of our internal control over financial reporting and\plain\cf10\f51\fs16\ql negatively impact the quality of disclosure to our investors. If we or our independent registered public accounting firm identify and report a material\plain\cf10\f51\fs16\ql weakness, it could adversely affect our stock price.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.\par\pard\plain\sb88\cf10\f51\fs16\ql Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the pro forma book value (deficit) per share of\plain\cf10\f51\fs16\ql our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of $3.04\plain\cf10\f51\fs16\ql per share, based on the expected initial public offering price of $5.00 per share, and our pro forma net tangible book value (deficit) as of September\~30,\plain\cf10\f51\fs16\ql 2010. Further, based on these assumptions, investors purchasing common stock in this offering will contribute approximately 37% of the total amount\plain\cf10\f51\fs16\ql invested by stockholders since our inception, but will own approximately 41% of the shares of common stock outstanding. For information on how the\plain\cf10\f51\fs16\ql foregoing amounts were calculated, see \u8220?Dilution.\u8221?\par\pard\plain\sb198\cf10\f51\fs16\ql This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the price offered to\plain\cf10\f51\fs16\ql the public in this offering, and the exercise of stock options granted to our employees. In addition, as of September\~30, 2010, options to purchase\plain\cf10\f51\fs16\ql 1,892,860 shares of our common stock at a weighted average exercise price at September\~30, 2010 of $1.88 per share (or $2.77 per share assuming that\plain\cf10\f51\fs16\ql the December 2010 stock option modification described under \u8220?Management\u8217?s Discussion and Analysis of Financial Condition and Results of\plain\cf10\f51\fs16\ql Operations\u8212?Critical Accounting Policies and Estimates\u8212?Stock-Based Compensation\u8221? had occurred as of September\~30, 2010) and\plain\cf10\f51\fs16\ql warrants exercisable for up to 231,678 shares of our common stock, that are expected to remain outstanding after completion of this offering at a\plain\cf10\f51\fs16\ql weighted average exercise price of approximately $3.94 per share, were outstanding. The exercise of any of these options or warrants would result in\plain\cf10\f51\fs16\ql additional dilution. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase\plain\cf10\f51\fs16\ql price paid in this offering, if anything, in the event of our liquidation.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall.\par\pard\plain\sb88\cf10\f51\fs16\ql Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market\plain\cf10\f51\fs16\ql price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect\plain\cf10\f51\fs16\ql that sales may have on the prevailing market price of our common stock.\par\pard\plain\sb198\cf10\f51\fs16\ql Substantially all of our existing stockholders are subject to lock-up agreements with the underwriters of this offering that restrict the stockholders\u8217?\plain\cf10\f51\fs16\ql ability to transfer shares of our common stock for at least\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 34
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql 180\~days from the date of this prospectus. The lock-up agreements limit the number of shares of common stock that may be sold immediately following\plain\cf10\f51\fs16\ql the public offering. Subject to certain limitations, approximately 16,171,750 shares will become eligible for sale upon expiration of the lock-up period, as\plain\cf10\f51\fs16\ql calculated and described in more detail in the section entitled \u8220?Shares Eligible for Future Sale\u8221?. In addition, shares issued or issuable upon\plain\cf10\f51\fs16\ql exercise of options and warrants vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of stock by these\plain\cf10\f51\fs16\ql stockholders could have a material adverse effect on the trading price of our common stock.\par\pard\plain\sb198\cf10\f51\fs16\ql Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act of 1933, as amended, or the\plain\cf10\f51\fs16\ql Securities Act, subject to the 180-day lock-up arrangement described above. Registration of these shares under the Securities Act would result in the\plain\cf10\f51\fs16\ql shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule\~144 under the\plain\cf10\f51\fs16\ql Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in\plain\cf10\f51\fs16\b\i\ql additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.\par\pard\plain\sb88\cf10\f51\fs16\ql We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by\plain\cf10\f51\fs16\ql issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities\plain\cf10\f51\fs16\ql in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity\plain\cf10\f51\fs16\ql securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our\plain\cf10\f51\fs16\ql existing stockholders, and new investors could gain rights superior to our existing stockholders.\par\pard\plain\sb198\cf10\f51\fs16\ql Pursuant to our 2011 Equity Incentive Plan, adopted by our board of directors in January 2011, or the 2011 Plan, our management is authorized to grant\plain\cf10\f51\fs16\ql stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under our 2011\plain\cf10\f51\fs16\ql Plan will automatically increase each year by 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to\plain\cf10\f51\fs16\ql the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number\plain\cf10\f51\fs16\ql of shares available for issuance under our 2011 Plan each year. If our board of directors elects to increase the number of shares available for future grant\plain\cf10\f51\fs16\ql by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We are at risk of securities class action litigation.\par\pard\plain\sb88\cf10\f51\fs16\ql In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is\plain\cf10\f51\fs16\ql especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it\plain\cf10\f51\fs16\ql could result in substantial costs and a diversion of management\u8217?s attention and resources, which could harm our business.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.\par\pard\plain\sb88\cf10\f51\fs16\ql Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section entitled\plain\cf10\f51\fs16\ql \u8220?Use of Proceeds,\u8221? and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being\plain\cf10\f51\fs16\ql used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use\plain\cf10\f51\fs16\ql may vary substantially from their currently intended use. The failure by our\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 35
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term,\plain\cf10\f51\fs16\ql investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.\par\pard\plain\sb88\cf10\f51\fs16\ql Under Section\~382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an \u8220?ownership change,\u8221? generally defined\plain\cf10\f51\fs16\ql as a greater than 50% change (by value) in its equity ownership over a three year period, the corporation\u8217?s ability to use its pre-change net\plain\cf10\f51\fs16\ql operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We\plain\cf10\f51\fs16\ql believe that, with our initial public offering, our most recent private placement and other transactions that have occurred over the past three years, we may\plain\cf10\f51\fs16\ql have triggered an \u8220?ownership change\u8221? limitation. We may also experience ownership changes in the future as a result of subsequent shifts in\plain\cf10\f51\fs16\ql our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset United States\plain\cf10\f51\fs16\ql federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.\par\pard\plain\sb88\cf10\f51\fs16\ql We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development,\plain\cf10\f51\fs16\ql operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to\plain\cf10\f51\fs16\ql stockholders will therefore be limited to the appreciation of their stock.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for\plain\cf10\f51\fs16\b\i\ql a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.\par\pard\plain\sb88\cf10\f51\fs16\ql Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if\plain\cf10\f51\fs16\ql an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These\plain\cf10\f51\fs16\ql provisions include:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql authorizing the issuance of \u8220?blank check\u8221? preferred stock, the terms of which may be established and shares of which\plain\intbl\cf10\f51\fs16\ql may be issued without stockholder approval;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7395\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql limiting the removal of directors by the stockholders;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7395\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6439\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql creating a staggered board of directors;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6439\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our\plain\intbl\cf10\f51\fs16\ql stockholders;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9069\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql eliminating the ability of stockholders to call a special meeting of stockholders; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9069\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be\plain\intbl\cf10\f51\fs16\ql acted upon at stockholder meetings.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\ql These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for\plain\cf10\f51\fs16\ql stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are\plain\cf10\f51\fs16\ql subject to Section\~203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range\plain\cf10\f51\fs16\ql of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested\plain\cf10\f51\fs16\ql stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of\plain\cf10\f51\fs16\ql control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may\~also discourage, delay or prevent\plain\cf10\f51\fs16\ql someone from acquiring us or merging with us.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 36
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart toc113475_3}{\*\bkmkend toc113475_3}\par\pard\plain\cf10\f51\fs16\b\qc SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\par\pard\plain\sb198\cf10\f51\fs16\ql Some of the statements under \u8220?Prospectus Summary,\u8221? \u8220?Risk Factors,\u8221? \u8220?Management\u8217?s Discussion and Analysis of\plain\cf10\f51\fs16\ql Financial Condition and Results of Operations\u8221? and \u8220?Business\u8221? and elsewhere in this prospectus contain forward-looking statements.\plain\cf10\f51\fs16\ql In some cases, you can identify forward-looking statements by the following words: \u8220?may,\u8221? \u8220?will,\u8221? \u8220?could,\u8221?\plain\cf10\f51\fs16\ql \u8220?would,\u8221? \u8220?should,\u8221? \u8220?expect,\u8221? \u8220?intend,\u8221? \u8220?plan,\u8221? \u8220?anticipate,\u8221?\plain\cf10\f51\fs16\ql \u8220?believe,\u8221? \u8220?estimate,\u8221? \u8220?predict,\u8221? \u8220?project,\u8221? \u8220?potential,\u8221? \u8220?continue,\u8221?\plain\cf10\f51\fs16\ql \u8220?ongoing\u8221? or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.\plain\cf10\f51\fs16\ql These statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be\plain\cf10\f51\fs16\ql materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis\plain\cf10\f51\fs16\ql for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors\plain\cf10\f51\fs16\ql currently known by us and our projections of the future, about which we cannot be certain. Many important factors affect our ability to achieve our\plain\cf10\f51\fs16\ql objectives, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9087\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the success, cost and timing of our product development activities and clinical trials;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9087\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or\plain\intbl\cf10\f51\fs16\ql warnings in the label of an approved product candidate;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to obtain funding for our operations, including funding necessary to complete the third ARX-01 Phase 3 clinical trial\plain\intbl\cf10\f51\fs16\ql required to file our NDA;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8541\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our plans to research, develop and commercialize our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8541\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9957\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to attract collaborators with development, regulatory and commercialization expertise;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9957\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10464\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the size and growth potential of the markets for our product candidates, and our ability to serve those markets;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10464\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8061\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to successfully commercialize our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8061\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8099\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the rate and degree of market acceptance of our product candidates;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8099\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10334\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10334\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8171\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql regulatory developments in the United States and foreign countries;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8171\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8025\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the performance of our third party suppliers and manufacturers;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8025\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7864\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the success of competing therapies that are or become available;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7864\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7277\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the loss of key scientific or management personnel;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7277\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6624\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our use of the proceeds from this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6624\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9402\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our ability to obtain and maintain intellectual property protection for our product candidates.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9402\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql In addition, you should refer to the \u8220?Risk Factors\u8221? section of this prospectus for a discussion of other important factors that may cause our\plain\cf10\f51\fs16\ql actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you\plain\cf10\f51\fs16\ql that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate,\plain\cf10\f51\fs16\ql the inaccuracy may be material. In light of the significant uncertainties\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 37
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will\plain\cf10\f51\fs16\ql achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements,\plain\cf10\f51\fs16\ql whether as a result of new information, future events or otherwise, except as required by law.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 38
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart item_1_3_3}{\*\bkmkend item_1_3_3}{\*\bkmkstart toc113475_4}{\*\bkmkend toc113475_4}\par\pard\plain\cf10\f51\fs16\b\qc USE OF PROCEEDS\par\pard\plain\sb198\cf10\f51\fs16\ql We estimate that our net proceeds from the sale of the common stock that we are offering will be approximately $35.6 million, based on the expected\plain\cf10\f51\fs16\ql initial public offering price of $5.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses\plain\cf10\f51\fs16\ql payable by us. If the underwriters\u8217? over-allotment option to purchase additional shares in this offering is exercised in full, we estimate that our net\plain\cf10\f51\fs16\ql proceeds will be approximately $41.2 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable\plain\cf10\f51\fs16\ql by us. Each $1.00 increase (decrease) in the expected initial public offering price of $5.00 per share would increase (decrease) the net proceeds to us from\plain\cf10\f51\fs16\ql this offering by approximately $7.4 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the\plain\cf10\f51\fs16\ql same. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1.0\~million shares in the number of shares\plain\cf10\f51\fs16\ql offered by us would increase (decrease) the net proceeds to us from this offering by approximately $4.7 million, assuming that the expected initial public\plain\cf10\f51\fs16\ql offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.\plain\cf10\f51\fs16\ql We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our uses of the proceeds\plain\cf10\f51\fs16\ql from this offering, although it may accelerate the time at which we will need to seek additional capital.\par\pard\plain\sb198\cf10\f51\fs16\ql We currently expect to use the net proceeds from this offering as follows:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql approximately $27.8 million of these net proceeds to fund two of our three planned ARX-01 Phase\~3 clinical trials; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8809\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql the remainder to fund working capital needs and other general corporate purposes.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8809\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The costs and timing of drug development and marketing approval, particularly conducting clinical trials, are highly uncertain, are subject to substantial\plain\cf10\f51\fs16\ql risks and can often change. Accordingly, we may change the allocation of use of these proceeds as a result of contingencies such as the progress and\plain\cf10\f51\fs16\ql results of our clinical trials and other development activities, the establishment of collaborations, our manufacturing requirements and regulatory or\plain\cf10\f51\fs16\ql competitive developments.\par\pard\plain\sb198\cf10\f51\fs16\ql Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade\plain\cf10\f51\fs16\ql instruments, certificates of deposit or direct or guaranteed obligations of the United States government.{\*\bkmkstart item_1_3_4}{\*\bkmkend item_1_3_4}{\*\bkmkstart toc113475_5}{\*\bkmkend toc113475_5}\par\pard\plain\sb198\cf10\f51\fs16\b\qc DIVIDEND POLICY\par\pard\plain\sb198\cf10\f51\fs16\ql We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to\plain\cf10\f51\fs16\ql support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the\plain\cf10\f51\fs16\ql foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend on\plain\cf10\f51\fs16\ql then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other\plain\cf10\f51\fs16\ql factors our board of directors may deem relevant.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 39
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart item_1_3_5}{\*\bkmkend item_1_3_5}{\*\bkmkstart toc113475_6}{\*\bkmkend toc113475_6}\par\pard\plain\cf10\f51\fs16\b\qc CAPITALIZATION\par\pard\plain\sb198\cf10\f51\fs16\ql The following table sets forth our cash, cash equivalents and short-term investments and our capitalization as of September\~30, 2010:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5164\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql on an actual basis;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx5164\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql on a pro forma basis to give effect to the following transactions and adjustments as if they had occurred as of September\~30, 2010:\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (1)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,555,713 shares of\plain\intbl\cf10\f51\fs16\ql common stock upon completion of this offering;\cell{
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (2)\cell\pard\plain\intbl\cf10\f51\fs16\ql the exercise, on a net issuance basis, of warrants outstanding as of September\~30, 2010 that we issued in connection with a\plain\intbl\cf10\f51\fs16\ql bridge loan financing in September 2010, or the 2010 warrants, which will be exercisable for shares of our Series\~C convertible\plain\intbl\cf10\f51\fs16\ql preferred stock immediately prior to this offering, and the concomitant conversion of the shares of Series\~C convertible preferred\plain\intbl\cf10\f51\fs16\ql stock acquired upon exercise into 107,246 shares of common stock upon completion of this offering, based on the expected\plain\intbl\cf10\f51\fs16\ql initial public offering price of $5.00 per share;\cell{
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (3)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of our remaining warrants to purchase convertible preferred stock, which warrants are expected to\plain\intbl\cf10\f51\fs16\ql remain outstanding upon the completion of this offering, into warrants to purchase an aggregate of 231,678 shares of common\plain\intbl\cf10\f51\fs16\ql stock upon completion of this offering;\cell{
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (4)\cell\pard\plain\intbl\cf10\f51\fs16\ql the reclassification of the liability associated with the warrants to purchase convertible preferred stock to additional paid-in\plain\intbl\cf10\f51\fs16\ql capital; and\cell{
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (5)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of the principal and accrued interest outstanding under our $8.0 million in aggregate principal amount\plain\intbl\cf10\f51\fs16\ql of convertible promissory notes, or the 2010 notes, into 2,034,438 shares of common stock immediately prior to the closing of\plain\intbl\cf10\f51\fs16\ql this offering at a conversion price equal to 80% of the initial public offering price, assuming an initial public offering price of\plain\intbl\cf10\f51\fs16\ql $5.00 per share, and assuming the conversion occurs on February\~16, 2011, and the reclassification of the convertible note\plain\intbl\cf10\f51\fs16\ql liability to common stock and additional paid-in capital in connection with the conversion; and\cell{
{\trowd\clvertalc\cellx1404\cellx1835\cellx10799\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql on a pro forma as adjusted basis to give further effect to the sale of 8,000,000 shares of common stock in this offering at the\plain\intbl\cf10\f51\fs16\ql expected initial public offering price of $5.00 per share, after deducting estimated underwriting discounts and commissions and\plain\intbl\cf10\f51\fs16\ql estimated offering expenses payable by us, as if the sale of the shares in this offering had occurred as of September\~30, 2010.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Because the number of shares of common stock that will be issued upon exercise of the 2010 warrants and conversion of the 2010 notes depends upon\plain\cf10\f51\fs16\ql the actual initial public offering price per share in this offering and, in the case of the 2010 notes, the closing date of this offering, the actual number of\plain\cf10\f51\fs16\ql shares issued upon such exercise and conversion may differ from the respective number of shares set forth above. See \u8220?Prospectus Summary\plain\cf10\f51\fs16\ql \u8211? The Offering.\u8221?\par\pard\plain\sb198\cf10\f51\fs16\ql You should read this table in conjunction with the sections titled \u8220?Selected Financial Data\u8221? and \u8220?Management\u8217?s Discussion and\plain\cf10\f51\fs16\ql Analysis of Financial Condition and Results of Operations\u8221? and our financial statements and related notes included elsewhere in this prospectus.\plain\cf10\f51\fs16\ql The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms\plain\cf10\f51\fs16\ql of this offering determined at pricing.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 40
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx5706\clvertalb\cellx6284\clvertalc\cellx6577\clvertalc\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clvertalc\cellx8235\clvertalc\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clvertalc\cellx10014\clvertalc\cellx10654\clvertalc\cellx10791\cellx10792\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5706\clvertalb\cellx6284\clvertalc\cellx6577\clvertalc\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clvertalc\cellx8235\clvertalc\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clvertalc\cellx10014\clvertalc\cellx10654\clvertalc\cellx10791\cellx10792\trrh-66\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10659\clvertalb\cellx10796\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10659\clvertalb\cellx10796\cellx10797\trrh172\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10655\clvertalb\cellx10792\cellx10793\trrh344
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Actual\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Pro Forma\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Pro\~Forma
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc as\~Adjusted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10655\clvertalb\cellx10792\cellx10793\trrh344\row}}}
{\trowd\clvertalb\clvmgf\cellx5706\clvertalb\cellx6284\clvertalb\cellx10659\clvertalb\cellx10796\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in\~thousands,\~except\~share\~and\~per\~share\~data)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\clvmgf\cellx5706\clvertalb\cellx6284\clvertalb\cellx10659\clvertalb\cellx10796\cellx10797\trrh172\row}}}
{\trowd\clvertalb\clvmrg\cellx5706\clvertalb\cellx6284\clvertalb\cellx10659\clvertalb\cellx10796\clvertalc\cellx10797\trrh172
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\clvmrg\cellx5706\clvertalb\cellx6284\clvertalb\cellx10659\clvertalb\cellx10796\clvertalc\cellx10797\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Cash, cash equivalents and short-term investments\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 43,722\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh63\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Long-term debt, including current portion\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,382\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,382\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,382\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible notes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 4,603\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Call option liability\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 476\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock warrant liability\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,219\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh619
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock, $0.001 par value: 46,736,125 shares authorized,\plain\intbl\li176\cf10\f51\fs16\ql 7,151,802 shares issued and outstanding, actual; no shares authorized, issued or\plain\intbl\li176\cf10\f51\fs16\ql outstanding, pro forma and pro forma as adjusted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 55,941\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh619\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Stockholders\u8217? equity (deficit):\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh619
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql Preferred stock, $0.001 par value: no shares authorized, issued or\plain\intbl\li572\cf10\f51\fs16\ql outstanding, actual and pro forma; 10,000,000\~shares authorized, no\plain\intbl\li572\cf10\f51\fs16\ql shares issued and outstanding, pro forma as adjusted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~
\par\pard\plain\intbl\fs16\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh619\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh1031
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql Common stock, $0.001 par value: 71,000,000 shares authorized, 674,353\plain\intbl\li572\cf10\f51\fs16\ql shares issued and outstanding, actual; 71,000,000 shares authorized,\plain\intbl\li572\cf10\f51\fs16\ql 11,371,750 shares issued and outstanding, pro forma; 100,000,000 shares\plain\intbl\li572\cf10\f51\fs16\ql authorized, 19,371,750 shares issued and outstanding, pro forma as\plain\intbl\li572\cf10\f51\fs16\ql adjusted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 11\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 19\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh1031\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql Additional paid-in capital\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 4,053\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 67,282\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 102,914\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li572\fi-176\cf10\f51\fs16\ql Deficit accumulated during the development stage\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (65,040\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (65,040\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (65,040\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh29\row}}}
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total stockholders\u8217? equity (deficit)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (60,986\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,253\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37,893\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5706\clvertalb\cellx6284\clvertalb\cellx6577\clvertalb\cellx7217\clvertalb\cellx7390\clvertalb\cellx7911\clvertalb\cellx8235\clvertalb\cellx8875\clvertalb\cellx9048\clvertalb\cellx9569\clvertalb\cellx10014\clvertalb\cellx10654\clvertalb\cellx10791\clvertalc\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total capitalization\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,635\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,635\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 44,275\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6284\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6577\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7217\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7390\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7911\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8235\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9048\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9569\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10014\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5706\clvertalb\cellx6284\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6577\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7217\clvertalc\cellx7390\clvertalb\cellx7911\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8235\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8875\clvertalc\cellx9048\clvertalb\cellx9569\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10014\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10791\clvertalc\cellx10792\trrh63\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Each $1.00 increase (decrease) in the expected initial public offering price of $5.00\~per share would increase (decrease) each of cash, cash equivalents and\plain\cf10\f51\fs16\ql short-term investments, additional paid-in capital, total stockholders\u8217? equity (deficit) and total capitalization by approximately $7.4\~million,\plain\cf10\f51\fs16\ql assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated\plain\cf10\f51\fs16\ql underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are\plain\cf10\f51\fs16\ql offering. Each increase (decrease) of 1.0\~million shares in the number of shares offered by us would increase (decrease) each of cash, cash equivalents and\plain\cf10\f51\fs16\ql short-term investments, additional paid-in capital, total stockholders\u8217? equity (deficit) and total capitalization by approximately $4.7 million,\plain\cf10\f51\fs16\ql assuming that the expected initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and\plain\cf10\f51\fs16\ql estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual\plain\cf10\f51\fs16\ql initial public offering price and other terms of this offering determined at pricing.\par\pard\plain\sb198\cf10\f51\fs16\ql The outstanding share information in the table above excludes:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,892,860 shares of common stock issuable upon the exercise of stock options outstanding as of September 30, 2010 under our 2006\plain\intbl\cf10\f51\fs16\ql Stock Plan having a weighted average exercise price at September 30, 2010 of $1.88 per share (or $2.77 per share assuming that the\plain\intbl\cf10\f51\fs16\ql December 2010 stock option modification described under \u8220?Management\u8217?s Discussion and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 41
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx1188\cellx10800\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql Analysis of Financial Condition and Results of Operations\u8212?Critical Accounting Policies and Estimates\u8212?Stock-Based\plain\intbl\cf10\f51\fs16\ql Compensation\u8221? had occurred as of September\~30, 2010);\cell{
{\trowd\clvertalc\cellx1188\cellx10800\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 167,630 shares of common stock reserved for future issuance under our 2006 Stock Plan as of September 30, 2010, which share\plain\intbl\cf10\f51\fs16\ql reserve will become available for issuance under our 2011 Equity Incentive Plan upon the execution and delivery of the underwriting\plain\intbl\cf10\f51\fs16\ql agreement for this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 231,678 shares of common stock issuable upon the exercise of warrants outstanding as of September 30, 2010 having a weighted\plain\intbl\cf10\f51\fs16\ql average exercise price of $3.94 per share, which warrants are expected to remain outstanding upon completion of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,875,000 shares of common stock (which will include the shares then reserved for issuance under our 2006 Stock Plan at the time of\plain\intbl\cf10\f51\fs16\ql the execution and delivery of the underwriting agreement for this offering) reserved for future issuance under our 2011 Equity\plain\intbl\cf10\f51\fs16\ql Incentive Plan, which will become effective immediately upon the execution and delivery of the underwriting agreement for this\plain\intbl\cf10\f51\fs16\ql offering, as well as any future increases in the number of shares of common stock reserved for issuance under this plan; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 250,000 shares of common stock reserved for future issuance under our 2011 Employee Stock Purchase Plan, which will\plain\intbl\cf10\f51\fs16\ql become effective immediately upon the execution and delivery of the underwriting agreement for this offering, as well as\plain\intbl\cf10\f51\fs16\ql any future increases in the number of shares of common stock reserved for issuance under this plan.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 42
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart toc113475_7}{\*\bkmkend toc113475_7}\par\pard\plain\cf10\f51\fs16\b\qc DILUTION\par\pard\plain\sb198\cf10\f51\fs16\ql If you invest in our common stock, you will experience immediate and substantial dilution to the extent of the difference between the initial public\plain\cf10\f51\fs16\ql offering price of our common stock and the pro forma as adjusted net tangible book value (deficit) per share of our common stock immediately after the\plain\cf10\f51\fs16\ql offering.\par\pard\plain\sb198\cf10\f51\fs16\ql Our historical net tangible book value (deficit) per share is determined by dividing our total tangible assets, less total liabilities and convertible preferred\plain\cf10\f51\fs16\ql stock, by the actual number of outstanding shares of our common stock. The historical net tangible book value (deficit) of our common stock as of\plain\cf10\f51\fs16\ql September\~30, 2010 was $(61.0) million, or $(90.44) per share. The pro forma net tangible book value (deficit) of our common stock as of September\~30,\plain\cf10\f51\fs16\ql 2010 was $2.3 million, or $0.20 per share. The pro forma net tangible book value (deficit) per share gives effect to:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (1)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,555,713 shares of common stock\plain\intbl\cf10\f51\fs16\ql upon completion of this offering;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh412\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (2)\cell\pard\plain\intbl\cf10\f51\fs16\ql the exercise, on a net issuance basis, of warrants outstanding as of September 30, 2010 that we issued in connection with a bridge loan\plain\intbl\cf10\f51\fs16\ql financing in September 2010, or the 2010 warrants, which will be exercisable for shares of our Series C convertible preferred stock\plain\intbl\cf10\f51\fs16\ql immediately prior to this offering, and the concomitant conversion of the shares of Series C convertible preferred stock acquired upon\plain\intbl\cf10\f51\fs16\ql exercise into 107,246 shares of common stock upon completion of this offering, based on the expected initial public offering price of $5.00\plain\intbl\cf10\f51\fs16\ql per share;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (3)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of our remaining warrants to purchase convertible preferred stock, which warrants are expected to remain\plain\intbl\cf10\f51\fs16\ql outstanding upon the completion of this offering, into warrants to purchase an aggregate of 231,678 shares of common stock upon completion\plain\intbl\cf10\f51\fs16\ql of this offering;\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (4)\cell\pard\plain\intbl\cf10\f51\fs16\ql the reclassification of the liability associated with the warrants to purchase convertible preferred stock to additional paid-in capital; and\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql (5)\cell\pard\plain\intbl\cf10\f51\fs16\ql the automatic conversion of the principal and accrued interest outstanding under our $8.0\~million in aggregate principal amount of convertible\plain\intbl\cf10\f51\fs16\ql promissory notes, or the 2010 notes, into 2,034,438 shares of common stock immediately prior to the closing of this offering at a conversion\plain\intbl\cf10\f51\fs16\ql price equal to 80% of the initial public offering price, based on the expected initial public offering price of $5.00 per share, and assuming the\plain\intbl\cf10\f51\fs16\ql conversion occurs on February\~16, 2011, and the reclassification of the convertible note liability to common stock and additional paid-in\plain\intbl\cf10\f51\fs16\ql capital in connection with the conversion.\cell{
{\trowd\clvertalc\cellx432\cellx864\cellx10800\trrh1031\row}}}\pard\plain\sb88\cf10\f51\fs16\ql Because the number of shares of common stock that will be issued upon exercise of the 2010 warrants and conversion of the 2010 notes depends upon\plain\cf10\f51\fs16\ql the actual initial public offering price per share in this offering and, in the case of the 2010 notes, the closing date of this offering, the actual number of\plain\cf10\f51\fs16\ql shares issuable upon such exercise and conversion may differ from the respective number of shares set forth above. See \u8220?Prospectus\plain\cf10\f51\fs16\ql Summary\~\u8211? The Offering.\u8221?\par\pard\plain\sb198\cf10\f51\fs16\ql The pro forma as adjusted net tangible book value (deficit) of our common stock as of September\~30, 2010 was $37.9 million, or $1.96 per share. The pro\plain\cf10\f51\fs16\ql forma as adjusted net tangible book value (deficit) gives effect to (1)\~the sale of 8,000,000 shares of common stock in this offering at the expected initial\plain\cf10\f51\fs16\ql public offering price of $5.00 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us,\plain\cf10\f51\fs16\ql and (2) the pro forma transactions and other adjustments described in the second preceding paragraph. The difference between the initial public offering\plain\cf10\f51\fs16\ql price and the pro forma as adjusted net tangible book value (deficit) per share represents an immediate dilution of $3.04 per share to new investors\plain\cf10\f51\fs16\ql purchasing common stock in this offering.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 43
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql The following table illustrates this dilution on a per share basis:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx8623\clvertalb\cellx9149\clvertalc\cellx9252\clvertalc\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalc\cellx10362\clvertalc\cellx10673\clvertalc\cellx10796\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalb\cellx9149\clvertalc\cellx9252\clvertalc\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalc\cellx10362\clvertalc\cellx10673\clvertalc\cellx10796\trrh-66\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9252\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9702\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10362\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Assumed initial public offering price per share\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.00\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9252\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9702\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10362\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh29\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Historical net tangible book value (deficit) per share as of September\~30, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (90.44\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh412
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Pro forma increase in net tangible book value (deficit) per share attributable to the pro forma transactions and other\plain\intbl\li176\cf10\f51\fs16\ql adjustments described in the preceding second paragraph\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 90.63\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh412\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Pro forma net tangible book value (deficit) per share before this offering\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 0.20\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Pro forma increase in net tangible book value (deficit) per share attributable to investors participating in this offering\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1.76\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9252\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9702\clvertalc\cellx9839\clvertalb\cellx10259\clvertalb\cellx10362\clvertalb\cellx10673\clvertalb\cellx10796\trrh29\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Pro forma as adjusted net tangible book value (deficit) per share after this offering\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1.96\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx8623\clvertalb\cellx9149\cellx9252\cellx9702\cellx9839\clvertalb\cellx10259\cellx10362\cellx10673\cellx10796\trrh206\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh29\row}}}
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx8623\clvertalc\cellx9840\clvertalc\cellx10799\trrh-66\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Dilution per share to new investors purchasing common stock in this offering\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 3.04\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx8623\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9149\clshdng100\clcfpat13\clcbpat13\cellx9252\clshdng100\clcfpat13\clcbpat13\cellx9702\clshdng100\clcfpat13\clcbpat13\cellx9839\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10259\clshdng100\clcfpat13\clcbpat13\cellx10362\clshdng100\clcfpat13\clcbpat13\cellx10673\clshdng100\clcfpat13\clcbpat13\cellx10796\trrh206\row}}}
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx8623\clvertalb\cellx9149\clvertalb\cellx9252\clvertalb\cellx9702\clvertalb\cellx9839\clvertalb\cellx10259\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10362\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10673\clvertalc\cellx10796\trrh63\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Each $1.00 increase (decrease) in the expected initial public offering price of $5.00 per share would increase (decrease) our pro forma as adjusted net\plain\cf10\f51\fs16\ql tangible book value (deficit) by approximately $7.4 million, or approximately $0.38 per share, and the dilution per share to new investors purchasing\plain\cf10\f51\fs16\ql common stock in this offering by approximately $0.62 per share, assuming that the number of shares offered by us, as set forth on the cover page of this\plain\cf10\f51\fs16\ql prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We\plain\cf10\f51\fs16\ql may also increase or decrease the number of shares we are offering. An increase of 1.0\~million shares in the number of shares offered by us would\plain\cf10\f51\fs16\ql increase our pro forma as adjusted net tangible book value (deficit) by approximately $4.7 million, or $0.13 per share, and the dilution per share to new\plain\cf10\f51\fs16\ql investors purchasing common stock in this offering would be $2.91 per share, assuming that the expected initial public offering price remains the same,\plain\cf10\f51\fs16\ql and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a decrease of 1.0\~million\plain\cf10\f51\fs16\ql shares in the number of shares offered by us would decrease our pro forma as adjusted net tangible book value (deficit) by approximately $4.7 million, or\plain\cf10\f51\fs16\ql $0.15 per share, and the dilution per share to new investors purchasing common stock in this offering would be $3.19 per share, assuming that the\plain\cf10\f51\fs16\ql expected initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering\plain\cf10\f51\fs16\ql expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual initial public\plain\cf10\f51\fs16\ql offering price and other terms of this offering determined at pricing.\par\pard\plain\sb198\cf10\f51\fs16\ql If the underwriters\u8217? over-allotment option to purchase additional shares from us is exercised in full, and assuming the initial public offering price is\plain\cf10\f51\fs16\ql $5.00 per share, the pro forma as adjusted net tangible book value (deficit) per share after this offering would be $2.11 per share, the increase in pro\plain\cf10\f51\fs16\ql forma as adjusted net tangible book value (deficit) per share to existing stockholders would be $0.15 per share and the dilution to new investors\plain\cf10\f51\fs16\ql purchasing shares in this offering would be $2.89 per share.\par\pard\plain\sb198\cf10\f51\fs16\ql The table below summarizes as of September\~30, 2010, on the pro forma as adjusted basis described above, the number of shares of our common stock\plain\cf10\f51\fs16\ql we issued and sold, the total consideration we received and the average price per share (1)\~paid to us by existing stockholders; (2)\~to be paid by new\plain\cf10\f51\fs16\ql investors purchasing our common stock in this offering at the expected initial public offering price of $5.00 per share, before deducting estimated\plain\cf10\f51\fs16\ql underwriting discounts and commissions and estimated offering expenses payable by us; and (3)\~the average price per share paid by existing stockholders\plain\cf10\f51\fs16\ql and by new investors who purchase shares of common stock in this offering.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 44
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx4145\clvertalb\cellx4608\clvertalc\cellx4864\clvertalc\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clvertalc\cellx6393\clvertalc\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clvertalc\cellx7515\clvertalc\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clvertalc\cellx8943\clvertalc\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalc\cellx10240\clvertalc\cellx10668\clvertalc\cellx10791\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4145\clvertalb\cellx4608\clvertalc\cellx4864\clvertalc\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clvertalc\cellx6393\clvertalc\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clvertalc\cellx7515\clvertalc\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clvertalc\cellx8943\clvertalc\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalc\cellx10240\clvertalc\cellx10668\clvertalc\cellx10791\trrh-66\row}}}
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6665\clvertalb\cellx6885\clvertalb\cellx7264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9216\clvertalb\cellx9436\clvertalb\cellx9815\clvertalb\clvmgf\cellx10671\clvertalb\clvmgf\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Shares Purchased\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Total\~Consideration\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Average\~Price
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Per Share\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6665\clvertalb\cellx6885\clvertalb\cellx7264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9216\clvertalb\cellx9436\clvertalb\cellx9815\clvertalb\clvmgf\cellx10671\clvertalb\clvmgf\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5634\clvertalb\cellx5757\clvertalb\cellx6157\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6664\clvertalb\cellx6884\clvertalb\cellx7263\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8077\clvertalb\cellx8279\clvertalb\cellx8707\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9214\clvertalb\cellx9434\clvertalb\cellx9813\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10669\clvertalb\clvmrg\cellx10792\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Number\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Percent\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Amount\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Percent\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5634\clvertalb\cellx5757\clvertalb\cellx6157\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6664\clvertalb\cellx6884\clvertalb\cellx7263\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8077\clvertalb\cellx8279\clvertalb\cellx8707\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9214\clvertalb\cellx9434\clvertalb\cellx9813\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10669\clvertalb\clvmrg\cellx10792\trrh172\row}}}
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clvertalb\cellx10675\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clvertalb\cellx10675\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4608\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4864\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5633\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6156\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6393\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6663\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6883\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7262\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8278\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8943\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9213\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9433\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9812\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10668\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Existing stockholders\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 11,371,750\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 59\cell\pard\plain\intbl\cf10\f51\fs16\ql %\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 67,282\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 63\cell\pard\plain\intbl\cf10\f51\fs16\ql %\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.92\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4608\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4864\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5633\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6156\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6393\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6663\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6883\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7262\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8278\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8943\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9213\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9433\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9812\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10668\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206\row}}}
{\trowd\cellx4145\clvertalb\cellx4608\clvertalb\cellx4864\clvertalb\cellx5633\clvertalb\cellx5756\clvertalb\cellx6156\clvertalb\cellx6393\clvertalb\cellx6663\clvertalb\cellx6883\clvertalb\cellx7262\clvertalb\cellx7515\clvertalb\cellx8076\clvertalb\cellx8278\clvertalb\cellx8706\clvertalb\cellx8943\clvertalb\cellx9213\clvertalb\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql New investors\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,000,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 41\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 40,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.00\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4145\clvertalb\cellx4608\clvertalb\cellx4864\clvertalb\cellx5633\clvertalb\cellx5756\clvertalb\cellx6156\clvertalb\cellx6393\clvertalb\cellx6663\clvertalb\cellx6883\clvertalb\cellx7262\clvertalb\cellx7515\clvertalb\cellx8076\clvertalb\cellx8278\clvertalb\cellx8706\clvertalb\cellx8943\clvertalb\cellx9213\clvertalb\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh206\row}}}
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4864\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6393\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7515\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8943\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4864\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6393\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7515\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8943\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4608\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4864\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5633\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6156\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6393\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6663\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6883\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7262\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8278\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8943\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9213\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9433\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9812\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10668\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Totals\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 19,371,750\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 100\cell\pard\plain\intbl\cf10\f51\fs16\ql %\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 107,282\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 100\cell\pard\plain\intbl\cf10\f51\fs16\ql %\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.54\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4608\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4864\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5633\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6156\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6393\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6663\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6883\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7262\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8278\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8706\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8943\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9213\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9433\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9812\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10668\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206\row}}}
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4864\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6393\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7515\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8943\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4145\clvertalb\cellx4608\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4864\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5633\clvertalc\cellx5756\clvertalb\cellx6156\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6393\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6663\clvertalc\cellx6883\clvertalb\cellx7262\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7515\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8076\clvertalc\cellx8278\clvertalb\cellx8706\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8943\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9213\clvertalc\cellx9433\clvertalb\cellx9812\clvertalb\cellx10240\clvertalb\cellx10668\clvertalb\cellx10791\trrh63\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The number of shares of common stock outstanding immediately after this offering is based on 11,371,750 shares of common stock outstanding as of\plain\cf10\f51\fs16\ql September\~30, 2010, after giving effect to the pro forma transactions described in the second preceding paragraph. This number excludes:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,892,860 shares of common stock issuable upon the exercise of stock options outstanding as of September 30, 2010 under our 2006\plain\intbl\cf10\f51\fs16\ql Stock Plan having a weighted average exercise price at September 30, 2010 of $1.88 per share (or $2.77 per share assuming that the\plain\intbl\cf10\f51\fs16\ql December 2010 stock option modification described under \u8220?Management\u8217?s Discussion and Analysis of Financial\plain\intbl\cf10\f51\fs16\ql Condition and Results of Operations \u8211? Critical Accounting Policies and Estimates \u8211? Stock-Based Compensation\u8221?\plain\intbl\cf10\f51\fs16\ql had occurred as of September\~30, 2010);\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh1031\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 167,630 shares of common stock reserved for future issuance under our 2006 Stock Plan as of September 30, 2010, which share\plain\intbl\cf10\f51\fs16\ql reserve will become available for issuance under our 2011 Equity Incentive Plan upon the execution and delivery of the underwriting\plain\intbl\cf10\f51\fs16\ql agreement for this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 231,678 shares of common stock issuable upon the exercise of warrants outstanding as of September 30, 2010 having a weighted\plain\intbl\cf10\f51\fs16\ql average exercise price of $3.94 per share, which warrants are expected to remain outstanding upon completion of this offering;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 1,875,000 shares of common stock (which will include the shares then reserved for issuance under our 2006 Stock Plan at the time of\plain\intbl\cf10\f51\fs16\ql the execution and delivery of the underwriting agreement for this offering) reserved for future issuance under our 2011 Equity\plain\intbl\cf10\f51\fs16\ql Incentive Plan, which will become effective immediately upon the execution and delivery of the underwriting agreement for this\plain\intbl\cf10\f51\fs16\ql offering, as well as any future increases in the number of shares of common stock reserved for issuance under this plan; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql 250,000 shares of common stock reserved for future issuance under our 2011 Employee Stock Purchase Plan, which will\plain\intbl\cf10\f51\fs16\ql become effective immediately upon the execution and delivery of the underwriting agreement for this offering, as well as\plain\intbl\cf10\f51\fs16\ql any future increases in the number of shares of common stock reserved for issuance under this plan.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10092\trrh619\row}}}\pard\plain\sb198\cf10\f51\fs16\ql If the underwriters\u8217? over-allotment option is exercised in full, the pro forma as adjusted number of shares held by the existing stockholders after\plain\cf10\f51\fs16\ql this offering would be 11,371,750, or 55% of the pro forma as adjusted total number of shares of our common stock outstanding after this offering, and\plain\cf10\f51\fs16\ql the number of shares held by new investors would increase to 9,200,000, or 45% of the pro forma as adjusted total number of shares of our common\plain\cf10\f51\fs16\ql stock outstanding after this offering.\par\pard\plain\sb198\cf10\f51\fs16\ql Certain of our current stockholders have indicated an interest in purchasing an aggregate of $24.0\~million of shares of common stock in this offering at\plain\cf10\f51\fs16\ql the expected initial public offering price of $5.00 per share. Because indications of interest are not binding agreements or commitments to purchase, these\plain\cf10\f51\fs16\ql stockholders may elect not to purchase any shares in this offering. The foregoing discussion and tables do not reflect any potential purchases by these\plain\cf10\f51\fs16\ql current stockholders or their affiliated entities.\par\pard\plain\sb198\cf10\f51\fs16\ql Effective upon the closing of this offering, an aggregate of up to 2,125,000 shares of our common stock will be reserved for future issuance under our\plain\cf10\f51\fs16\ql equity benefit plans, and the number of reserved shares will also be subject to automatic annual increases in accordance with the terms of the plans. To\plain\cf10\f51\fs16\ql the extent that new options are issued under our equity benefit plans or we issue additional shares of common stock in the future, there will be further\plain\cf10\f51\fs16\ql dilution to investors purchasing common stock in this offering.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 45
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart toc113475_8}{\*\bkmkend toc113475_8}\par\pard\plain\cf10\f51\fs16\b\qc SELECTED FINANCIAL DATA\par\pard\plain\sb198\cf10\f51\fs16\ql We derived the selected statements of operations data for the years ended December\~31, 2007, 2008 and 2009 and the balance sheet data as of\plain\cf10\f51\fs16\ql December\~31, 2008 and 2009 from our audited financial statements included elsewhere in this prospectus. The summary statement of operations data for\plain\cf10\f51\fs16\ql the nine months ended September\~30, 2009 and 2010 and the balance sheet data as of September\~30, 2010 have been derived from our unaudited financial\plain\cf10\f51\fs16\ql statements included elsewhere in this prospectus. We derived the selected statements of operations data for the period from July\~13, 2005 (inception)\plain\cf10\f51\fs16\ql through December\~31, 2005 and the year ended December\~31, 2006 and the balance sheet data as of December\~31, 2005, 2006 and 2007 from our audited\plain\cf10\f51\fs16\ql financial statements which are not included in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in\plain\cf10\f51\fs16\ql the future. You should read the following selected financial data below in conjunction with \u8220?Management\u8217?s Discussion and Analysis of\plain\cf10\f51\fs16\ql Financial Condition and Results of Operations\u8221? and our financial statements and related notes included elsewhere in this prospectus. The selected\plain\cf10\f51\fs16\ql financial data in this section is not intended to replace the financial statements and is qualified in its entirety by the financial statements and related notes\plain\cf10\f51\fs16\ql included in this prospectus.\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3155\clvertalb\cellx3381\clvertalc\cellx3795\clvertalc\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clvertalc\cellx4825\clvertalc\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clvertalc\cellx5858\clvertalc\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clvertalc\cellx6891\clvertalc\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clvertalc\cellx7924\clvertalc\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalc\cellx8993\clvertalc\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clvertalc\cellx10079\clvertalc\cellx10654\clvertalc\cellx10774\cellx10779\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3155\clvertalb\cellx3381\clvertalc\cellx3795\clvertalc\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clvertalc\cellx4825\clvertalc\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clvertalc\cellx5858\clvertalc\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clvertalc\cellx6891\clvertalc\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clvertalc\cellx7924\clvertalc\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalc\cellx8993\clvertalc\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clvertalc\cellx10079\clvertalc\cellx10654\clvertalc\cellx10774\cellx10779\trrh-66\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\clvmgf\cellx4332\clvertalb\clvmgf\cellx4452\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8510\clvertalb\cellx8630\clvertalb\cellx8856\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10669\clvertalb\cellx10789\cellx10794\trrh419
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Period from
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc July\~13, 2005
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Inception)
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Through
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc December\~31,
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc 2005\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year Ended December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine Months Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\clvmgf\cellx4332\clvertalb\clvmgf\cellx4452\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8510\clvertalb\cellx8630\clvertalb\cellx8856\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10669\clvertalb\cellx10789\cellx10794\trrh419\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx4332\clvertalb\clvmrg\cellx4452\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5363\clvertalb\cellx5483\clvertalb\cellx5712\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6397\clvertalb\cellx6517\clvertalb\cellx6746\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7431\clvertalb\cellx7551\clvertalb\cellx7780\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8504\clvertalb\cellx8624\clvertalb\cellx8850\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9535\clvertalb\cellx9679\clvertalb\cellx9937\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10661\clvertalb\cellx10781\clvertalc\cellx10782\clvertalc\cellx10783\clvertalc\cellx10784\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2006\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2007\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2008\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx4332\clvertalb\clvmrg\cellx4452\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5363\clvertalb\cellx5483\clvertalb\cellx5712\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6397\clvertalb\cellx6517\clvertalb\cellx6746\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7431\clvertalb\cellx7551\clvertalb\cellx7780\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8504\clvertalb\cellx8624\clvertalb\cellx8850\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9535\clvertalb\cellx9679\clvertalb\cellx9937\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10661\clvertalb\cellx10781\clvertalc\cellx10782\clvertalc\cellx10783\clvertalc\cellx10784\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx4332\clvertalb\cellx4452\clvertalb\cellx4678\clvertalb\cellx8510\clvertalb\cellx8630\clvertalb\cellx8856\clvertalb\cellx10669\clvertalb\cellx10789\clvertalc\cellx10790\clvertalc\cellx10791\clvertalc\cellx10792\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx4332\clvertalb\cellx4452\clvertalb\cellx4678\clvertalb\cellx8510\clvertalb\cellx8630\clvertalb\cellx8856\clvertalb\cellx10669\clvertalb\cellx10789\clvertalc\cellx10790\clvertalc\cellx10791\clvertalc\cellx10792\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx4332\clvertalb\cellx4452\clvertalb\cellx4678\clvertalb\cellx10671\clvertalb\cellx10791\clvertalc\cellx10792\clvertalc\cellx10793\clvertalc\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands, except share and per share data)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx4332\clvertalb\cellx4452\clvertalb\cellx4678\clvertalb\cellx10671\clvertalb\cellx10791\clvertalc\cellx10792\clvertalc\cellx10793\clvertalc\cellx10794\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\b\ql Statement of Operations Data:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Operating Expenses:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li572\fi-176\cf10\f51\fs13\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 35\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 3,533\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 8,209\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 18,325\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 15,502\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 13,180\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 6,309\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li572\fi-176\cf10\f51\fs13\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 5\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 520\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 2,082\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 2,365\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 3,529\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 2,510\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 3,033\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Total operating expenses\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 40\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 4,053\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 10,291\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 20,690\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 19,031\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 15,690\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 9,342\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Loss from operations\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (40\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (4,053\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (10,291\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (20,690\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (19,031\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (15,690\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (9,342\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li572\fi-176\cf10\f51\fs13\ql Interest income\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 347\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 687\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 484\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 33\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 37\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 2\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li572\fi-176\cf10\f51\fs13\ql Interest expense\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (62\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (25\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (404\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (1,242\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (965\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (656\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li572\fi-176\cf10\f51\fs13\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (1\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (52\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 121\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 196\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (825\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrs\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrs\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh29\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Loss before provision for income taxes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (40\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (3,768\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (9,630\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (20,662\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (20,119\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (16,422\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (10,821\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Provision for income taxes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr (40\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (3,768\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (9,630\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (20,662\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (20,119\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (16,422\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (10,821\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh172\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh344
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Net loss per share of common stock, basic and\plain\intbl\li176\cf10\f51\fs13\ql diluted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr 0.00\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (36.90\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (26.45\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (43.69\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (34.93\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (29.09\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (16.63\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh344\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh344
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Shares used in computing net loss per share of\plain\intbl\li176\cf10\f51\fs13\ql common stock, basic and diluted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 102,102\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 364,039\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 472,914\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 576,021\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 564,571\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 650,774\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh344\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx3795\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4331\clvertalc\cellx4451\clvertalb\cellx4677\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx4825\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5361\clvertalc\cellx5481\clvertalb\cellx5710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx5858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6394\clvertalc\cellx6514\clvertalb\cellx6743\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6891\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7427\clvertalc\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8993\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9529\clvertalc\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh344
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Pro forma net loss per share of common stock, basic\plain\intbl\li176\cf10\f51\fs13\ql and diluted (unaudited)\plain\intbl\li176\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (3.51\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql $\cell\pard\plain\intbl\cf10\f51\fs13\qr (1.09\cell\pard\plain\intbl\cf10\f51\fs13\ql )\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3155\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3381\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3795\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4331\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4451\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4677\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4825\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5481\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6394\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6743\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6891\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7427\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7547\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7776\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7924\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8499\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8993\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9529\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9673\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9931\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10774\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10775\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10776\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10777\trrh344\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh516
\pard\plain\intbl\li176\fi-176\cf10\f51\fs13\ql Shares used in computing pro forma net loss per\plain\intbl\li176\cf10\f51\fs13\ql share of common stock, basic and diluted\plain\intbl\li176\cf10\f51\fs13\ql (unaudited)\plain\intbl\li176\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 5,746,372\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\qr 9,204,999\cell\pard\plain\intbl\cf10\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clvertalb\cellx7924\clvertalb\cellx8499\clvertalb\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clvertalb\cellx10079\clvertalb\cellx10654\clvertalb\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh516\row}}}
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3155\clvertalb\cellx3381\clvertalb\cellx3795\clvertalb\cellx4331\clvertalb\cellx4451\clvertalb\cellx4677\clvertalb\cellx4825\clvertalb\cellx5361\clvertalb\cellx5481\clvertalb\cellx5710\clvertalb\cellx5858\clvertalb\cellx6394\clvertalb\cellx6514\clvertalb\cellx6743\clvertalb\cellx6891\clvertalb\cellx7427\clvertalb\cellx7547\clvertalb\cellx7776\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7924\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8499\clvertalc\cellx8619\clvertalb\cellx8845\clvertalb\cellx8993\clvertalb\cellx9529\clvertalb\cellx9673\clvertalb\cellx9931\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10079\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10654\clvertalc\cellx10774\clvertalc\cellx10775\clvertalc\cellx10776\clvertalc\cellx10777\trrh63\row}}}\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx154\cellx10799\trrh344
\pard\plain\intbl\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf10\f51\fs13\ql See Note\~11 of the audited financial statements included elsewhere in this prospectus for discussion regarding the calculations for the net loss per share and the pro forma net loss\plain\intbl\cf10\f51\fs13\ql per share and the shares used in these calculations.\cell{
{\trowd\cellx154\cellx10799\trrh344\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 46
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx3307\clvertalb\cellx3686\clvertalc\cellx3834\clvertalc\cellx4494\clvertalc\cellx4631\clvertalb\cellx4928\clvertalc\cellx5076\clvertalc\cellx5716\clvertalc\cellx5853\clvertalb\cellx6150\clvertalc\cellx6298\clvertalc\cellx6938\clvertalc\cellx7075\clvertalb\cellx7372\clvertalc\cellx7520\clvertalc\cellx8053\clvertalc\cellx8190\clvertalb\cellx8487\clvertalc\cellx8635\clvertalc\cellx9168\clvertalc\cellx9305\clvertalb\cellx9684\clvertalc\cellx10118\clvertalc\cellx10651\clvertalc\cellx10788\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3307\clvertalb\cellx3686\clvertalc\cellx3834\clvertalc\cellx4494\clvertalc\cellx4631\clvertalb\cellx4928\clvertalc\cellx5076\clvertalc\cellx5716\clvertalc\cellx5853\clvertalb\cellx6150\clvertalc\cellx6298\clvertalc\cellx6938\clvertalc\cellx7075\clvertalb\cellx7372\clvertalc\cellx7520\clvertalc\cellx8053\clvertalc\cellx8190\clvertalb\cellx8487\clvertalc\cellx8635\clvertalc\cellx9168\clvertalc\cellx9305\clvertalb\cellx9684\clvertalc\cellx10118\clvertalc\cellx10651\clvertalc\cellx10788\trrh-66\row}}}
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9177\clvertalb\cellx9314\clvertalb\cellx9693\clvertalb\clvmgf\cellx10661\clvertalb\clvmgf\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc As of December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9177\clvertalb\cellx9314\clvertalb\cellx9693\clvertalb\clvmgf\cellx10661\clvertalb\clvmgf\cellx10798\trrh172\row}}}
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5718\clvertalb\cellx5855\clvertalb\cellx6152\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6941\clvertalb\cellx7078\clvertalb\cellx7375\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8057\clvertalb\cellx8194\clvertalb\cellx8491\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9173\clvertalb\cellx9310\clvertalb\cellx9689\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10657\clvertalb\clvmrg\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2005\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2006\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2007\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2008\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5718\clvertalb\cellx5855\clvertalb\cellx6152\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6941\clvertalb\cellx7078\clvertalb\cellx7375\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8057\clvertalb\cellx8194\clvertalb\cellx8491\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9173\clvertalb\cellx9310\clvertalb\cellx9689\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10657\clvertalb\clvmrg\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clvertalb\cellx5718\clvertalb\cellx5855\clvertalb\cellx6152\clvertalb\cellx6941\clvertalb\cellx7078\clvertalb\cellx7375\clvertalb\cellx8057\clvertalb\cellx8194\clvertalb\cellx8491\clvertalb\cellx9173\clvertalb\cellx9310\clvertalb\cellx9689\clvertalb\cellx10657\clvertalb\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clvertalb\cellx5718\clvertalb\cellx5855\clvertalb\cellx6152\clvertalb\cellx6941\clvertalb\cellx7078\clvertalb\cellx7375\clvertalb\cellx8057\clvertalb\cellx8194\clvertalb\cellx8491\clvertalb\cellx9173\clvertalb\cellx9310\clvertalb\cellx9689\clvertalb\cellx10657\clvertalb\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clvertalb\cellx10661\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx3307\clvertalb\cellx3686\clvertalb\cellx4495\clvertalb\cellx4632\clvertalb\cellx4929\clvertalb\cellx10661\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\b\ql Balance Sheet Data:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh412
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Cash, cash equivalents and short-term\plain\intbl\li176\cf10\f51\fs16\ql investments\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 17,098\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 7,699\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 20,207\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 12,546\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh412\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Working capital (deficit)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (40\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 16,537\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,959\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 16,450\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,931\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,894\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total assets\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 18,193\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,038\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 22,679\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 14,491\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,786\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total debt, including convertible notes\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 525\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 12,334\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 9,734\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,985\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock warrant liability\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 240\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 169\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,219\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Convertible preferred stock\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 21,016\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 21,016\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 41,156\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 55,871\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 55,941\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3307\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3686\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3834\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4494\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4631\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4928\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5076\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5716\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5853\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6150\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6938\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7075\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7372\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7520\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8190\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8487\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8635\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9168\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9305\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9684\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10118\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total stockholders\u8217? deficit\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (40\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (3,715\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (13,189\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (33,335\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (52,994\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (60,986\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\cellx3307\clvertalb\cellx3686\clvertalb\cellx3834\clvertalb\cellx4494\clvertalb\cellx4631\clvertalb\cellx4928\clvertalb\cellx5076\clvertalb\cellx5716\clvertalb\cellx5853\clvertalb\cellx6150\clvertalb\cellx6298\clvertalb\cellx6938\clvertalb\cellx7075\clvertalb\cellx7372\clvertalb\cellx7520\clvertalb\cellx8053\clvertalb\cellx8190\clvertalb\cellx8487\clvertalb\cellx8635\clvertalb\cellx9168\clvertalb\cellx9305\clvertalb\cellx9684\clvertalb\cellx10118\clvertalb\cellx10651\clvertalb\cellx10788\trrh206\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 47
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart toc113475_9}{\*\bkmkend toc113475_9}\par\pard\plain\cf10\f51\fs16\b\qc MANAGEMENT\u8217?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND\par\pard\plain\cf10\f51\fs16\b\qc RESULTS OF OPERATIONS\par\pard\plain\sb198\cf10\f51\fs16\i\ql The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and\plain\cf10\f51\fs16\i\ql the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks, uncertainties and\plain\cf10\f51\fs16\i\ql assumptions. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but\plain\cf10\f51\fs16\i\ql are not limited to, those identified below and those discussed in the section entitled \u8220?Risk Factors\u8221? included elsewhere in this prospectus.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Overview\par\pard\plain\sb88\cf10\f51\fs16\ql We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and\plain\cf10\f51\fs16\ql breakthrough pain. We were founded to solve the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. Although\plain\cf10\f51\fs16\ql widely used, IV PCA has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of\plain\cf10\f51\fs16\ql delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. We are preparing to initiate two\plain\cf10\f51\fs16\ql Phase\~3 clinical trials for our lead product candidate, the Sufentanil NanoTab PCA System, or ARX-01. The system is designed to address these problems\plain\cf10\f51\fs16\ql by utilizing:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql sufentanil, a high therapeutic index opioid;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql NanoTabs, our proprietary, non-invasive sublingual dosage form; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our novel handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the\plain\intbl\cf10\f51\fs16\ql risk of programming errors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\ql We have completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02,\plain\cf10\f51\fs16\ql for the treatment of cancer breakthrough pain, or BTP, and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety\plain\cf10\f51\fs16\ql reduction and pain relief for patients undergoing painful procedures in a physician\u8217?s office.\par\pard\plain\sb198\cf10\f51\fs16\ql We are a development stage company with a limited operating history. We have funded our operations to date primarily from the private placement of\plain\cf10\f51\fs16\ql convertible preferred stock and proceeds received from our debt financings. From inception through September\~30, 2010, we have received net proceeds of\plain\cf10\f51\fs16\ql $54.9 million from the sale of convertible preferred stock and $21.6 million from proceeds of our debt financings. As of September\~30, 2010, we had\plain\cf10\f51\fs16\ql $14.4 million of debt outstanding, of which $6.4 million relates to our loan and security agreement and $8.0 million, which does not include the debt\plain\cf10\f51\fs16\ql discount of $3.4 million, relates to our convertible note agreement.\par\pard\plain\sb198\cf10\f51\fs16\ql Since our inception in July 2005, we have not generated any revenue from the sale of our products and do not anticipate generating any revenues for the\plain\cf10\f51\fs16\ql foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. Our net losses were $20.1 million and\plain\cf10\f51\fs16\ql $10.8 million for the year ended December\~31, 2009 and the nine months ended September\~30, 2010. As of September\~30, 2010, we had an accumulated\plain\cf10\f51\fs16\ql deficit of $65.0 million. Substantially all of our operating losses resulted from costs incurred in connection with our development programs and from\plain\cf10\f51\fs16\ql general and administrative costs associated with our operations. As of September\~30, 2010, our principal sources of liquidity are our cash, cash equivalents\plain\cf10\f51\fs16\ql and short-term investments, which totaled $8.1 million.\par\pard\plain\sb198\cf10\f51\fs16\ql We expect to incur increasing expenses over the next several years, principally to develop ARX-01, including completion of the first two Phase 3 clinical\plain\cf10\f51\fs16\ql trials, as well as to further increase our spending to manufacture, sell and market our product candidates. Contingent on our ability to secure additional\plain\cf10\f51\fs16\ql funding, we plan to complete the third ARX-01 Phase 3 clinical trial required to submit an NDA. In\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 48
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql addition, based on the availability of additional financial resources, subsequent to this offering, we plan to advance ARX-02 into Phase 3 trials, submit an\plain\cf10\f51\fs16\ql NDA and commercialize it ourselves or with a partner in the United States. Further development of ARX-03 will depend on the identification of a\plain\cf10\f51\fs16\ql partner to support this effort.\par\pard\plain\sb198\cf10\f51\fs16\ql Furthermore, upon closing of this offering, we expect to incur additional costs associated with operating as a public company. As a result, we expect to\plain\cf10\f51\fs16\ql continue to incur significant and increasing operating losses for the foreseeable future.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Financial Overview\par\pard\plain\sb88\cf10\f51\fs16\b\i\ql Revenue\par\pard\plain\sb88\cf10\f51\fs16\ql To date, we have not generated any revenue. We do not expect to receive any revenues from any product candidates that we develop until we obtain\plain\cf10\f51\fs16\ql regulatory approval and commercialize our products or enter into collaborative agreements with third parties.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Research and Development Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql The majority of our operating expenses to date have been for research and development activities related to ARX-01, ARX-02 and ARX-03. Research\plain\cf10\f51\fs16\ql and development expenses consist of:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10272\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql expenses incurred under agreements with contract research organizations, or CROs, and clinical trial sites;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10272\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10470\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql employee and consultant-related expenses, which include salaries, benefits and stock-based compensation;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10470\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8949\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql payments to third party pharmaceutical and engineering development contractors;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8949\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6911\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql payments to third party manufacturers; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6911\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and\plain\intbl\cf10\f51\fs16\ql equipment, depreciation of leasehold improvements and equipment and laboratory and other supply costs.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Conducting research and development is central to our business model. Product candidates in late stages of clinical development generally have higher\plain\cf10\f51\fs16\ql development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of late stage clinical trials. We\plain\cf10\f51\fs16\ql plan to increase our research and development expenses for the foreseeable future as we seek to complete development of ARX-01, and subsequently\plain\cf10\f51\fs16\ql advance the development of ARX-02 and ARX-03.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 49
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql Prior to January\~1, 2009, we did not track our internal research and development costs or our personnel and personnel-related costs on a\plain\cf10\f51\fs16\ql project-by-project basis. Our development resources are shared among all of our programs. Since January\~1, 2009, we have tracked external development\plain\cf10\f51\fs16\ql expenses on a program-by-program basis. Compensation and benefits, facilities, depreciation, stock-based compensation, and development support\plain\cf10\f51\fs16\ql services are not allocated specifically to projects and are considered research and development overhead. Below is a summary of our research and\plain\cf10\f51\fs16\ql development expenses for the year ended December\~31, 2009 and the nine months ended September\~30, 2010:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\trqc\clvertalc\cellx5792\clvertalb\cellx6521\clvertalc\cellx6935\clvertalc\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clvertalc\cellx8619\clvertalc\cellx9053\clvertalc\cellx9176\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx5792\clvertalb\cellx6521\clvertalc\cellx6935\clvertalc\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clvertalc\cellx8619\clvertalc\cellx9053\clvertalc\cellx9176\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7414\clvertalb\cellx7537\clvertalb\cellx8186\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9054\clvertalb\cellx9177\trrh688
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc December\~31,
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine Months
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7414\clvertalb\cellx7537\clvertalb\cellx8186\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9054\clvertalb\cellx9177\trrh688\row}}}
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clvertalb\cellx9055\clvertalb\cellx9178\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in\~thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clvertalb\cellx9055\clvertalb\cellx9178\trrh172\row}}}
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-01\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,343\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 505\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206\row}}}
{\trowd\trqc\cellx5792\clvertalb\cellx6521\clvertalb\cellx6935\clvertalb\cellx7413\clvertalb\cellx7536\clvertalb\cellx8185\clvertalb\cellx8619\clvertalb\cellx9053\clvertalb\cellx9176\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-02\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,721\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 517\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5792\clvertalb\cellx6521\clvertalb\cellx6935\clvertalb\cellx7413\clvertalb\cellx7536\clvertalb\cellx8185\clvertalb\cellx8619\clvertalb\cellx9053\clvertalb\cellx9176\trrh206\row}}}
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql ARX-03\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1,426\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1,538\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206\row}}}
{\trowd\trqc\cellx5792\clvertalb\cellx6521\clvertalb\cellx6935\clvertalb\cellx7413\clvertalb\cellx7536\clvertalb\cellx8185\clvertalb\cellx8619\clvertalb\cellx9053\clvertalb\cellx9176\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Overhead\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,012\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 3,749\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5792\clvertalb\cellx6521\clvertalb\cellx6935\clvertalb\cellx7413\clvertalb\cellx7536\clvertalb\cellx8185\clvertalb\cellx8619\clvertalb\cellx9053\clvertalb\cellx9176\trrh206\row}}}
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6935\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8619\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9053\clvertalc\cellx9176\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6935\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8619\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9053\clvertalc\cellx9176\trrh29\row}}}
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total Research & Development Expenses\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 15,502\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,309\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\clshdng100\clcfpat13\clcbpat13\cellx5792\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6935\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7413\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7536\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8185\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8619\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9176\trrh206\row}}}
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6935\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8619\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9053\clvertalc\cellx9176\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\trqc\clvertalb\cellx5792\clvertalb\cellx6521\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6935\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7413\clvertalc\cellx7536\clvertalb\cellx8185\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8619\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9053\clvertalc\cellx9176\trrh63\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Due to the inherently unpredictable nature of product development, we are unable to estimate the costs we will incur in the continued development of\plain\cf10\f51\fs16\ql ARX-01, ARX-02 and ARX-03. Development timelines, the probability of success and development costs can differ materially from expectations. While\plain\cf10\f51\fs16\ql we are currently focused on advancing ARX-01, and subsequently ARX-02 and ARX-03, our future research and development expenses will depend on\plain\cf10\f51\fs16\ql the clinical success of each product candidate as well as ongoing assessments of the commercial potential of our product candidates. In addition, we\plain\cf10\f51\fs16\ql cannot predict which product candidates may be subject to future collaborations, when these arrangements will be secured, if at all, and to what degree\plain\cf10\f51\fs16\ql these arrangements would affect our development plans and capital requirements. We expect to incur increased research and development expenses as we\plain\cf10\f51\fs16\ql commence two of our planned ARX-01 Phase\~3 clinical trials, and subject to additional funding, our third Phase 3 clinical trial required to file our NDA.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql General and Administrative Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql General and administrative expenses consist primarily of salaries, benefits and stock-based compensation for personnel in administration, finance and\plain\cf10\f51\fs16\ql business development. Other significant expenses include legal expenses to pursue patent protection of our intellectual property, allocated facility costs and\plain\cf10\f51\fs16\ql professional fees for general legal and consulting services. We expect general and administrative expenses to increase as we begin operating as a public\plain\cf10\f51\fs16\ql company and continue to build our corporate infrastructure in support of continued development of our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Income\par\pard\plain\sb88\cf10\f51\fs16\ql Interest income consists of interest earned on our cash, cash equivalents and short-term investments.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Expense\par\pard\plain\sb88\cf10\f51\fs16\ql Interest expense consists primarily of interest accrued or paid on our loan and security agreement and our convertible notes.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Other Income (Expense), net\par\pard\plain\sb88\cf10\f51\fs16\ql Other income (expense), net consists primarily of the change in the fair value of our warrants to purchase convertible preferred stock. Our outstanding\plain\cf10\f51\fs16\ql warrants to purchase convertible preferred stock are classified as liabilities and, as such, are remeasured to fair value at each balance sheet date with the\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 50
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql corresponding gain or loss from the adjustment recorded as other income (expense), net. We will continue to record adjustments to the fair value of the\plain\cf10\f51\fs16\ql warrants until they are exercised, converted to warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at\plain\cf10\f51\fs16\ql each balance sheet date. Upon the closing of this offering, our outstanding warrants to purchase convertible preferred stock will automatically convert into\plain\cf10\f51\fs16\ql warrants to purchase common stock.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Provision for Income Taxes\par\pard\plain\sb88\cf10\f51\fs16\ql Since inception, we have incurred net losses and have not recorded any U.S. federal or state income tax provisions as these losses have been offset by\plain\cf10\f51\fs16\ql valuation allowances.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Reduction in Work Force\par\pard\plain\sb88\cf10\f51\fs16\ql On December\~7, 2009, we announced a workforce reduction of approximately 44%, or 14 employees, a majority of whom were employed in product\plain\cf10\f51\fs16\ql development and related support functions. This decision was made based on the challenging economic conditions and a decline in forecasted research and\plain\cf10\f51\fs16\ql development activities then expected for the year ended December\~31, 2010.\par\pard\plain\sb198\cf10\f51\fs16\ql As a result of this workforce reduction, we recorded a charge of $0.1 million related to employee severance and other benefits which was included as\plain\cf10\f51\fs16\ql operating expenses in the statement of operations for the year ended December\~31, 2009. As of December\~31, 2009, we had paid $30,000 for these\plain\cf10\f51\fs16\ql employee severance and other termination benefits and had accrued the remaining $89,000 on the balance sheet. During the nine months ended\plain\cf10\f51\fs16\ql September\~30, 2010, we paid the remaining amounts outstanding.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Critical Accounting Policies and Estimates\par\pard\plain\sb88\cf10\f51\fs16\ql Our financial statements are prepared in accordance with generally accepted accounting principles in the United States which requires us to make\plain\cf10\f51\fs16\ql estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We base our\plain\cf10\f51\fs16\ql estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. In many instances, we could\plain\cf10\f51\fs16\ql have reasonably used different accounting estimates, and in other instances, changes in the accounting estimates are reasonably likely to occur from\plain\cf10\f51\fs16\ql period-to-period. Accordingly, actual results could differ significantly from the estimates made by our management. To the extent that there are material\plain\cf10\f51\fs16\ql differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows\plain\cf10\f51\fs16\ql will be affected. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these\plain\cf10\f51\fs16\ql policies relate to the more significant areas involving management\u8217?s judgments and estimates.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Stock-Based Compensation\par\pard\plain\sb88\cf10\f51\fs16\ql We recognize compensation costs related to stock options and shares of restricted stock granted to employees based on the estimated fair value of the\plain\cf10\f51\fs16\ql awards on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense, using\plain\cf10\f51\fs16\ql the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the\plain\cf10\f51\fs16\ql requisite service period, which is generally the vesting period of the respective awards.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 51
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql The fair value of the stock-based awards granted to our employees was estimated on the grant dates using the Black-Scholes option-pricing model with\plain\cf10\f51\fs16\ql the following assumptions:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3328\clvertalb\cellx4015\clvertalc\cellx5101\clvertalb\cellx5756\clvertalc\cellx6490\clvertalb\cellx7145\clvertalc\cellx7879\clvertalb\cellx8475\clvertalc\cellx9209\clvertalb\cellx9884\clvertalc\cellx10795\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3328\clvertalb\cellx4015\clvertalc\cellx5101\clvertalb\cellx5756\clvertalc\cellx6490\clvertalb\cellx7145\clvertalc\cellx7879\clvertalb\cellx8475\clvertalc\cellx9209\clvertalb\cellx9884\clvertalc\cellx10795\trrh-66\row}}}
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7881\clvertalb\cellx8477\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10798\trrh419
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year\~Ended\~December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine\~Months\~Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,\cell{
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7881\clvertalb\cellx8477\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10798\trrh419\row}}}
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6490\clvertalb\cellx7145\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7879\clvertalb\cellx8475\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9209\clvertalb\cellx9884\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10795\trrh211
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\qc \~\~\~\~\~\~\~\~\~\~2007\~\~\~\~\~\~\~ \~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~\~\~2008\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~\~\~2009\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~\~\~2009\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~2010\~\~\~\~\cell{
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6490\clvertalb\cellx7145\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7879\clvertalb\cellx8475\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9209\clvertalb\cellx9884\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10795\trrh211\row}}}
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx10796\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell{
{\trowd\clvertalb\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx10796\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3328\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4015\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5101\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6490\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7879\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8475\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9209\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9884\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10795\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Expected volatility\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\qc 72%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 74%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 73%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 73%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 75%\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3328\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4015\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5101\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6490\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7879\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8475\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9209\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9884\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10795\trrh206\row}}}
{\trowd\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx9209\clvertalb\cellx9884\clvertalb\cellx10795\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Expected term (in years)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\qc 6.25\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 6.25\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 6.25\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 6.25\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 5.75\~- 6.25\cell{
{\trowd\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx9209\clvertalb\cellx9884\clvertalb\cellx10795\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3328\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4015\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5101\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6490\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7879\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8475\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9209\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9884\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10795\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Risk-free interest rate\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\qc 3.6%\~-\~4.6%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 3.5%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 3.0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 3.0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 1.6%\~-\~2.4%\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3328\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4015\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5101\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5756\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6490\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7145\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7879\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8475\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9209\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9884\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10795\trrh206\row}}}
{\trowd\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx9209\clvertalb\cellx9884\clvertalb\cellx10795\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Expected dividend yield\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\qc 0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 0%\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qc 0%\cell{
{\trowd\cellx3328\clvertalb\cellx4015\clvertalb\cellx5101\clvertalb\cellx5756\clvertalb\cellx6490\clvertalb\cellx7145\clvertalb\cellx7879\clvertalb\cellx8475\clvertalb\cellx9209\clvertalb\cellx9884\clvertalb\cellx10795\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The Black-Scholes model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including\plain\cf10\f51\fs16\ql the option\u8217?s expected term and the price volatility of the underlying stock. These assumptions include:\par\pard\plain\sb88\cf10\f51\fs16\i\ql Expected Term\plain\cf10\f51\fs16\ql .\~\~\~\~The expected term represents the period that our share-based awards are expected to be outstanding and was primarily determined using\plain\cf10\f51\fs16\ql the simplified method in accordance with guidance provided by the SEC. For option grants considered to be \u8220?plain vanilla,\u8221? the simplified\plain\cf10\f51\fs16\ql method calculates the expected term as the average of the time-to-vesting and the contractual life of the awards. For awards that are not considered\plain\cf10\f51\fs16\ql \u8220?plain vanilla,\u8221? the expected term is based on the historical option exercise behavior of our employees and post-vesting cancellations.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Expected Volatility\plain\cf10\f51\fs16\ql .\~\~\~\~The expected volatility is derived from historical volatilities of several unrelated public companies within our industry that are\plain\cf10\f51\fs16\ql deemed to be comparable to our business because we have limited information on the volatility of our common stock since we have no trading history.\plain\cf10\f51\fs16\ql When making the selections of our industry peer companies to be used in the volatility calculation, we considered the size, operational and economic\plain\cf10\f51\fs16\ql similarities to our principle business operations.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Expected Dividend\plain\cf10\f51\fs16\ql .\~\~\~\~The expected dividend was assumed to be zero as we have never paid dividends and have no current plans to do so.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Risk-Free Interest Rate\plain\cf10\f51\fs16\ql .\~\~\~\~The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury\plain\cf10\f51\fs16\ql notes with maturities approximately equal to each award\u8217?s expected term.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition to assumptions used in the Black-Scholes option-pricing model, we must also estimate a forfeiture rate to calculate the stock-based\plain\cf10\f51\fs16\ql compensation for our awards. Our forfeiture rate is based on an analysis of our actual forfeitures. We will continue to evaluate the appropriateness of the\plain\cf10\f51\fs16\ql forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. Quarterly changes in the estimated forfeiture rate can\plain\cf10\f51\fs16\ql have a significant impact on our stock-based compensation expense as the cumulative effect of adjusting the rate is recognized in the period the forfeiture\plain\cf10\f51\fs16\ql estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease\plain\cf10\f51\fs16\ql to the stock-based compensation expense recognized in the financial statements. If a revised forfeiture rate is lower than the previously estimated\plain\cf10\f51\fs16\ql forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in the financial statements.\par\pard\plain\sb198\cf10\f51\fs16\ql We will continue to use judgment in evaluating the expected term, expected volatility and forfeiture rate related to our own stock-based compensation on\plain\cf10\f51\fs16\ql a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to the estimates of our expected\plain\cf10\f51\fs16\ql volatility, expected terms and forfeiture rates, which could materially impact our future stock-based compensation expense.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 52
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql We are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations with\plain\cf10\f51\fs16\ql the Black-Scholes option-pricing model. The fair values of the common stock underlying our stock-based awards were estimated on each grant date by\plain\cf10\f51\fs16\ql our board of directors, with input from management. Our board of directors is comprised of a majority of non-employee directors with significant\plain\cf10\f51\fs16\ql experience in the pharmaceutical and biotechnology industries. We believe that our board of directors has the relevant experience and expertise to\plain\cf10\f51\fs16\ql determine a fair value of our common stock on each respective grant date. Given the absence of a public trading market of our common stock, and in\plain\cf10\f51\fs16\ql accordance with the American Institute of Certified Public Accountants Practice Guide,\plain\cf10\f51\fs16\i\ql Valuation of Privately-Held-Company Equity Securities Issued as\plain\cf10\f51\fs16\i\ql Compensation\plain\cf10\f51\fs16\ql , our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best\plain\cf10\f51\fs16\ql estimate of the fair value of our common stock including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9616\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql contemporaneous and retrospective valuations performed by unrelated third party specialists;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9616\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10390\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql prices for our convertible preferred stock sold to outside investors in arm\u8217?s-length transactions;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10390\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10214\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql rights, preferences and privileges of our convertible preferred stock relative to those of our common stock;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10214\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6822\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql actual operating and financial performance;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6822\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7968\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql hiring of key personnel and the experience of our management;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7968\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10437\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql status of research and development efforts, including the clinical results for ARX-01, ARX-02 and ARX-03;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10437\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7913\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql risks inherent in the development of our products and services;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7913\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given prevailing market\plain\intbl\cf10\f51\fs16\ql conditions and the nature and history of our business;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql market value of a comparable group of privately held pharmaceutical and biotechnology companies that are in a similar state of\plain\intbl\cf10\f51\fs16\ql development to ours;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8540\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql illiquidity of stock-based awards involving securities in a private company;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8540\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7560\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql industry information such as market size and growth; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7560\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6019\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql macroeconomic conditions.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6019\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql In valuing our common stock, the board of directors determined the equity value of our business by taking a weighted combination of the value\plain\cf10\f51\fs16\ql indications under two valuation approaches, an income approach and a market approach. The income approach estimates the present value of future\plain\cf10\f51\fs16\ql estimated cash flows, based upon forecasted revenue and costs. These future cash flows are discounted to their present values using a discount rate\plain\cf10\f51\fs16\ql derived from an analysis of the cost of capital of comparable publicly traded companies in our industry or similar lines of business as of each valuation\plain\cf10\f51\fs16\ql date and is adjusted to reflect the risks inherent in our cash flows. The market approach estimates the fair value of a company by applying market\plain\cf10\f51\fs16\ql multiples of comparable publicly traded companies in our industry or similar lines of business which are based on key metrics implied by the enterprise\plain\cf10\f51\fs16\ql values or acquisition values of our comparable publicly traded companies.\par\pard\plain\sb198\cf10\f51\fs16\ql The fair value of our business was then allocated to each of our classes of stock using either the Option Pricing Method or the Probability Weighted\plain\cf10\f51\fs16\ql Expected Return Method.\par\pard\plain\sb198\cf10\f51\fs16\ql The Option Pricing Method, or OPM, treats common stock and convertible preferred stock as call options on an enterprise value, with exercise prices\plain\cf10\f51\fs16\ql based on the liquidation preference of the convertible\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 53
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql preferred stock. Therefore, the common stock has value only if the funds available for distribution to the stockholders exceeds the value of the liquidation\plain\cf10\f51\fs16\ql preference at the time of a liquidity event such as a merger, sale or initial public offering, assuming the enterprise has funds available to make a\plain\cf10\f51\fs16\ql liquidation preference meaningful and collectible by the stockholders. The common stock is modeled to be a call option with a claim on the enterprise at\plain\cf10\f51\fs16\ql an exercise price equal to the remaining value immediately after the convertible preferred stock is liquidated. The OPM uses the Black-Scholes\plain\cf10\f51\fs16\ql option-pricing model to price the call option. The OPM is appropriate to use when the range of possible future outcomes is so difficult to predict that\plain\cf10\f51\fs16\ql forecasts would be highly speculative.\par\pard\plain\sb198\cf10\f51\fs16\ql The Probability Weighted Expected Return Method, or PWERM, involves a forward-looking analysis of the possible future outcomes of the enterprise.\plain\cf10\f51\fs16\ql This method is particularly useful when discrete future outcomes can be predicted at a high confidence level with a probability distribution. Discrete future\plain\cf10\f51\fs16\ql outcomes considered under the PWERM included non-IPO market based outcomes as well as IPO scenarios. In the non-IPO scenarios, a large portion of\plain\cf10\f51\fs16\ql the equity value is allocated to the convertible preferred stock to incorporate higher aggregate liquidation preferences. In the IPO scenarios, the equity\plain\cf10\f51\fs16\ql value is allocated pro rata among the shares of common stock and each series of convertible preferred stock, which causes the common stock to have a\plain\cf10\f51\fs16\ql higher relative value per share than under the non-IPO scenario. The fair value of the enterprise determined using the IPO and non-IPO scenarios will be\plain\cf10\f51\fs16\ql weighted according to the board of directors\u8217? estimate of the probability of each scenario.\par\pard\plain\sb198\cf10\f51\fs16\ql Over time, as certainty developed regarding possible discrete events, including an IPO, the allocation methodology utilized to allocate our enterprise value\plain\cf10\f51\fs16\ql to our common stock transitioned from the OPM, which was utilized through July 2009, to the PWERM, which has been utilized since July 2009.\par\pard\plain\sb198\cf10\f51\fs16\ql Information regarding stock option grants to our employees since January\~1, 2009 is summarized as follows:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3306\clvertalb\cellx3961\clvertalc\cellx4555\clvertalc\cellx5241\clvertalc\cellx5364\clvertalb\cellx5950\clvertalc\cellx6220\clvertalc\cellx6531\clvertalc\cellx6654\clvertalb\cellx7240\clvertalc\cellx7965\clvertalc\cellx8690\clvertalc\cellx8813\clvertalb\cellx9399\clvertalc\cellx9980\clvertalc\cellx10666\clvertalc\cellx10789\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3306\clvertalb\cellx3961\clvertalc\cellx4555\clvertalc\cellx5241\clvertalc\cellx5364\clvertalb\cellx5950\clvertalc\cellx6220\clvertalc\cellx6531\clvertalc\cellx6654\clvertalb\cellx7240\clvertalc\cellx7965\clvertalc\cellx8690\clvertalc\cellx8813\clvertalb\cellx9399\clvertalc\cellx9980\clvertalc\cellx10666\clvertalc\cellx10789\trrh-66\row}}}
{\trowd\clvertalb\cellx3306\clvertalb\cellx3961\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5242\clvertalb\cellx5365\clvertalb\cellx5951\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6533\clvertalb\cellx6656\clvertalb\cellx7242\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8693\clvertalb\cellx8816\clvertalb\cellx9402\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10670\clvertalb\cellx10793\trrh419
\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Grant Date\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Number\~of\~Options
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Granted\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Exercise
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Price\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Fair\~Value\~Per\~Share\~of
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Common Stock\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Aggregate\~Grant
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Date\~Fair\~Value\plain\intbl\cf10\f51\fs11\b\qc\super (1)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx3306\clvertalb\cellx3961\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5242\clvertalb\cellx5365\clvertalb\cellx5951\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6533\clvertalb\cellx6656\clvertalb\cellx7242\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8693\clvertalb\cellx8816\clvertalb\cellx9402\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10670\clvertalb\cellx10793\trrh419\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3306\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3961\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4555\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5364\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6220\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6531\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7965\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8690\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8813\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10666\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql July\~1, 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 231,875\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.52\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.52\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 452,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3306\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3961\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4555\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5364\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6220\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6531\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7965\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8690\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8813\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10666\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\cellx3306\clvertalb\cellx3961\clvertalb\cellx4555\clvertalb\cellx5241\clvertalb\cellx5364\clvertalb\cellx5950\clvertalb\cellx6220\clvertalb\cellx6531\clvertalb\cellx6654\clvertalb\cellx7240\clvertalb\cellx7965\clvertalb\cellx8690\clvertalb\cellx8813\clvertalb\cellx9399\clvertalb\cellx9980\clvertalb\cellx10666\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql June\~15, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 83,125\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1.20\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2.56\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 165,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx3306\clvertalb\cellx3961\clvertalb\cellx4555\clvertalb\cellx5241\clvertalb\cellx5364\clvertalb\cellx5950\clvertalb\cellx6220\clvertalb\cellx6531\clvertalb\cellx6654\clvertalb\cellx7240\clvertalb\cellx7965\clvertalb\cellx8690\clvertalb\cellx8813\clvertalb\cellx9399\clvertalb\cellx9980\clvertalb\cellx10666\clvertalb\cellx10789\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3306\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3961\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4555\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5364\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6220\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6531\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7965\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8690\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8813\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10666\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql June 15, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1,233,485\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2.56\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2.56\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,471,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3306\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx3961\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4555\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5364\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5950\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6220\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6531\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6654\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7240\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7965\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8690\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8813\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10666\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10789\trrh206\row}}}
{\trowd\cellx3306\clvertalb\cellx3961\clvertalb\cellx4555\clvertalb\cellx5241\clvertalb\cellx5364\clvertalb\cellx5950\clvertalb\cellx6220\clvertalb\cellx6531\clvertalb\cellx6654\clvertalb\cellx7240\clvertalb\cellx7965\clvertalb\cellx8690\clvertalb\cellx8813\clvertalb\cellx9399\clvertalb\cellx9980\clvertalb\cellx10666\clvertalb\cellx10789\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql November\~4, 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 125,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.32\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 5.32\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 450,000\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx3306\clvertalb\cellx3961\clvertalb\cellx4555\clvertalb\cellx5241\clvertalb\cellx5364\clvertalb\cellx5950\clvertalb\cellx6220\clvertalb\cellx6531\clvertalb\cellx6654\clvertalb\cellx7240\clvertalb\cellx7965\clvertalb\cellx8690\clvertalb\cellx8813\clvertalb\cellx9399\clvertalb\cellx9980\clvertalb\cellx10666\clvertalb\cellx10789\trrh206\row}}}\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx154\cellx8832\trrh172
\pard\plain\intbl\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf10\f51\fs13\ql Aggregate grant date fair value was determined using the Black-Scholes option pricing model.\cell{
{\trowd\cellx154\cellx8832\trrh172\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The intrinsic value of all outstanding options as September\~30, 2010 was $5.9 million based on the estimated fair value for our common stock of $5.00\plain\cf10\f51\fs16\ql per share, the expected initial public offering price.\par\pard\plain\sb198\cf10\f51\fs16\ql No single event caused the valuation of our common stock to increase or decrease through September\~30, 2010. Instead, a combination of the factors\plain\cf10\f51\fs16\ql described below in each period led to the changes in the fair value of the underlying common stock.\par\pard\plain\sb198\cf10\f51\fs16\i\ql October 2008 to July 2009\plain\cf10\f51\fs16\ql .\~\~\~\~After a period of significant volatility in the United States and global capital markets during the third and fourth quarters of\plain\cf10\f51\fs16\ql 2008, capital market conditions began to stabilize and recover in early 2009. During this time period, we reported our first successful ARX-01 Phase 2\plain\cf10\f51\fs16\ql study results in November 2008, in the midst of significant financial market turmoil. We reported positive results for an additional efficacy study for\plain\cf10\f51\fs16\ql ARX-01 in April 2009 and a device functionality study for ARX-01 in July 2009.\par\pard\plain\sb198\cf10\f51\fs16\ql As of December\~31, 2008, the board determined a fair value of our common stock to be $5.52 per share. The December\~31, 2008 contemporaneous\plain\cf10\f51\fs16\ql valuation determined the enterprise value using a market\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 54
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql approach due to the uncertain nature of the financial projections underlying the income approach and the significant ongoing capital requirements for our\plain\cf10\f51\fs16\ql business to reach profitability. In applying the OPM to the enterprise value during this period, the expected time to a liquidity event of 3.0 years was\plain\cf10\f51\fs16\ql based on a reasonable time frame for us to achieve significant milestones in our business strategy and experience a liquidity event. The volatility of 62%\plain\cf10\f51\fs16\ql was based on the median volatility over the expected time to a liquidity event for our comparable publicly traded companies. The risk-free interest rate of\plain\cf10\f51\fs16\ql 1.0% was based on the yield on a three-year U.S. Treasury bond corresponding to the expected time to a liquidity event. Based on a lack of a public\plain\cf10\f51\fs16\ql market for our common stock, a discount of 39% was based upon a protective put analysis using the same assumptions for the term, volatility and\plain\cf10\f51\fs16\ql risk-free rate. For options granted during this period, our board of directors determined that the fair value of our common stock remained unchanged at\plain\cf10\f51\fs16\ql $5.52 per share as the positive clinical data results were offset by the deterioration of the financial markets during the period.\par\pard\plain\sb198\cf10\f51\fs16\i\ql December 2009 to June 2010\plain\cf10\f51\fs16\ql .\~\~\~\~In late October 2009, we completed a successful ARX-01 End of Phase 2 meeting with the FDA. Between November\plain\cf10\f51\fs16\ql 2009 and April 2010, the United States economy and capital markets continued to improve. We also reported our first positive Phase 2 data from our\plain\cf10\f51\fs16\ql ARX-03 program in October 2009. In early 2010, we were successful in hiring a new Chief Executive Officer. During the second quarter of 2010, we\plain\cf10\f51\fs16\ql received positive Phase\~2 data on our ARX-02 program and completed an End of Phase\~2 meeting with the FDA for our ARX-03 program. Despite our\plain\cf10\f51\fs16\ql positive clinical results, the End of Phase 2 meetings with the FDA and the improved conditions of the public markets, there was a limited availability for\plain\cf10\f51\fs16\ql private capital. In November 2009, we closed our Series C convertible preferred stock financing for approximately $3.94 per share raising a total of $14.7\plain\cf10\f51\fs16\ql million in proceeds, which was below the $16.00 per share we received in connection with our Series B convertible preferred stock financing in February\plain\cf10\f51\fs16\ql 2008. During the first quarter of 2010, we continued to focus on private sources of capital, but traditional venture capital investors continued to be highly\plain\cf10\f51\fs16\ql risk averse and faced significant industry-wide challenges. During the second quarter of 2010, we became focused on establishing a financing strategy that\plain\cf10\f51\fs16\ql would enable our product candidates to advance into Phase\~3 development. Despite the challenges in the private financing, we began to have initial\plain\cf10\f51\fs16\ql discussions with a small number of banks regarding our prospects for an IPO.\par\pard\plain\sb198\cf10\f51\fs16\ql As of December\~31, 2009, the board determined a fair value of our common stock to be $1.20 per share. As noted previously, the OPM is preferred when\plain\cf10\f51\fs16\ql future outcomes are difficult to predict and the PWERM becomes useful when discrete future outcomes become more predictable. During the period\plain\cf10\f51\fs16\ql between July\~2, 2009 and December\~30, 2009, when the board of directors did not make valuation determinations or grant any stock-based awards, the\plain\cf10\f51\fs16\ql range of discrete events, specifically IPO scenarios, became fairly well established; therefore, the PWERM was utilized to estimate the fair value of our\plain\cf10\f51\fs16\ql common stock during this period. The PWERM allocation method used a risk-adjusted discount rate of 46% based upon an adjusted capital asset pricing\plain\cf10\f51\fs16\ql model and a lack of marketability discount rate of 30% in the remaining private scenario. The expected outcomes were weighted as follows: (1)\~20%\plain\cf10\f51\fs16\ql towards IPO scenarios occurring during late 2010 and through 2012, valued using the market approach; (2)\~20% towards a sale occurring during late 2010\plain\cf10\f51\fs16\ql and through 2012, valued using the market approach; (3)\~20% towards a recapitalization, valued using the income approach; and (4)\~40% to remaining a\plain\cf10\f51\fs16\ql private operating company, valued using the income approach. For options granted in June 2010, our board of directors originally estimated the fair value\plain\cf10\f51\fs16\ql of our common stock to be $1.20 per share. However, this fair value, which was used as the exercise price for the stock options granted in June 2010,\plain\cf10\f51\fs16\ql was subsequently revisited for financial reporting purposes when our board of directors began to analyze the prospects of an IPO. As such, our board of\plain\cf10\f51\fs16\ql directors subsequently determined a fair value of our common stock for financial reporting purposes to be $2.56 per share. The PWERM allocation\plain\cf10\f51\fs16\ql method was used with a risk-adjusted discount rate of 39% based upon an adjusted capital asset pricing model and a lack of marketability discount rate\plain\cf10\f51\fs16\ql of 30% in the remaining private scenario. The slight decrease in the discount rate from the December\~31, 2009 valuation was due to changes in industry\plain\cf10\f51\fs16\ql and market conditions. The expected outcomes were weighted as follows: (1)\~32.5% towards IPO scenarios\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 55
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql occurring during late 2010 and through 2012, valued using the market approach; (2)\~20% towards a sale occurring during late 2010 and through 2012,\plain\cf10\f51\fs16\ql valued using the market approach; (3)\~20% towards a recapitalization, valued using the income approach; and (4)\~27.5% to remaining a private operating\plain\cf10\f51\fs16\ql company, valued using the income approach. The increase in the fair value of our common stock from our December\~30, 2009 valuation was primarily\plain\cf10\f51\fs16\ql attributable to our business developments in 2010 along with our move towards an IPO, including meeting with banks to discuss our IPO prospects. For\plain\cf10\f51\fs16\ql the stock options we granted in June 2010, we recorded our stock-based compensation utilizing the updated fair value of $2.56 per share because our\plain\cf10\f51\fs16\ql board determined that there were no events in the period between the option grants on June\~15, 2010 and the date of the retrospective valuation on\plain\cf10\f51\fs16\ql June\~30, 2010 that would result in a change to the fair value of the underlying common stock. Most of the stock options granted in June 2010 were\plain\cf10\f51\fs16\ql subsequently modified in December 2010 as discussed further below.\par\pard\plain\sb198\cf10\f51\fs16\i\ql July 2010 to November 2010\plain\cf10\f51\fs16\ql .\~\~\~\~As of September\~30, 2010, the board determined a fair value of our common stock to be $5.32 per share. The PWERM\plain\cf10\f51\fs16\ql allocation method was used with a risk-adjusted discount rate of 33.7% based upon an adjusted capital asset pricing model and a lack of marketability\plain\cf10\f51\fs16\ql discount rate of 30% in the remaining private scenario. The slight decrease in the discount rate from the June\~30, 2010 retrospective valuation was due to\plain\cf10\f51\fs16\ql changes in industry and market conditions. The expected outcomes were weighted as follows: (1)\~57.5% towards IPO scenarios occurring during 2011 and\plain\cf10\f51\fs16\ql through 2012, valued using the market approach; (2)\~20% towards a sale occurring during 2011, valued using the market approach; (3)\~12.5% towards a\plain\cf10\f51\fs16\ql recapitalization, valued using the income approach; and (4)\~10% to remaining a private operating company, valued using the income approach. The\plain\cf10\f51\fs16\ql increase in the fair value of our common stock from our June 2010 valuation was primarily attributable to our progress towards an IPO, including\plain\cf10\f51\fs16\ql discussions with investment banks regarding our IPO.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Stock option modification in December 2010\plain\cf10\f51\fs16\ql .\~\~\~\~In December 2010, our board of directors, out of an abundance of caution, allowed all employees and\plain\cf10\f51\fs16\ql non-employees to increase the exercise price of stock options granted to them on June\~15, 2010 in light of the potential risk of adverse tax consequences\plain\cf10\f51\fs16\ql under Internal Revenue Service Code Section\~409A. Under Section\~409A, stock options with an exercise price that is less than the fair market value of the\plain\cf10\f51\fs16\ql stock on the date of grant may be deemed deferred compensation subject to adverse taxation under Section\~409A.\~As described above, when setting the\plain\cf10\f51\fs16\ql exercise price for the June\~15, 2010 stock option grants, the board determined the fair market value of our common stock to be $1.20 per share, which\plain\cf10\f51\fs16\ql valuation was subsequently revisited for financial reporting purposes, when our board of directors began to analyze the prospects of an IPO, and\plain\cf10\f51\fs16\ql determined it to be $2.56 per share. We believe that the board\u8217?s determination of the fair market value of our common stock on June\~15, 2010 in\plain\cf10\f51\fs16\ql reliance upon all material facts available to the board on that date, was reasonable.\~However, given the potential adverse tax consequences to the optionees\plain\cf10\f51\fs16\ql if the Internal Revenue Service determines that our original determination was grossly unreasonable, our board decided, out of an abundance of caution, to\plain\cf10\f51\fs16\ql make the offer to amend.\~Based on the elections made by the optionees, 1,233,485 of the 1,316,610 options granted on June\~15, 2010, including vested\plain\cf10\f51\fs16\ql and unvested options, were amended on December\~27, 2010, such that the original exercise prices of $1.20 per share were increased to $2.56 per share.\plain\cf10\f51\fs16\ql Accordingly, holders of options to purchase an aggregate 83,125 shares of common stock elected to leave their options unchanged. No other terms of the\plain\cf10\f51\fs16\ql options were modified and there were no incremental stock-based compensation charges as a result of the re-pricing.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 56
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\ql Our stock-based compensation expense for awards granted to our employees is as follows:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5298\clvertalb\cellx5824\clvertalc\cellx6042\clvertalc\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clvertalc\cellx7091\clvertalc\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clvertalc\cellx8192\clvertalc\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clvertalc\cellx9244\clvertalc\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clvertalc\cellx10399\clvertalc\cellx10669\clvertalc\cellx10792\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5298\clvertalb\cellx5824\clvertalc\cellx6042\clvertalc\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clvertalc\cellx7091\clvertalc\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clvertalc\cellx8192\clvertalc\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clvertalc\cellx9244\clvertalc\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clvertalc\cellx10399\clvertalc\cellx10669\clvertalc\cellx10792\trrh-66\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8466\clvertalb\cellx8589\clvertalb\cellx9030\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10674\clvertalb\cellx10797\trrh419
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year\~Ended\~December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine\~Months\~Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8466\clvertalb\cellx8589\clvertalb\cellx9030\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10674\clvertalb\cellx10797\trrh419\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6260\clvertalb\cellx6417\clvertalb\cellx6873\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7361\clvertalb\cellx7518\clvertalb\cellx7974\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8462\clvertalb\cellx8585\clvertalb\cellx9026\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9514\clvertalb\cellx9715\clvertalb\cellx10181\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10669\clvertalb\cellx10792\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~2007\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~2008\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~2009\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~2009\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~2010\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6260\clvertalb\cellx6417\clvertalb\cellx6873\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7361\clvertalb\cellx7518\clvertalb\cellx7974\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8462\clvertalb\cellx8585\clvertalb\cellx9026\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9514\clvertalb\cellx9715\clvertalb\cellx10181\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10669\clvertalb\cellx10792\trrh172\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clvertalb\cellx8466\clvertalb\cellx8589\clvertalb\cellx9030\clvertalb\cellx10674\clvertalb\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clvertalb\cellx8466\clvertalb\cellx8589\clvertalb\cellx9030\clvertalb\cellx10674\clvertalb\cellx10797\trrh172\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clvertalb\cellx10676\clvertalb\cellx10799\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clvertalb\cellx10676\clvertalb\cellx10799\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5824\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6042\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6260\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6417\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6873\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7091\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7974\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8192\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8462\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8585\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9026\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9244\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9715\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10181\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10669\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 25\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 66\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 167\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 74\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 539\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5824\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6042\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6260\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6417\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6873\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7091\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7974\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8192\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8462\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8585\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9026\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9244\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9715\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10181\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10669\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\cellx5298\clvertalb\cellx5824\clvertalb\cellx6042\clvertalb\cellx6260\clvertalb\cellx6417\clvertalb\cellx6873\clvertalb\cellx7091\clvertalb\cellx7361\clvertalb\cellx7518\clvertalb\cellx7974\clvertalb\cellx8192\clvertalb\cellx8462\clvertalb\cellx8585\clvertalb\cellx9026\clvertalb\cellx9244\clvertalb\cellx9514\clvertalb\cellx9715\clvertalb\cellx10181\clvertalb\cellx10399\clvertalb\cellx10669\clvertalb\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 4\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 60\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 115\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 97\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 444\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx5298\clvertalb\cellx5824\clvertalb\cellx6042\clvertalb\cellx6260\clvertalb\cellx6417\clvertalb\cellx6873\clvertalb\cellx7091\clvertalb\cellx7361\clvertalb\cellx7518\clvertalb\cellx7974\clvertalb\cellx8192\clvertalb\cellx8462\clvertalb\cellx8585\clvertalb\cellx9026\clvertalb\cellx9244\clvertalb\cellx9514\clvertalb\cellx9715\clvertalb\cellx10181\clvertalb\cellx10399\clvertalb\cellx10669\clvertalb\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6042\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7091\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8192\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9244\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10399\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10669\clvertalc\cellx10792\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6042\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7091\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8192\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9244\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10399\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10669\clvertalc\cellx10792\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5824\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6042\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6260\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6417\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6873\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7091\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7974\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8192\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8462\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8585\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9026\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9244\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9715\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10181\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10669\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total stock-based compensation\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 29\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 126\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 282\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 171\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 983\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5298\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5824\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6042\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6260\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6417\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6873\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7091\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7361\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7974\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8192\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8462\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8585\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9026\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9244\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9514\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9715\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10181\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10399\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10669\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\trrh206\row}}}
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6042\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7091\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8192\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9244\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10399\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10669\clvertalc\cellx10792\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx5298\clvertalb\cellx5824\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6042\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6260\clvertalc\cellx6417\clvertalb\cellx6873\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7091\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7361\clvertalc\cellx7518\clvertalb\cellx7974\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8192\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8462\clvertalc\cellx8585\clvertalb\cellx9026\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9244\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9514\clvertalc\cellx9715\clvertalb\cellx10181\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10399\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10669\clvertalc\cellx10792\trrh63\row}}}\pard\plain\sb198\cf10\f51\fs16\ql As of December\~31, 2009 and September\~30, 2010, we had $710,000 and $2.3 million of unrecognized stock-based compensation expense, net of\plain\cf10\f51\fs16\ql estimated forfeitures, that is expected to be recognized over a weighted average period of 2.7 and 1.6 years. In future periods, our stock-based\plain\cf10\f51\fs16\ql compensation expense is expected to increase as a result of our existing unrecognized stock-based compensation to be recognized as these awards vest\plain\cf10\f51\fs16\ql and as we issue additional stock-based awards to attract and retain employees.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Non-Employee Stock-Based Compensation\par\pard\plain\sb88\cf10\f51\fs16\ql We account for stock options and shares of restricted stock granted to non-employees based on the estimated fair value of the awards using the\plain\cf10\f51\fs16\ql Black-Scholes option-pricing model. The measurement of stock-based compensation for awards granted to non-employees is subject to periodic\plain\cf10\f51\fs16\ql adjustments as the awards vest, and the resulting change in value, if any, is recognized in our statement of operations during the period the related\plain\cf10\f51\fs16\ql services are rendered.\par\pard\plain\sb198\cf10\f51\fs16\ql Stock-based compensation expense for awards granted to non-employees was $4,000, $71,000, $30,000, $30,000 and $31,000 during the years ended\plain\cf10\f51\fs16\ql December\~31, 2007, 2008, 2009 and the nine months ended September\~30, 2009 and 2010.\par\pard\plain\sb198\cf10\f51\fs16\ql There is inherent uncertainty in these estimates and if different assumptions had been used, the fair value of the awards granted to non-employees and the\plain\cf10\f51\fs16\ql related stock-based compensation expense could have been significantly different.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Liability Associated with Warrants to Purchase Convertible Preferred Stock\par\pard\plain\sb88\cf10\f51\fs16\ql Freestanding warrants to purchase shares of our convertible preferred stock are classified as liabilities on our balance sheets at fair value because the\plain\cf10\f51\fs16\ql warrants may conditionally obligate us to redeem the underlying convertible preferred stock at some point in the future. The warrants are subject to\plain\cf10\f51\fs16\ql remeasurement at each balance sheet date, and any change in fair value is recognized as a component of other income (expense), net, in the statements of\plain\cf10\f51\fs16\ql operations. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option-pricing model. We use\plain\cf10\f51\fs16\ql assumptions to estimate the fair value of the warrants including the remaining contractual terms of the warrants, risk-free interest rates, expected dividend\plain\cf10\f51\fs16\ql yields and the expected volatility of the underlying stock. These assumptions are subjective and the fair value of the warrants to purchase convertible\plain\cf10\f51\fs16\ql preferred stock could have differed significantly had we used different assumptions.\par\pard\plain\sb198\cf10\f51\fs16\ql In connection with an equipment financing agreement entered into in March 2007, we issued warrants to purchase 2,500 shares of our Series A\plain\cf10\f51\fs16\ql convertible preferred stock. The relative fair value of our Series A warrants of $1,000 was recorded on our balance sheet upon issuance as a warrant\plain\cf10\f51\fs16\ql liability and as a deferred financing cost in other assets. The Series A warrant liability has subsequently been remeasured to fair value at each reporting\plain\cf10\f51\fs16\ql date and, as of December\~31, 2009 and September\~30, 2010, the Series A warrant liability was $2,000 and $10,000. The change in the fair value of these\plain\cf10\f51\fs16\ql warrants resulted in a\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 57
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql gain of $8,000 during the year ended December\~31, 2009 and a charge of $8,000 for the nine months ended September\~30, 2010 to other income\plain\cf10\f51\fs16\ql (expense), net.\par\pard\plain\sb198\cf10\f51\fs16\ql In connection with a loan and security agreement entered into in September 2008, we issued warrants to purchase 56,250 shares of our Series B\plain\cf10\f51\fs16\ql convertible preferred stock. At the close of our Series C convertible preferred stock offering in November 2009, these warrants became exercisable for the\plain\cf10\f51\fs16\ql Series C convertible preferred stock and the number of exercisable shares increased to 228,264. The relative fair value of these warrants of $0.2 million\plain\cf10\f51\fs16\ql upon issuance was recorded on our balance sheet as a warrant liability and as a deferred financing cost in other assets. The Series C warrant liability\plain\cf10\f51\fs16\ql related to the loan and security agreement has subsequently been remeasured to fair value at each reporting date and, as of December\~31, 2009 and\plain\cf10\f51\fs16\ql September\~30, 2010, the warrant liability was $0.2\~million and $1.0\~million. The change in the fair value of these warrants resulted in a gain of\plain\cf10\f51\fs16\ql $0.1\~million during the year ended December\~31, 2009 and a charge of $0.8\~million during the nine months ended September\~30, 2010 to other income\plain\cf10\f51\fs16\ql (expense), net.\par\pard\plain\sb198\cf10\f51\fs16\ql In connection with the issuance of a bridge loan financing in September 2010, we issued convertible notes, or the 2010 notes, and warrants, or the 2010\plain\cf10\f51\fs16\ql warrants, that are exercisable into (1) shares of preferred stock sold in the next equity financing with proceeds in excess of $15.0 million with an exercise\plain\cf10\f51\fs16\ql price equal to the price of the preferred stock sold in such equity financing or (2) shares of our Series C convertible preferred stock at a price $3.94 per\plain\cf10\f51\fs16\ql share. The aggregate number of shares exercisable under the 2010 warrants will equal 25% of the principal amount of the corresponding 2010 notes\plain\cf10\f51\fs16\ql divided by (1)\~the per share price of the equity securities sold in the next qualified equity financing or (2) the price of the Series\~C convertible preferred\plain\cf10\f51\fs16\ql stock of $3.94 per share. In order to determine a fair value for the 2010 warrants upon issuance of the bridge loan, we evaluated multiple potential\plain\cf10\f51\fs16\ql outcomes using the intrinsic value or Black-Scholes value depending on the scenario and discounted these values back to September 30, 2010 while\plain\cf10\f51\fs16\ql applying our estimated probabilities to each scenario value. These scenarios included a potential initial public offering or potential merger or sale at\plain\cf10\f51\fs16\ql different times during 2011 and 2012 as well as remaining private with estimated future qualifying equity financings. Accordingly, we determined the fair\plain\cf10\f51\fs16\ql value of the 2010 warrants to be $1.2 million, which was recorded as a convertible preferred stock warrant liability and a debt discount. There was no\plain\cf10\f51\fs16\ql change in the fair value of these between the time of issuance on September\~14, 2010 and the end of the period on September 30, 2010.\par\pard\plain\sb198\cf10\f51\fs16\ql We will continue to record adjustments to the fair value of the warrants to purchase convertible preferred stock until they are exercised, converted into\plain\cf10\f51\fs16\ql warrants to purchase common stock or expire, at which time the warrants will no longer be remeasured at each balance sheet date. At that time, the\plain\cf10\f51\fs16\ql then-current aggregate fair value of these warrants will be reclassified from liabilities to additional paid-in capital and we will no longer remeasure the\plain\cf10\f51\fs16\ql liability associated with these warrants to purchase convertible preferred stock to fair value.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Bridge Loan and Beneficial Conversion Features\par\pard\plain\sb88\cf10\f51\fs16\ql On September 14, 2010, we entered into a bridge loan financing, in which we issued 2010 notes to certain existing investors for an aggregate purchase\plain\cf10\f51\fs16\ql price of $8.0 million. The 2010 notes cannot be prepaid without written consent of the holders of the 2010 notes, accrue interest at a rate of 4.0% per\plain\cf10\f51\fs16\ql annum and have a maturity date of the earliest of (1)\~September 14, 2011 or (2)\~an event of default. The principal and the interest under the 2010 notes\plain\cf10\f51\fs16\ql are automatically convertible (1)\~into the securities that are sold in our next equity financing prior to September 14, 2011, with total proceeds of not less\plain\cf10\f51\fs16\ql than $15.0 million, or qualified financing, at the price at which such securities are sold to other investors in the qualified financing, (2)\~into securities that\plain\cf10\f51\fs16\ql are sold in our initial public offering at a conversion price\~equal to 80% of the initial public offering price or (3)\~following September\~14, 2011, with the\plain\cf10\f51\fs16\ql consent of the holders of a majority of the principal amount of the 2010 notes still outstanding, into shares of Series C convertible preferred stock at the\plain\cf10\f51\fs16\ql Series C price of $3.94 per share. In addition, holders of the 2010 notes have the option to convert the 2010 notes into shares of Series C convertible\plain\cf10\f51\fs16\ql preferred stock in connection with a\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 58
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql liquidation, sale of substantially all of our assets, or merger, if such liquidation, sale of substantially all of our assets, or merger occurs before the\plain\cf10\f51\fs16\ql qualified financing or initial public offering.\par\pard\plain\sb198\cf10\f51\fs16\ql Upon the election of the holders of a majority of the aggregate principal amount payable under the 2010 notes, we will issue an additional $4.0 million\plain\cf10\f51\fs16\ql 2010 notes. This additional $4.0 million was determined to be a call option that has been recorded at its fair value of $0.5 million as a debt discount that\plain\cf10\f51\fs16\ql will be amortized to interest expense over the one-year term of the loan. The fair value of the call option was determined by evaluating multiple potential\plain\cf10\f51\fs16\ql outcomes using a market approach and an income approach depending on the scenario and discounted these values back to September\~30, 2010 while\plain\cf10\f51\fs16\ql applying estimated probabilities to each scenario value. As of September 30, 2010, these scenarios include a potential initial public offering, merger or\plain\cf10\f51\fs16\ql sale at different times during 2011 and 2012 as well as remaining private. The call option will be remeasured to its fair value at the end of each reporting\plain\cf10\f51\fs16\ql period until expired or exercised. During the first quarter of the year ending December 31, 2011, the 2010 notes were amended so that the call option will\plain\cf10\f51\fs16\ql expire upon the closing of this offering.\par\pard\plain\sb198\cf10\f51\fs16\ql Also in connection with the bridge loan financing, we issued the 2010 warrants with a fair value of $1.2 million, which were recorded as a debt discount\plain\cf10\f51\fs16\ql that will be amortized to interest expense over the one-year term of the loan.\par\pard\plain\sb198\cf10\f51\fs16\ql We used considerable judgment in determining the fair value of these instruments and had we used different assumptions, the resulting fair values could\plain\cf10\f51\fs16\ql have been materially different.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition, we also recognized a beneficial conversion feature related to the 2010 warrants and the call option discussed above in the aggregate amount\plain\cf10\f51\fs16\ql of $1.7 million as an additional debt discount that will also be amortized to interest expense over the one-year term of the bridge loan. In addition to\plain\cf10\f51\fs16\ql these beneficial conversion features, the 2010 notes have contingent beneficial conversion features related to the conversion options following the maturity\plain\cf10\f51\fs16\ql of the 2010 notes or in connection with a liquidation, sale or merger into Series\~C convertible preferred stock. The contingent beneficial features were\plain\cf10\f51\fs16\ql determined on the date of the issuance of the 2010 notes based on the intrinsic value of this feature in the amount of $2.8 million. This beneficial\plain\cf10\f51\fs16\ql conversion feature will be recorded if and when the related contingent event occurs.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Income Taxes\par\pard\plain\sb88\cf10\f51\fs16\ql Significant management judgment is required in determining our provision or benefit for income taxes, any uncertain tax positions, deferred tax assets and\plain\cf10\f51\fs16\ql liabilities, and any valuation allowance recorded against our net deferred tax assets. We make these estimates and judgments about our future taxable\plain\cf10\f51\fs16\ql income that are based on assumptions that are consistent with our future plans. As of December\~31, 2008 and 2009, we have recorded a full valuation\plain\cf10\f51\fs16\ql allowance on our net deferred tax assets due to uncertainties related to our ability to utilize our deferred tax assets in the foreseeable future. These\plain\cf10\f51\fs16\ql deferred tax assets primarily consist of certain net operating loss carryforwards and research and development tax credits. Should the actual amounts differ\plain\cf10\f51\fs16\ql from our estimates, the amount of our valuation allowance could be materially impacted.\par\pard\plain\sb198\cf10\f51\fs16\ql Since inception, we have incurred operating losses and, accordingly, we have not recorded a provision for income taxes for any of the periods presented.\plain\cf10\f51\fs16\ql Accordingly, there have not been significant changes to our provision or benefit for income taxes during the years ended December\~31, 2007, 2008 or\plain\cf10\f51\fs16\ql 2009 and we do not expect any significant changes until we are no longer incurring losses.\par\pard\plain\sb198\cf10\f51\fs16\ql As of December\~31, 2009, we had federal net operating loss carryforwards of $52.9 million and state net operating loss carryforwards of $52.8 million.\plain\cf10\f51\fs16\ql We also had federal and state research credit carryforwards of $0.9 million and $0.6 million. Realization of deferred tax assets is dependent upon future\plain\cf10\f51\fs16\ql earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 59
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql assets have been fully offset by a valuation allowance. If not utilized, the federal net operating loss and tax credit carryforwards will expire beginning in\plain\cf10\f51\fs16\ql 2025 and the state net operating loss will begin expiring in 2017. Utilization of these net operating losses and credit carryforwards may be subject to an\plain\cf10\f51\fs16\ql annual limitation due to applicable provisions of the Internal Revenue Section\~382 and state and local tax laws if we experience an \u8220?ownership\plain\cf10\f51\fs16\ql change\u8221? in the future including, for example, as a result of the shares issued in this offering aggregated with certain other sales of our stock before\plain\cf10\f51\fs16\ql or after this offering.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Results of Operations\u8212?Comparison of the Nine Months Ended September\~30, 2009 and 2010\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx3980\clvertalb\cellx4678\clvertalc\cellx5035\clvertalc\cellx5513\clvertalc\cellx5861\clvertalb\cellx6714\clvertalc\cellx7071\clvertalc\cellx7466\clvertalc\cellx7603\clvertalb\cellx8227\clvertalc\cellx8549\clvertalc\cellx8999\clvertalc\cellx9136\clvertalb\cellx9749\clvertalc\cellx10133\clvertalc\cellx10517\clvertalc\cellx10792\cellx10793\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx3980\clvertalb\cellx4678\clvertalc\cellx5035\clvertalc\cellx5513\clvertalc\cellx5861\clvertalb\cellx6714\clvertalc\cellx7071\clvertalc\cellx7466\clvertalc\cellx7603\clvertalb\cellx8227\clvertalc\cellx8549\clvertalc\cellx8999\clvertalc\cellx9136\clvertalb\cellx9749\clvertalc\cellx10133\clvertalc\cellx10517\clvertalc\cellx10792\cellx10793\trrh-66\row}}}
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7467\clvertalb\cellx7604\clvertalb\cellx8228\clvertalb\clvmgf\cellx9000\clvertalb\clvmgf\cellx9137\clvertalb\cellx9750\clvertalb\clvmgf\cellx10518\clvertalb\clvmgf\cellx10793\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine\~Months\~Ended\~September\~30,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Increase /
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc %\~Increase\~/
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7467\clvertalb\cellx7604\clvertalb\cellx8228\clvertalb\clvmgf\cellx9000\clvertalb\clvmgf\cellx9137\clvertalb\cellx9750\clvertalb\clvmgf\cellx10518\clvertalb\clvmgf\cellx10793\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx8999\clvertalb\clvmrg\cellx9136\clvertalb\cellx9749\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10517\clvertalb\clvmrg\cellx10792\clvertalc\cellx10793\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~\~\~2009\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~\~\~2010\~\~\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx8999\clvertalb\clvmrg\cellx9136\clvertalb\cellx9749\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10517\clvertalb\clvmrg\cellx10792\clvertalc\cellx10793\trrh172\row}}}
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172\row}}}
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (dollars in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx3980\clvertalb\cellx4678\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 13,180\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 6,309\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (6,871\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (52\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}
{\trowd\cellx3980\clvertalb\cellx4678\clvertalb\cellx5035\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clvertalb\cellx7071\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clvertalb\cellx8549\clvertalb\cellx8999\clvertalb\cellx9136\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,510\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 3,033\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 523\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 21\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3980\clvertalb\cellx4678\clvertalb\cellx5035\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clvertalb\cellx7071\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clvertalb\cellx8549\clvertalb\cellx8999\clvertalb\cellx9136\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest income\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 37\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (35\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (95\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}
{\trowd\cellx3980\clvertalb\cellx4678\clvertalb\cellx5035\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clvertalb\cellx7071\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clvertalb\cellx8549\clvertalb\cellx8999\clvertalb\cellx9136\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest expense\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (965\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (656\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (309\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (32\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx3980\clvertalb\cellx4678\clvertalb\cellx5035\clvertalb\cellx5513\clvertalb\cellx5861\clvertalb\cellx6714\clvertalb\cellx7071\clvertalb\cellx7466\clvertalb\cellx7603\clvertalb\cellx8227\clvertalb\cellx8549\clvertalb\cellx8999\clvertalb\cellx9136\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 196\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (825\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,021\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (521\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx3980\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx4678\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5035\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5513\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5861\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6714\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7071\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7466\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7603\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8227\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8549\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8999\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9136\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\b\i\ql Revenue\par\pard\plain\sb88\cf10\f51\fs16\ql We did not generate any revenue during the nine months ended September\~30, 2009 or 2010.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Research and Development Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql Research and development expenses decreased by $6.9 million, or 52%, to $6.3 million during the nine months ended September\~30, 2010 from $13.2\plain\cf10\f51\fs16\ql million during the nine months ended September\~30, 2009. The $6.8 million decrease reflects a decrease of $4.6 million in development expenses related\plain\cf10\f51\fs16\ql to our ARX-01 development program and a decrease of $1.8 million in development expenses related to our ARX-02 development program.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql General and Administrative Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql General and administrative expenses increased by $0.5 million, or 21%, to $3.0 million during the nine months ended September\~30, 2010 from $2.5\plain\cf10\f51\fs16\ql million during the nine months ended September\~30, 2009. This increase was due to $0.3 million in stock option compensation expense, $0.1 million in\plain\cf10\f51\fs16\ql personnel related expense and $0.1 million in legal expense.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Income\par\pard\plain\sb88\cf10\f51\fs16\ql Interest income decreased by $35,000 to $2,000 during the nine months ended September\~30, 2010 from $37,000 during the nine months ended\plain\cf10\f51\fs16\ql September\~30, 2009. This decrease was due to a decrease in our average cash, cash equivalent and short-term investment balances during the nine months\plain\cf10\f51\fs16\ql ended September\~30, 2010.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Expense\par\pard\plain\sb88\cf10\f51\fs16\ql Interest expense decreased by $0.3 million to $0.7 million during the nine months ended September\~30, 2010 from $1.0 million during the nine months\plain\cf10\f51\fs16\ql ended September\~30, 2009. This decrease was primarily attributable to our paying down of our outstanding debt during the related periods without\plain\cf10\f51\fs16\ql incurring additional debt until the end of the nine months ended September\~30, 2010, therefore, maintaining lower average debt balance during the nine\plain\cf10\f51\fs16\ql months ended September\~30, 2010.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Other Income (Expense), net\par\pard\plain\sb88\cf10\f51\fs16\ql Other income (expense), net changed by $1.0 million to an expense of $0.8 million during the nine months ended September\~30, 2010 from income of\plain\cf10\f51\fs16\ql $0.2 million during the nine months ended\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 60
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql September\~30, 2009. The change in other income (expense), net primarily reflects the remeasurement of our convertible preferred stock warrant liabilities.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Results of Operations\u8212?Comparison of the Years Ended December\~31, 2008 and 2009\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx5079\clvertalb\cellx5582\clvertalc\cellx5845\clvertalc\cellx6323\clvertalc\cellx6586\clvertalb\cellx7134\clvertalc\cellx7397\clvertalc\cellx7875\clvertalc\cellx8012\clvertalb\cellx8426\clvertalc\cellx8748\clvertalc\cellx9198\clvertalc\cellx9335\clvertalb\cellx9749\clvertalc\cellx10133\clvertalc\cellx10517\clvertalc\cellx10792\cellx10793\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx5079\clvertalb\cellx5582\clvertalc\cellx5845\clvertalc\cellx6323\clvertalc\cellx6586\clvertalb\cellx7134\clvertalc\cellx7397\clvertalc\cellx7875\clvertalc\cellx8012\clvertalb\cellx8426\clvertalc\cellx8748\clvertalc\cellx9198\clvertalc\cellx9335\clvertalb\cellx9749\clvertalc\cellx10133\clvertalc\cellx10517\clvertalc\cellx10792\cellx10793\trrh-66\row}}}
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7876\clvertalb\cellx8013\clvertalb\cellx8427\clvertalb\clvmgf\cellx9199\clvertalb\clvmgf\cellx9336\clvertalb\cellx9750\clvertalb\clvmgf\cellx10518\clvertalb\clvmgf\cellx10793\cellx10794\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year\~Ended\~December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Increase /
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc %\~Increase\~/
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7876\clvertalb\cellx8013\clvertalb\cellx8427\clvertalb\clvmgf\cellx9199\clvertalb\clvmgf\cellx9336\clvertalb\cellx9750\clvertalb\clvmgf\cellx10518\clvertalb\clvmgf\cellx10793\cellx10794\trrh172\row}}}
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx9198\clvertalb\clvmrg\cellx9335\clvertalb\cellx9749\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10517\clvertalb\clvmrg\cellx10792\clvertalc\cellx10793\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2008\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx9198\clvertalb\clvmrg\cellx9335\clvertalb\cellx9749\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10517\clvertalb\clvmrg\cellx10792\clvertalc\cellx10793\trrh172\row}}}
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (dollars in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx5079\clvertalb\cellx5582\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 18,325\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 15,502\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (2,823\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (15\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}
{\trowd\cellx5079\clvertalb\cellx5582\clvertalb\cellx5845\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clvertalb\cellx7397\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clvertalb\cellx8748\clvertalb\cellx9198\clvertalb\cellx9335\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,365\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 3,529\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1,164\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 49\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5079\clvertalb\cellx5582\clvertalb\cellx5845\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clvertalb\cellx7397\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clvertalb\cellx8748\clvertalb\cellx9198\clvertalb\cellx9335\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest income\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 484\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 33\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (451\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (93\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}
{\trowd\cellx5079\clvertalb\cellx5582\clvertalb\cellx5845\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clvertalb\cellx7397\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clvertalb\cellx8748\clvertalb\cellx9198\clvertalb\cellx9335\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest expense\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (404\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,242\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 838\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 207\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx5079\clvertalb\cellx5582\clvertalb\cellx5845\clvertalb\cellx6323\clvertalb\cellx6586\clvertalb\cellx7134\clvertalb\cellx7397\clvertalb\cellx7875\clvertalb\cellx8012\clvertalb\cellx8426\clvertalb\cellx8748\clvertalb\cellx9198\clvertalb\cellx9335\clvertalb\cellx9749\clvertalb\cellx10133\clvertalb\cellx10517\clvertalb\cellx10792\clvertalc\cellx10793\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (52\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 121\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 173\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 333\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx5079\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5582\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5845\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6323\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7134\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7397\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7875\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8012\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8426\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8748\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9198\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9335\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9749\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10133\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10517\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10792\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10793\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\b\i\ql Revenue\par\pard\plain\sb88\cf10\f51\fs16\ql We did not generate any revenue for the years ended December\~31, 2008 or 2009.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Research and Development Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql Research and development expenses decreased by $2.8 million, or 15%, to $15.5 million during the year ended December\~31, 2009 from $18.3 million\plain\cf10\f51\fs16\ql during the year ended December\~31, 2008. This decrease was primarily attributable to a $1.9 million reduction in clinical development costs for ARX-01\plain\cf10\f51\fs16\ql as two Phase 2 studies, which were initiated in the year ended December\~31, 2008 and completed later that year and early in the year ended December\~31,\plain\cf10\f51\fs16\ql 2009. This resulted in fewer contract pharmaceutical, engineering and manufacturing costs and lab expenses during the year ended December\~31, 2009.\plain\cf10\f51\fs16\ql The remaining decrease was attributable to a reduction in activity related to contract pharmaceutical, engineering and manufacturing efforts associated with\plain\cf10\f51\fs16\ql our ARX-02 and ARX-03 development programs during the year ended December\~31, 2009.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql General and Administrative Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql General and administrative expenses increased by $1.1 million, or 49%, to $3.5 million during the year ended December\~31, 2009 from $2.4 million\plain\cf10\f51\fs16\ql during the year ended December\~31, 2008. This increase was attributable to a $0.5 million increase in personnel costs as result of increased headcount, a\plain\cf10\f51\fs16\ql $0.4 million increase in consulting and professional services related to market research for ARX-01, ARX-02 and ARX-03, and a $0.1 million increase\plain\cf10\f51\fs16\ql in travel costs related to business development and legal fees to pursue international and domestic patents of our intellectual property during the year\plain\cf10\f51\fs16\ql ended December\~31, 2009.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Income\par\pard\plain\sb88\cf10\f51\fs16\ql Interest income decreased by $0.5 million to $33,000 during the year ended December\~31, 2009 from $0.5 million during the year ended December\~31,\plain\cf10\f51\fs16\ql 2008. This decrease was directly attributable to the $9.5 million decrease in our working capital during the year ended December\~31, 2009 as we used the\plain\cf10\f51\fs16\ql proceeds received from our Series B convertible preferred stock financing and debt financing during the year ended December\~31, 2008 to fund operations\plain\cf10\f51\fs16\ql until we completed our Series C convertible preferred stock financing in November 2009.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Expense\par\pard\plain\sb88\cf10\f51\fs16\ql Interest expense increased by $0.8 million to $1.2 million during the year ended December\~31, 2009 from $0.4 million during the year ended\plain\cf10\f51\fs16\ql December\~31, 2008. This increase was primarily due to the interest and deferred financing costs we incurred as a result of the $12.0 million in proceeds\plain\cf10\f51\fs16\ql received from our debt financing in November 2008.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 61
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Other Income (Expense), net\par\pard\plain\sb88\cf10\f51\fs16\ql Other income (expense), net changed by $0.2 million to income of $0.1 million during the year ended December\~31, 2009 from an expense of $0.1\plain\cf10\f51\fs16\ql million during the year ended December\~31, 2008. The change in other income (expense), net was due to the decrease in the fair value of our warrants to\plain\cf10\f51\fs16\ql purchase convertible preferred stock combined with realized gains on the sale of investments during the year ended December\~31, 2009.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Results of Operations\u8212?Comparison of the Years Ended December\~31, 2007 and 2008\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx4759\clvertalb\cellx5343\clvertalc\cellx5630\clvertalc\cellx6025\clvertalc\cellx6288\clvertalb\cellx6836\clvertalc\cellx7123\clvertalc\cellx7601\clvertalc\cellx7738\clvertalb\cellx8241\clvertalc\cellx8563\clvertalc\cellx9041\clvertalc\cellx9178\clvertalb\cellx9681\clvertalc\cellx10065\clvertalc\cellx10515\clvertalc\cellx10790\cellx10791\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4759\clvertalb\cellx5343\clvertalc\cellx5630\clvertalc\cellx6025\clvertalc\cellx6288\clvertalb\cellx6836\clvertalc\cellx7123\clvertalc\cellx7601\clvertalc\cellx7738\clvertalb\cellx8241\clvertalc\cellx8563\clvertalc\cellx9041\clvertalc\cellx9178\clvertalb\cellx9681\clvertalc\cellx10065\clvertalc\cellx10515\clvertalc\cellx10790\cellx10791\trrh-66\row}}}
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7740\clvertalb\cellx8243\clvertalb\clvmgf\cellx9043\clvertalb\clvmgf\cellx9180\clvertalb\cellx9683\clvertalb\clvmgf\cellx10517\clvertalb\clvmgf\cellx10792\cellx10793\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year\~Ended\~December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Increase /
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc %\~Increase\~/
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc (Decrease)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7740\clvertalb\cellx8243\clvertalb\clvmgf\cellx9043\clvertalb\clvmgf\cellx9180\clvertalb\cellx9683\clvertalb\clvmgf\cellx10517\clvertalb\clvmgf\cellx10792\cellx10793\trrh172\row}}}
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7602\clvertalb\cellx7739\clvertalb\cellx8242\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx9042\clvertalb\clvmrg\cellx9179\clvertalb\cellx9682\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10516\clvertalb\clvmrg\cellx10791\clvertalc\cellx10792\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~2007\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc \~\~\~\~2008\~\~\~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7602\clvertalb\cellx7739\clvertalb\cellx8242\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx9042\clvertalb\clvmrg\cellx9179\clvertalb\cellx9682\clbrdrb\brdrs\brdrcf1\clvertalb\clvmrg\cellx10516\clvertalb\clvmrg\cellx10791\clvertalc\cellx10792\trrh172\row}}}
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (dollars in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalb\cellx4759\clvertalb\cellx5343\clvertalb\cellx10521\clvertalb\cellx10796\clvertalc\cellx10797\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,209\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 18,325\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,116\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 123\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206\row}}}
{\trowd\cellx4759\clvertalb\cellx5343\clvertalb\cellx5630\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clvertalb\cellx7123\clvertalb\cellx7601\clvertalb\cellx7738\clvertalb\cellx8241\clvertalb\cellx8563\clvertalb\cellx9041\clvertalb\cellx9178\clvertalb\cellx9681\clvertalb\cellx10065\clvertalb\cellx10515\clvertalb\cellx10790\clvertalc\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,082\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 2,365\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 283\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 14\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx4759\clvertalb\cellx5343\clvertalb\cellx5630\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clvertalb\cellx7123\clvertalb\cellx7601\clvertalb\cellx7738\clvertalb\cellx8241\clvertalb\cellx8563\clvertalb\cellx9041\clvertalb\cellx9178\clvertalb\cellx9681\clvertalb\cellx10065\clvertalb\cellx10515\clvertalb\cellx10790\clvertalc\cellx10791\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest income\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 687\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 484\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (203\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (30\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206\row}}}
{\trowd\cellx4759\clvertalb\cellx5343\clvertalb\cellx5630\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clvertalb\cellx7123\clvertalb\cellx7601\clvertalb\cellx7738\clvertalb\cellx8241\clvertalb\cellx8563\clvertalb\cellx9041\clvertalb\cellx9178\clvertalb\cellx9681\clvertalb\cellx10065\clvertalb\cellx10515\clvertalb\cellx10790\clvertalc\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Interest expense\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (25\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (404\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 379\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 1,516\cell\pard\plain\intbl\cf10\f51\fs16\ql \~%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\cellx4759\clvertalb\cellx5343\clvertalb\cellx5630\clvertalb\cellx6025\clvertalb\cellx6288\clvertalb\cellx6836\clvertalb\cellx7123\clvertalb\cellx7601\clvertalb\cellx7738\clvertalb\cellx8241\clvertalb\cellx8563\clvertalb\cellx9041\clvertalb\cellx9178\clvertalb\cellx9681\clvertalb\cellx10065\clvertalb\cellx10515\clvertalb\cellx10790\clvertalc\cellx10791\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (52\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (51\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (5,100\cell\pard\plain\intbl\cf10\f51\fs16\ql )%\~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4759\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5343\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5630\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6025\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6288\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6836\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7123\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7601\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7738\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8241\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8563\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9041\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9178\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9681\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10065\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10515\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10790\clvertalc\clshdng100\clcfpat13\clcbpat13\cellx10791\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\b\i\ql Revenue\par\pard\plain\sb88\cf10\f51\fs16\ql We did not generate any revenue for the years ended December\~31, 2007 or 2008.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Research and Development Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql Research and development expenses increased by $10.1 million, or 123%, to $18.3 million during the year ended December\~31, 2008 from $8.2 million\plain\cf10\f51\fs16\ql during the year ended December\~31, 2007. This increase in research and development costs was directly attributable to an additional $3.7 million in\plain\cf10\f51\fs16\ql clinical research costs, $3.8 million in pharmaceutical, engineering and manufacturing costs, $1.1 million in increased personnel costs to support our Phase\plain\cf10\f51\fs16\ql 2 clinical trials for ARX-01 and the commencement and completion of our Phase 1 trial for ARX-03 during the year ended December\~31, 2008. In\plain\cf10\f51\fs16\ql addition, we also incurred costs later in the year ended December\~31, 2008 associated with the ARX-02 Phase 2 trial and related development.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql General and Administrative Expenses\par\pard\plain\sb88\cf10\f51\fs16\ql General and administrative expenses increased by $0.3 million, or 14%, to $2.4 million during the year ended December\~31, 2008 from $2.1 million\plain\cf10\f51\fs16\ql during the year ended December\~31, 2007. This increase was primarily attributable to higher personnel costs including stock-based compensation costs due\plain\cf10\f51\fs16\ql to increased headcount.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Income\par\pard\plain\sb88\cf10\f51\fs16\ql Interest income decreased by $0.2 million to $0.5 million during the year ended December\~31, 2008 from $0.7 million during the year ended\plain\cf10\f51\fs16\ql December\~31, 2007. This decrease was primarily attributable to the use of the proceeds from our Series A convertible preferred financing in August 2006,\plain\cf10\f51\fs16\ql combined with lower yields on our cash equivalents and short-term investments due to adverse market conditions during the year ended December\~31,\plain\cf10\f51\fs16\ql 2008.\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Interest Expense\par\pard\plain\sb88\cf10\f51\fs16\ql Interest expense increased by $0.4 million during the year ended December\~31, 2008 from $25,000 during the year ended December\~31, 2007. The\plain\cf10\f51\fs16\ql increase was primarily due to the interest and deferred financing costs related to the proceeds received from the $12.0 million loan and security agreement\plain\cf10\f51\fs16\ql in November 2008.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 62
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Other Income (Expense), net\par\pard\plain\sb88\cf10\f51\fs16\ql Other income (expense), net changed by $0.1 million during the year ended December\~31, 2008 from an expense of $1,000 during the year ended\plain\cf10\f51\fs16\ql December\~31, 2007. The change is primarily attributable to the increase in the fair value of our convertible preferred stock warrant liability due to the\plain\cf10\f51\fs16\ql issuance of warrants in conjunction with the loan and security agreement entered into during the year ended December\~31, 2008.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Liquidity and Capital Resources\par\pard\plain\sb88\cf10\f51\fs16\ql To date, we have funded our operations primarily with proceeds from the sale of convertible preferred stock and the proceeds received from our debt\plain\cf10\f51\fs16\ql financings. To date, we have not generated any revenue from the sale of our product candidates and do not anticipate generating any revenues for the\plain\cf10\f51\fs16\ql foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of September\~30, 2010, our principal\plain\cf10\f51\fs16\ql sources of liquidity are our cash, cash equivalents and short-term investments, which totaled $8.1 million. We believe that our available cash, cash\plain\cf10\f51\fs16\ql equivalents and short-term investments, not including the proceeds we will receive in this offering, will allow us to meet our obligations through at least\plain\cf10\f51\fs16\ql March 2011. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is\plain\cf10\f51\fs16\ql forward-looking statement that involves risks and uncertainties, and actual results could vary materially.\par\pard\plain\sb198\cf10\f51\fs16\ql From inception through September\~30, 2010, we have received net proceeds of $54.9 million from the sale of convertible preferred stock and $21.6\plain\cf10\f51\fs16\ql million from our debt agreements. As of September\~30, 2010, we have $14.4 million of debt outstanding, of which $6.4 million relates to our loan and\plain\cf10\f51\fs16\ql security agreement and $8.0 million relates to our convertible notes.\par\pard\plain\sb198\cf10\f51\fs16\ql Our recurring operating losses and our need for additional sources of capital to fund our ongoing operations raise substantial doubt about our ability to\plain\cf10\f51\fs16\ql continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our\plain\cf10\f51\fs16\ql financial statements as of and for the year ended December\~31, 2009 with respect to this uncertainty. We have no current source of revenue to sustain our\plain\cf10\f51\fs16\ql present activities, and we do not expect to generate revenue for the foreseeable future. Accordingly, our ability to continue as a going concern will require\plain\cf10\f51\fs16\ql us to obtain additional financing to fund our operations and there can be no assurance that additional financing will be available to us or that such\plain\cf10\f51\fs16\ql financing, if available, will be available on terms favorable to us.\par\pard\plain\sb198\cf10\f51\fs16\ql While we believe that our current cash and cash equivalents and the net proceeds from this offering and the interest earned on the proceeds will be\plain\cf10\f51\fs16\ql sufficient to fund our current operations through the second quarter of 2012, we may raise additional funds within this period of time through\plain\cf10\f51\fs16\ql collaborations, public or private debt or equity financings. Our existing capital resources and the net proceeds received from this offering will not be\plain\cf10\f51\fs16\ql sufficient to enable us to fund our third Phase 3 trial for ARX-01 and, if we choose, to initiate clinical trials for our product candidates other than\plain\cf10\f51\fs16\ql ARX-01. We will need to raise substantial additional capital to fund our operations, continue to develop our product candidates and commercialize and\plain\cf10\f51\fs16\ql market our product candidates.\par\pard\plain\sb198\cf10\f51\fs16\ql The sale of additional equity securities could result in additional dilution to our stockholders and those securities may have rights senior to those of our\plain\cf10\f51\fs16\ql common stock. The incurrence of indebtedness would result in increased debt service obligations and could result in operating and financing covenants\plain\cf10\f51\fs16\ql that would restrict our operations. We cannot assure you that financing will be available in the amounts we need or on terms acceptable to us, if at all.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 63
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\i\ql Cash Flows\par\pard\plain\sb88\cf10\f51\fs16\ql The following summary of our cash flows for the periods indicated and has been derived from our financial statements which are included elsewhere in\plain\cf10\f51\fs16\ql this prospectus:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx4842\clvertalb\cellx5319\clvertalc\cellx5467\clvertalc\cellx5917\clvertalc\cellx6054\clvertalb\cellx6438\clvertalc\cellx6586\clvertalc\cellx7119\clvertalc\cellx7256\clvertalb\cellx7640\clvertalc\cellx7788\clvertalc\cellx8321\clvertalc\cellx8458\clvertalb\cellx8837\clvertalc\cellx8985\clvertalc\cellx9518\clvertalc\cellx9662\clvertalb\cellx10053\clvertalc\cellx10201\clvertalc\cellx10651\clvertalc\cellx10788\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx4842\clvertalb\cellx5319\clvertalc\cellx5467\clvertalc\cellx5917\clvertalc\cellx6054\clvertalb\cellx6438\clvertalc\cellx6586\clvertalc\cellx7119\clvertalc\cellx7256\clvertalb\cellx7640\clvertalc\cellx7788\clvertalc\cellx8321\clvertalc\cellx8458\clvertalb\cellx8837\clvertalc\cellx8985\clvertalc\cellx9518\clvertalc\cellx9662\clvertalb\cellx10053\clvertalc\cellx10201\clvertalc\cellx10651\clvertalc\cellx10788\trrh-66\row}}}
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8326\clvertalb\cellx8463\clvertalb\cellx8842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10660\clvertalb\cellx10797\trrh419
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Year Ended December\~31,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Nine Months Ended
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc September\~30,\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8326\clvertalb\cellx8463\clvertalb\cellx8842\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10660\clvertalb\cellx10797\trrh419\row}}}
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5918\clvertalb\cellx6055\clvertalb\cellx6439\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7121\clvertalb\cellx7258\clvertalb\cellx7642\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8324\clvertalb\cellx8461\clvertalb\cellx8840\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9522\clvertalb\cellx9666\clvertalb\cellx10057\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10656\clvertalb\cellx10793\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2007\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2008\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2009\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5918\clvertalb\cellx6055\clvertalb\cellx6439\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7121\clvertalb\cellx7258\clvertalb\cellx7642\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8324\clvertalb\cellx8461\clvertalb\cellx8840\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9522\clvertalb\cellx9666\clvertalb\cellx10057\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10656\clvertalb\cellx10793\trrh172\row}}}
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clvertalb\cellx8326\clvertalb\cellx8463\clvertalb\cellx8842\clvertalb\cellx10660\clvertalb\cellx10797\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (Unaudited)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clvertalb\cellx8326\clvertalb\cellx8463\clvertalb\cellx8842\clvertalb\cellx10660\clvertalb\cellx10797\trrh172\row}}}
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clvertalb\cellx10661\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx4842\clvertalb\cellx5319\clvertalb\cellx10661\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4842\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5319\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5467\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5917\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6438\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7119\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7256\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7640\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7788\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8321\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8837\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8985\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9662\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10201\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Net cash used in operating activities\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (8,861\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (18,903\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (19,418\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (15,241\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr (9,042\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4842\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5319\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5467\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5917\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6438\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7119\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7256\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7640\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7788\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8321\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8837\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8985\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9662\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10201\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}
{\trowd\cellx4842\clvertalb\cellx5319\clvertalb\cellx5467\clvertalb\cellx5917\clvertalb\cellx6054\clvertalb\cellx6438\clvertalb\cellx6586\clvertalb\cellx7119\clvertalb\cellx7256\clvertalb\cellx7640\clvertalb\cellx7788\clvertalb\cellx8321\clvertalb\cellx8458\clvertalb\cellx8837\clvertalb\cellx8985\clvertalb\cellx9518\clvertalb\cellx9662\clvertalb\cellx10053\clvertalb\cellx10201\clvertalb\cellx10651\clvertalb\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Net cash (used in) provided by investing activities\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (2,217\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (9,935\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 8,616\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 12,524\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 4,865\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx4842\clvertalb\cellx5319\clvertalb\cellx5467\clvertalb\cellx5917\clvertalb\cellx6054\clvertalb\cellx6438\clvertalb\cellx6586\clvertalb\cellx7119\clvertalb\cellx7256\clvertalb\cellx7640\clvertalb\cellx7788\clvertalb\cellx8321\clvertalb\cellx8458\clvertalb\cellx8837\clvertalb\cellx8985\clvertalb\cellx9518\clvertalb\cellx9662\clvertalb\cellx10053\clvertalb\cellx10201\clvertalb\cellx10651\clvertalb\cellx10788\trrh206\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4842\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5319\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5467\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5917\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6438\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7119\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7256\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7640\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7788\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8321\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8837\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8985\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9662\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10201\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Net cash (used in) provided by financing activities\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 525\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 31,899\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 11,880\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr (1,627\cell\pard\plain\intbl\cf10\f51\fs16\ql )\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 4,585\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx4842\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5319\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5467\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx5917\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6438\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6586\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7119\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7256\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7640\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7788\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8321\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8458\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8837\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8985\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9518\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9662\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10053\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10201\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10651\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10788\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\i\ql Cash Flows from Operating Activities\par\pard\plain\sb88\cf10\f51\fs16\ql Net cash used in operating activities amounted to $8.9 million, $18.9 million, $19.4 million, $15.2 million and $9.0 million for the years ended\plain\cf10\f51\fs16\ql December\~31, 2007, 2008, 2009 and the nine months ended September\~30, 2009 and 2010. The primary use of cash for our operating activities during\plain\cf10\f51\fs16\ql these periods was to fund the development of our product candidates. Our cash used for operating activities also reflected changes in our working capital\plain\cf10\f51\fs16\ql and adjustments for non-cash charges, such as depreciation and amortization of our fixed assets, stock-based compensation, interest expense related to our\plain\cf10\f51\fs16\ql debt financings, and the revaluation of our convertible preferred stock warrant liability.\par\pard\plain\sb198\cf10\f51\fs16\ql Cash used in operating activities of $9.0 million for the nine months ended September\~30, 2010 reflected a net loss of $10.8 million, partially offset by\plain\cf10\f51\fs16\ql aggregate non-cash charges of $2.5 million and a net change of $0.7 million in our net operating assets and liabilities. Non-cash charges primarily\plain\cf10\f51\fs16\ql included $0.4 million of depreciation and amortization, $0.8 million for the revaluation of the convertible preferred stock warrant liability and $1.1 million\plain\cf10\f51\fs16\ql in stock-based compensation. The net change in our operating assets and liabilities was primarily a result of accounts payable of $0.3 million.\par\pard\plain\sb198\cf10\f51\fs16\ql Cash used in operating activities of $19.4 million during the year ended December\~31, 2009 reflected a net loss of $20.1 million, partially offset by\plain\cf10\f51\fs16\ql aggregate non-cash charges of $1.1 million and a net change of $0.4 million in our net operating assets and liabilities. Non-cash charges primarily\plain\cf10\f51\fs16\ql included $0.5 million of depreciation and amortization, $0.5 million of stock-based compensation and $0.3 million of interest expense relating to our debt\plain\cf10\f51\fs16\ql offset by a $0.1 million gain on the revaluation of our convertible preferred stock warrant liability. The net change in our operating assets and liabilities\plain\cf10\f51\fs16\ql was primarily a result of a $0.4 million decrease in accounts payable and accrued liabilities during the year.\par\pard\plain\sb198\cf10\f51\fs16\ql Cash used in operating activities of $18.9 million during the year ended December\~31, 2008 reflected a net loss of $20.7 million, partially offset by\plain\cf10\f51\fs16\ql aggregate non-cash charges of $1.1 million and a net change of $0.7 million in our net operating assets and liabilities. Non-cash charges primarily\plain\cf10\f51\fs16\ql included $0.4 million of depreciation and amortization, $0.5 million of stock-based compensation, $0.1 million on the revaluation of the convertible\plain\cf10\f51\fs16\ql preferred stock warrant liability and $0.2 million of interest expense relating to our debt. The net change in our operating assets and liabilities was\plain\cf10\f51\fs16\ql primarily a result of a $0.7 million increase in our accounts payable and accrued expenses during the year.\par\pard\plain\sb198\cf10\f51\fs16\ql Cash used in operating activities of $8.9 million during the year ended December\~31, 2007 reflected a net loss of $9.6 million, partially offset by\plain\cf10\f51\fs16\ql aggregate non-cash charges of $0.3 million and a net change of $0.4 million in our net operating assets and liabilities. Non-cash charges included $0.2\plain\cf10\f51\fs16\ql million of depreciation and amortization and $0.1 million of stock-based compensation. The net change in our\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 64
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql operating assets and liabilities was primarily a result of the $0.6 million increase in the deferred rent liability during the year ended December\~31, 2007\plain\cf10\f51\fs16\ql relating to the tenant improvement allowance we received from our landlord when we entered into our lease agreement for the office and laboratory\plain\cf10\f51\fs16\ql facilities and also as a result of a $0.4 million increase in our prepaids and other assets.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Cash Flows from Investing Activities\par\pard\plain\sb88\cf10\f51\fs16\ql Our investing activities have consisted primarily of our capital expenditures and purchases and sales of our available-for-sale investments. To date, we\plain\cf10\f51\fs16\ql have not had significant capital expenditures and we do not have any significant capital expenditures currently planned.\par\pard\plain\sb198\cf10\f51\fs16\ql During the nine months ended September\~30, 2010, cash provided by investing activities was $4.9 million primarily as a result of $9.7 million in proceeds\plain\cf10\f51\fs16\ql from the sale of our investments, partially offset by $4.8 million of purchases of investments.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2009, cash provided by investing activities of $8.6 million was primarily a result of $22.6 million in proceeds\plain\cf10\f51\fs16\ql received from the sale of our investments to fund our working capital needs, partially offset by $13.9 million used for purchases of our investments.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2008, cash used in investing activities of $9.9 million was primarily a result of $0.5 million in capital expenditures\plain\cf10\f51\fs16\ql and $14.1 million in purchases of investments using the proceeds we received in our Series B convertible preferred stock financing and the proceeds from\plain\cf10\f51\fs16\ql a debt financing, partially offset by $4.7 million in proceeds received from sales of our investments.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2007, cash used in investing activities of $2.2 million was primarily a result of our capital expenditures of $1.6\plain\cf10\f51\fs16\ql million relating to the acquisition of pharmaceutical and development equipment and $8.1 million in purchases of investments, partially offset by $7.5\plain\cf10\f51\fs16\ql million in proceeds received from sales of our investments.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Cash Flows from Financing Activities\par\pard\plain\sb88\cf10\f51\fs16\ql To date, we have financed our operations primarily with proceeds from the sale of convertible preferred stock and the proceeds received from our debt\plain\cf10\f51\fs16\ql financings. As of September\~30, 2010, we had outstanding debt of $14.4 million.\par\pard\plain\sb198\cf10\f51\fs16\ql During the nine months ended September\~30, 2010, cash provided by financing activities was $4.6 million, primarily as a result of the receipt of $8.0\plain\cf10\f51\fs16\ql million in borrowings received from the convertible note agreement entered into in September 2010 with certain existing investors, partially offset by\plain\cf10\f51\fs16\ql principal repayments on our long-term debt of $3.5 million.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2009, cash provided by financing activities of $11.9 million was primarily a result of the receipt of $14.7 million\plain\cf10\f51\fs16\ql from the sale of our Series C convertible preferred stock in November 2009, partially offset by principal repayments on our long-term debt of $2.9\plain\cf10\f51\fs16\ql million.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2008, cash provided by financing activities of $31.9 million was primarily a result of the receipt of $20.1 million in\plain\cf10\f51\fs16\ql proceeds from the sale of our Series B convertible preferred stock in February 2008 combined with the receipt of $12.0 million in proceeds from our loan\plain\cf10\f51\fs16\ql and security agreement in November 2008.\par\pard\plain\sb198\cf10\f51\fs16\ql During the year ended December\~31, 2007, cash provided by financing activities of $0.5 million was primarily a result of the receipt of $0.6 million from\plain\cf10\f51\fs16\ql the issuance of long-term debt, partially offset by principal repayments on our long-term debt of $0.1 million.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 65
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\b\ql Contractual Obligations\par\pard\plain\sb88\cf10\f51\fs16\ql The following table summarizes our outstanding contractual obligations and commitments as of December\~31, 2009:\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx6054\clvertalb\cellx6521\clvertalc\cellx6689\clvertalc\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clvertalc\cellx7815\clvertalc\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clvertalc\cellx8858\clvertalc\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clvertalc\cellx10031\clvertalc\cellx10671\clvertalc\cellx10794\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\clvertalc\cellx6054\clvertalb\cellx6521\clvertalc\cellx6689\clvertalc\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clvertalc\cellx7815\clvertalc\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clvertalc\cellx8858\clvertalc\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clvertalc\cellx10031\clvertalc\cellx10671\clvertalc\cellx10794\trrh-66\row}}}
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Payment by Period\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10675\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7167\clvertalb\cellx7290\clvertalb\cellx7667\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8210\clvertalb\cellx8333\clvertalb\cellx8710\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9253\clvertalb\cellx9376\clvertalb\cellx9753\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10671\clvertalb\cellx10794\trrh344
\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Contractual Obligations:\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Total\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2010\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2011\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc 2012\~and
\par\pard\plain\intbl\fs16\pard\plain\intbl\cf10\f51\fs13\b\qc Beyond\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7167\clvertalb\cellx7290\clvertalb\cellx7667\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8210\clvertalb\cellx8333\clvertalb\cellx8710\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9253\clvertalb\cellx9376\clvertalb\cellx9753\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10671\clvertalb\cellx10794\trrh344\row}}}
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clvertalb\cellx10675\clvertalb\cellx10798\trrh172
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc (in thousands)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clvertalb\cellx10675\clvertalb\cellx10798\trrh172\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6689\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7167\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7290\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7667\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7815\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8210\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8333\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9253\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9376\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9753\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Long-term debt obligations, including current portion\plain\intbl\li176\cf10\f51\fs11\ql\super (1)(2)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 10,772\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,307\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,465\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr \u8212?\~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6689\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7167\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7290\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7667\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7815\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8210\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8333\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9253\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9376\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9753\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\cellx6054\clvertalb\cellx6521\clvertalb\cellx6689\clvertalb\cellx7167\clvertalb\cellx7290\clvertalb\cellx7667\clvertalb\cellx7815\clvertalb\cellx8210\clvertalb\cellx8333\clvertalb\cellx8710\clvertalb\cellx8858\clvertalb\cellx9253\clvertalb\cellx9376\clvertalb\cellx9753\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Operating lease agreements\plain\intbl\li176\cf10\f51\fs11\ql\super (3)\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 783\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 338\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 348\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 97\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\cellx6054\clvertalb\cellx6521\clvertalb\cellx6689\clvertalb\cellx7167\clvertalb\cellx7290\clvertalb\cellx7667\clvertalb\cellx7815\clvertalb\cellx8210\clvertalb\cellx8333\clvertalb\cellx8710\clvertalb\cellx8858\clvertalb\cellx9253\clvertalb\cellx9376\clvertalb\cellx9753\clvertalb\cellx10031\clvertalb\cellx10671\clvertalb\cellx10794\trrh206\row}}}
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6689\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7815\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10031\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10671\clvertalc\cellx10794\trrh29
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrt\brdrs\brdrcf1\clvertalb\cellx6689\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clbrdrt\brdrs\brdrcf1\clvertalb\cellx7815\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clbrdrt\brdrs\brdrcf1\clvertalb\cellx8858\clbrdrt\brdrs\brdrcf1\clvertalb\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10031\clbrdrt\brdrs\brdrcf1\clvertalb\cellx10671\clvertalc\cellx10794\trrh29\row}}}
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6689\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7167\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7290\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7667\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7815\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8210\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8333\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9253\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9376\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9753\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Total\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 11,555\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,645\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 5,813\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql $\cell\pard\plain\intbl\cf10\f51\fs16\qr 97\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\clshdng100\clcfpat13\clcbpat13\cellx6054\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6521\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx6689\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7167\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7290\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7667\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx7815\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8210\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8333\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8710\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx8858\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9253\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9376\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx9753\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10031\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10671\clvertalb\clshdng100\clcfpat13\clcbpat13\cellx10794\trrh206\row}}}
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6689\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7815\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10031\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10671\clvertalc\cellx10794\trrh63
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell\pard\plain\intbl\cf1\f51\fs1\ql \~\cell{
{\trowd\clvertalb\cellx6054\clvertalb\cellx6521\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx6689\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7167\clvertalc\cellx7290\clvertalb\cellx7667\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx7815\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8210\clvertalc\cellx8333\clvertalb\cellx8710\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx8858\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx9253\clvertalc\cellx9376\clvertalb\cellx9753\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10031\clbrdrt\brdrdb\brdrcf1\clvertalb\cellx10671\clvertalc\cellx10794\trrh63\row}}}\pard\plain\brdrb\brdrs\sa22\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx216\cellx10800\trrh516
\pard\plain\intbl\cf10\f51\fs11\ql\super (1)\cell\pard\plain\intbl\cf10\f51\fs13\ql Long-term debt includes principal and accrued interest ($1.0 million) under the $12.0 million loan and security agreement entered into in September 2008. As of September\~30,\plain\intbl\cf10\f51\fs13\ql 2010, our outstanding obligations under the loan and security agreement have decreased to $6.4 million, of which $5.0 million is the current portion, due to regular loan repayments\plain\intbl\cf10\f51\fs13\ql of $3.4 million during the nine months ended September\~30, 2010.\cell{
{\trowd\cellx216\cellx10800\trrh516\row}}}
\pard\plain
{\trowd\cellx216\cellx10800\trrh688
\pard\plain\intbl\cf10\f51\fs11\ql\super (2)\cell\pard\plain\intbl\cf10\f51\fs13\ql Long-term debt obligations as of December\~31, 2009 do not reflect our obligations under the convertible note agreement entered into in September 2010, of which $8.0 million in\plain\intbl\cf10\f51\fs13\ql proceeds were received. The principal and accrued interest under the convertible note agreement is repayable on September\~14, 2011 unless certain conversion criteria have been\plain\intbl\cf10\f51\fs13\ql achieved, including the completion of a qualified initial public offering, other qualified equity financing or liquidation event, which would result in the notes converting into certain\plain\intbl\cf10\f51\fs13\ql equity securities depending on the event that triggers the conversion.\cell{
{\trowd\cellx216\cellx10800\trrh688\row}}}
\pard\plain
{\trowd\cellx216\cellx10800\trrh344
\pard\plain\intbl\cf10\f51\fs11\ql\super (3)\cell\pard\plain\intbl\cf10\f51\fs13\ql Operating lease agreements represent our obligation to make payments under our non-cancelable lease agreement for office and laboratory facilities in Redwood City, California.\plain\intbl\cf10\f51\fs13\ql During the nine months ended September\~30, 2010, we made regular lease payments of $0.3 million under the operating lease agreements.\cell{
{\trowd\cellx216\cellx10800\trrh344\row}}}\pard\plain\sb198\cf10\f51\fs16\b\ql Off-Balance Sheet Arrangements\par\pard\plain\sb88\cf10\f51\fs16\ql Through September\~30, 2010, we had not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Segment Information\par\pard\plain\sb88\cf10\f51\fs16\ql We have one business activity, which is the development and commercialization of product candidates for the treatment of pain, and a single reporting\plain\cf10\f51\fs16\ql and operating unit structure.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Quantitative and Qualitative Disclosures about Market Risk\par\pard\plain\sb88\cf10\f51\fs16\ql We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities.\par\pard\plain\sb198\cf10\f51\fs16\i\ql Interest Rate Risk\par\pard\plain\sb88\cf10\f51\fs16\ql Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. Our cash, cash\plain\cf10\f51\fs16\ql equivalents and investment accounts as of September\~30, 2010 total $8.1 million and consist primarily of cash, money market funds and U.S. government\plain\cf10\f51\fs16\ql obligations with maturities of less than one year from the date of purchase. Our primary exposure to market risk is interest income sensitivity, which is\plain\cf10\f51\fs16\ql affected by changes in the general level of the interest rates in the United States. However, because of the short-term nature of the instruments in our\plain\cf10\f51\fs16\ql portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or our results of operation.\par\pard\plain\sb198\cf10\f51\fs16\ql We have long-term debt of $14.4 million as of September\~30, 2010 consisting of our outstanding obligations under a loan and security agreement and a\plain\cf10\f51\fs16\ql convertible note agreement. Our obligations under these debt agreements carry interest rates that are fixed and are not subject to fluctuations. However, to\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 66
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\cf10\f51\fs16\ql the extent in the future we enter into other long-term debt arrangements, we would be subject to fluctuations in interest rates which could have a material\plain\cf10\f51\fs16\ql impact on our future financial condition and results of operation.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Recent Accounting Pronouncements\par\pard\plain\sb88\cf10\f51\fs16\ql In October 2009, the Financial Accounting Standards Board, or FASB, issued an accounting standards update that provides application guidance on\plain\cf10\f51\fs16\ql whether multiple deliverables exist, how the deliverables should be separated and how the consideration should be allocated to one or more units of\plain\cf10\f51\fs16\ql accounting. This update establishes a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable\plain\cf10\f51\fs16\ql will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated\plain\cf10\f51\fs16\ql selling price if neither vendor-specific nor third-party evidence is available. We will be required to apply this guidance prospectively for revenue\plain\cf10\f51\fs16\ql arrangements entered into or materially modified after January\~1, 2011. We have not recognized any revenue since inception. Therefore, adoption of this\plain\cf10\f51\fs16\ql guidance is not expected to have a material impact on our financial statements.\par\pard\plain\sb198\cf10\f51\fs16\ql In January 2010, the FASB issued an amendment to an accounting standard which requires new disclosures for fair value measurements and provides\plain\cf10\f51\fs16\ql clarification for existing fair value disclosure requirements. The amendment will require an entity to disclose separately the amounts of significant transfers\plain\cf10\f51\fs16\ql in and out of Levels I and II fair value measurements and to describe the reasons for the transfers; and to disclose information about purchases, sales,\plain\cf10\f51\fs16\ql issuances and settlements separately in the reconciliation for fair value measurements using significant unobservable inputs, or Level III inputs. This\plain\cf10\f51\fs16\ql amendment clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and\plain\cf10\f51\fs16\ql require disclosures about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using\plain\cf10\f51\fs16\ql Level II and Level III inputs. This guidance is effective for interim and annual reporting periods beginning after December\~15, 2009, except for certain\plain\cf10\f51\fs16\ql Level 3 activity disclosure requirements that will be effective for reporting periods beginning after December\~15, 2010. Accordingly, we adopted this\plain\cf10\f51\fs16\ql amendment on January\~1, 2010, except for the additional Level 3 requirements which will be adopted in 2011.\par\pard\plain\sb198\cf10\f51\fs16\ql In April 2010, the FASB issued an accounting standards update which provides guidance on the criteria to be followed in recognizing revenue under the\plain\cf10\f51\fs16\ql milestone method. The milestone method of recognition allows a vendor who is involved with the provision of deliverables to recognize the full amount\plain\cf10\f51\fs16\ql of a milestone payment upon achievement, if, at the inception of the revenue arrangement, the milestone is determined to be substantive as defined in the\plain\cf10\f51\fs16\ql standard. The guidance is effective on a prospective basis for milestones achieved in fiscal years and interim periods within those fiscal years, beginning\plain\cf10\f51\fs16\ql on or after June\~15, 2010. We have not recognized any revenue since inception. Therefore, adoption of this guidance is not expected to have a material\plain\cf10\f51\fs16\ql impact on our financial statements.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 67
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}{\*\bkmkstart item_1_3_6}{\*\bkmkend item_1_3_6}{\*\bkmkstart toc113475_10}{\*\bkmkend toc113475_10}\par\pard\plain\cf10\f51\fs16\b\qc BUSINESS\par\pard\plain\sb198\cf10\f51\fs16\b\ql Overview\par\pard\plain\sb88\cf10\f51\fs16\ql We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and\plain\cf10\f51\fs16\ql breakthrough pain. We were founded to solve the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. Although\plain\cf10\f51\fs16\ql widely used, IV PCA has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of\plain\cf10\f51\fs16\ql delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. We are preparing to initiate two\plain\cf10\f51\fs16\ql Phase 3 clinical trials for our lead product candidate, the Sufentanil NanoTab PCA System, or ARX-01. The system is designed to address these problems\plain\cf10\f51\fs16\ql by utilizing:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql sufentanil, a high therapeutic index opioid;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6707\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql NanoTabs, our proprietary, non-invasive sublingual dosage form; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8258\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql our novel handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the\plain\intbl\cf10\f51\fs16\ql risk of programming errors.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh412\row}}}\pard\plain\sb198\cf10\f51\fs16\ql We have completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02,\plain\cf10\f51\fs16\ql for the treatment of cancer breakthrough pain, or BTP, and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety\plain\cf10\f51\fs16\ql reduction and pain relief for patients undergoing painful procedures in a physician\u8217?s office.\par\pard\plain\sb198\cf10\f51\fs16\b\ql The Market Opportunity for Our Product Candidates\par\pard\plain\sb88\cf10\f51\fs16\i\ql ARX-01\u8212?Acute Post-Operative Pain\par\pard\plain\sb88\cf10\f51\fs16\ql According to the 2010 Decision Resources Acute Pain report, the 2018 post-operative pain market is projected to be $6.5 billion for the United States,\plain\cf10\f51\fs16\ql Europe and Japan. Opioids are the most efficacious analgesics available to control acute pain and are estimated to represent 74% of the overall\plain\cf10\f51\fs16\ql post-operative pain market in the United States. Despite the broad array of pain products available, the need for adequate pain relief continues to be a\plain\cf10\f51\fs16\ql significant issue. According to a report published in 2008 by Datamonitor, 75% of patients reported inadequate pain relief after surgery.\par\pard\plain\sb198\cf10\f51\fs16\ql In the post-operative environment, the most common method for the treatment of acute pain is through IV PCA, in which patients self-dose by pushing a\plain\cf10\f51\fs16\ql button to administer morphine via a programmable intravenous pump. Despite the common use of IV PCA, there are many deficiencies associated with\plain\cf10\f51\fs16\ql this treatment that create a significant unmet medical need, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Drug-Related Side Effects\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~Morphine, the most commonly used opioid for post-operative pain control, can produce many side\plain\intbl\cf10\f51\fs16\ql effects, such as excessive somnolence, delirium, oxygen desaturation and respiratory depression. Morphine has active metabolites, the\plain\intbl\cf10\f51\fs16\ql compounds that are produced when the body breaks down, or metabolizes, morphine, which amplify these side effects.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh619\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Complications Associated with IV Delivery\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~IV PCA poses infection risk and creates opportunities for analgesic gaps due to\plain\intbl\cf10\f51\fs16\ql dislodged catheters. Peripheral venous catheters have been associated with a 7% to 9% incidence of phlebitis and a 0.2% to 0.4%\plain\intbl\cf10\f51\fs16\ql incidence of bacteremia. Catheter tubing tethering the patient to the PCA pump also hinders early post-operative mobility that can\plain\intbl\cf10\f51\fs16\ql lead to increased post-operative complications.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh825\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\i\ql Medication Delivery Errors\plain\intbl\cf10\f51\fs16\ql .\~\~\~\~The complexity associated with ordering, dispensing, preparing, programming and administering the IV\plain\intbl\cf10\f51\fs16\ql PCA pump results in many analgesia related errors. Human factors, such as programming the PCA pump, or administering the\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx10799\trrh413\row}}}\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 68
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}
\par\pard\plain
{\trowd\clvertalc\cellx1188\cellx10800\trrh2062
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql wrong dose, are among the most common and serious type of errors. According to published literature, the estimated annual error rate is\plain\intbl\cf10\f51\fs16\ql 407 errors per 10,000 people treated with IV PCA in the United States. Published analysis of a national medication error-reporting\plain\intbl\cf10\f51\fs16\ql program, or Medmarx, from 2000 to 2005 reveals that IV PCA errors represent a four-fold higher relative risk of harm compared to all\plain\intbl\cf10\f51\fs16\ql other medication errors. The most recent published analysis of the FDA Manufacturer and User Facility Device Experience, or MAUDE,\plain\intbl\cf10\f51\fs16\ql database reports that 5% of IV PCA operator errors reported during a two-year index period, from 2002 to 2003, resulted in patient\plain\intbl\cf10\f51\fs16\ql deaths. Recently, the risks associated with the use of infusion pumps, such as those used in IV PCA, have been the subject of scrutiny\plain\intbl\cf10\f51\fs16\ql by the FDA, resulting in a new initiative to address the safety problems associated with infusion pumps and the underreporting of errors.\plain\intbl\cf10\f51\fs16\ql Approximately 56,000 adverse events were reported to the FDA between 2005 and 2009, prompting 70 Class II infusion pump recalls of\plain\intbl\cf10\f51\fs16\ql devices that could cause temporary or reversible adverse effects and 14 Class I infusion pump recalls of devices that could cause serious\plain\intbl\cf10\f51\fs16\ql injury or death.\cell{
{\trowd\clvertalc\cellx1188\cellx10800\trrh2062\row}}}\pard\plain\sb198\cf10\f51\fs16\ql ARX-01 is designed to avoid many of the limitations of IV PCA by delivering sufentanil, a high therapeutic index opioid, using our proprietary NanoTab\plain\cf10\f51\fs16\ql sublingual tablet via non-invasive, pre-programmed, handheld PCA device. We have completed three Phase 2 studies with ARX-01 and had an End of\plain\cf10\f51\fs16\ql Phase 2 meeting with the FDA which defined the required scope and scale for Phase 3 studies, certain formulation requirements, non-clinical and\plain\cf10\f51\fs16\ql regulatory requirements. We believe ARX-01 has the opportunity to become the new standard of care for post-operative patient-controlled analgesia.\par\pard\plain\sb198\cf10\f51\fs16\i\ql ARX-02\u8212?Cancer Breakthrough Pain\par\pard\plain\sb88\cf10\f51\fs16\ql Breakthrough pain is a common component of chronic pain and is characterized by its rapid onset, intensity and relatively short duration, which breaks\plain\cf10\f51\fs16\ql through the analgesic effect of chronic pain medication. According to data published in 2006, more than 700,000 cancer patients in the United States\plain\cf10\f51\fs16\ql experienced breakthrough pain. Fentanyl-based products are the only medications indicated to treat cancer breakthrough pain and account for less than\plain\cf10\f51\fs16\ql 20,000 prescriptions per month. We believe this demonstrates a need for additional and improved cancer breakthrough pain medications. Data from the\plain\cf10\f51\fs16\ql 2010 Decision Resources Acute Pain report indicates that the worldwide breakthrough pain market will grow to $2.9\~billion by 2018.\par\pard\plain\sb198\cf10\f51\fs16\ql Currently available fentanyl-based cancer breakthrough pain products have limited ability to provide effective and focused pain relief because their\plain\cf10\f51\fs16\ql average half-lives extend to 6 to 14 hours, which is significantly longer than the average 15 to 60 minute duration of a cancer breakthrough pain episode.\plain\cf10\f51\fs16\ql Oral transmucosal fentanyl, unlike sufentanil, is extensively absorbed through the gastrointestinal, or GI, tract in addition to the oral mucosal tissue,\plain\cf10\f51\fs16\ql leading to erratic and delayed timing to peak plasma levels, ranging from 20 to 240 minutes. This can result in a dangerous phenomenon, known as\plain\cf10\f51\fs16\ql dose-stacking, which occurs when a repeat dose is administered before the peak effect of the previous dose, and can lead to significant side effects, such\plain\cf10\f51\fs16\ql as respiratory depression.\par\pard\plain\sb198\cf10\f51\fs16\ql In addition to the medical limitations of currently approved opioids, the abuse of opioid pain medications is a significant medical and social problem.\plain\cf10\f51\fs16\ql According to the 2010 National Survey on Drug Use and Health, during 2009 approximately 5.2\~million people in the United States used prescription pain\plain\cf10\f51\fs16\ql relievers for nonmedical purposes, an increase from the estimated 4.7\~million in 2005. We believe none of the currently approved cancer breakthrough\plain\cf10\f51\fs16\ql pain products have effective abuse-deterrent features to address these problems.\par\pard\plain\sb198\cf10\f51\fs16\ql ARX-02 is designed to avoid many of the limitations of currently available cancer breakthrough pain medications by combining the rapid onset and\plain\cf10\f51\fs16\ql appropriate offset of sufentanil with abuse-deterrent packaging. We have completed a Phase 2 study with ARX-02 and had an End of Phase 2 meeting\plain\cf10\f51\fs16\ql with the FDA that defined the required criteria for Phase 3 studies.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 69
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\i\ql ARX-03\u8212?Mild Sedation and Pain Relief for Procedures in a Physician\u8217?s Office\par\pard\plain\sb88\cf10\f51\fs16\ql Each year in the United States, more than 100\~million procedures take place in a physician\u8217?s office. A substantial subset of these procedures are\plain\cf10\f51\fs16\ql painful and anxiety inducing, including many interventional radiology procedures, diagnostic procedures such as breast and prostate biopsies, cosmetic\plain\cf10\f51\fs16\ql procedures such as liposuction and dermal abrasions, and therapeutic procedures such as vasectomies. Ninety-six percent of men report moderate pain\plain\cf10\f51\fs16\ql immediately after prostate biopsy, with only 4% of patients reporting no pain during the biopsy. In addition, women undergoing breast biopsies have\plain\cf10\f51\fs16\ql pre-procedural scores averaging 60 to 70 out of 100 for visual analog scale measurements of nervousness, tension and fearfulness.\par\pard\plain\sb198\cf10\f51\fs16\ql Intravenous sedation requires specialized monitoring, resuscitative equipment and appropriately trained staff for effective management of patients. As a\plain\cf10\f51\fs16\ql result, many practitioners have stopped providing any sedation or analgesic medications to their patients prior to or during short duration procedures, and\plain\cf10\f51\fs16\ql instead rely solely on local anesthetic injections, which are often insufficient in providing effective pain relief and anxiety reduction.\par\pard\plain\sb198\cf10\f51\fs16\ql We are developing ARX-03 as a non-invasive method to produce sedation, anxiety reduction and pain relief in patients undergoing painful procedures in\plain\cf10\f51\fs16\ql a physician\u8217?s office. ARX-03 is designed to eliminate the need for specialized personnel and requires only minimal monitoring equipment. We\plain\cf10\f51\fs16\ql have completed a Phase 2 study with ARX-03, and have preliminary guidance as to a clinical development path for this product as a result of completion\plain\cf10\f51\fs16\ql of an End of Phase 2 meeting with the FDA.\par\pard\plain\sb198\cf10\f51\fs16\b\ql Sufentanil NanoTabs\par\pard\plain\sb88\cf10\f51\fs16\ql Sufentanil, a high therapeutic index opioid, which has no active metabolites, is 5 to 10 times more potent than fentanyl and is used intravenously as a\plain\cf10\f51\fs16\ql primary anesthetic to produce balanced general anesthesia for surgery, and for epidural administration during labor and delivery. Sufentanil has many\plain\cf10\f51\fs16\ql pharmacological advantages over other opioids. Published studies demonstrate that sufentanil produces significantly less respiratory depressive effects\plain\cf10\f51\fs16\ql relative to its analgesic effects compared to other opioids, including morphine, alfentanil and fentanyl. These third party clinical results correlate well with\plain\cf10\f51\fs16\ql preclinical studies demonstrating sufentanil\u8217?s high therapeutic index, or the ratio of the toxic dose to the therapeutic dose of a drug, used as a\plain\cf10\f51\fs16\ql measure of the relative safety of the drug for a particular treatment. Accordingly, we believe that despite its potency, sufentanil can be developed to\plain\cf10\f51\fs16\ql provide an effective and relatively safe solution for the treatment of acute and breakthrough pain. The following table illustrates the difference between the\plain\cf10\f51\fs16\ql therapeutic index of different opioids.\par\pard\plain\cf1\f51\fs18\ql \~
\par\pard\plain
{\trowd\trqc\clvertalc\cellx5028\clvertalb\cellx6100\clvertalc\cellx6659\clvertalc\cellx7218\clvertalc\cellx7341\trrh-66
\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell\pard\plain\intbl\f0\fs16\ql \~\cell{
{\trowd\trqc\clvertalc\cellx5028\clvertalb\cellx6100\clvertalc\cellx6659\clvertalc\cellx7218\clvertalc\cellx7341\trrh-66\row}}}
{\trowd\trqc\clvertalb\cellx5028\clvertalb\cellx6100\clbrdrb\brdrs\brdrcf10\clvertalb\cellx7219\clvertalb\cellx7342\trrh211
\pard\plain\intbl\brdrb\brdrs\cf10\f51\fs13\b\ql Opioid\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs13\b\qc Therapeutic\~Index\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell{
{\trowd\trqc\clvertalb\cellx5028\clvertalb\cellx6100\clbrdrb\brdrs\brdrcf10\clvertalb\cellx7219\clvertalb\cellx7342\trrh211\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Meperidine\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 5\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Methadone\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 12\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Morphine\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 71\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Hydromorphone\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 232\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Fentanyl\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 277\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206
\pard\plain\intbl\li176\fi-176\cf10\f51\fs16\ql Sufentanil\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\~\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\qr 26,716\cell\pard\plain\intbl\cf10\f51\fs16\ql \~\~\cell{
{\trowd\trqc\cellx5028\clvertalb\cellx6100\clvertalb\cellx6659\clvertalb\cellx7218\clvertalb\cellx7341\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql Although the analgesic efficacy of sufentanil has been well established, its use has been limited due to its short duration of action when delivered\plain\cf10\f51\fs16\ql intravenously. The pharmaceutical attributes of sufentanil, including lipid solubility and ionization, result in rapid cell membrane penetration and onset of\plain\cf10\f51\fs16\ql action, which we believe make sufentanil an optimal opioid for the treatment of both acute pain and breakthrough pain. In addition, its pharmacokinetic,\plain\cf10\f51\fs16\ql or PK, profile when delivered sublingually avoids the high peak plasma levels and short duration of action of IV administration.\par\pard\plain\cf1\f51\fs13\ql \~\par\pard\plain\cf10\f51\fs16\qc 70
\page\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "toc" }{\*\fldrslt\cf3\f52\fs16\b\ql Table of Contents}}\par\pard\plain\sb198\cf10\f51\fs16\i\ql Sublingual Delivery of Sufentanil: Summary of Phase 1 Clinical Studies Results\par\pard\plain\sb88\cf10\f51\fs16\ql We have completed four Phase 1 PK studies with our proprietary sublingual sufentanil NanoTabs to support our three products under development. These\plain\cf10\f51\fs16\ql studies demonstrated desirable and consistent PK parameters, including:\par\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9064\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql relatively high bioavailability via the oral mucosa and very low GI bioavailability;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9064\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6885\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql prolonged plasma levels relative to IV delivery;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx6885\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9242\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql PK parameters proportional to dose across a wide range of doses (2.5 mcg to 80 mcg);\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9242\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7863\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql lower peak plasma concentration, or C\plain\intbl\cf10\f51\fs11\ql\sub max\plain\intbl\cf10\f51\fs16\ql , than IV delivery;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7863\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9011\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql time to maximum plasma concentrations, or T\plain\intbl\cf10\f51\fs11\ql\sub max\plain\intbl\cf10\f51\fs16\ql , range from 30 to 90 minutes;\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx9011\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7975\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql relatively low patient to patient variability in T\plain\intbl\cf10\f51\fs11\ql\sub max\plain\intbl\cf10\f51\fs16\ql and C\plain\intbl\cf10\f51\fs11\ql\sub max\plain\intbl\cf10\f51\fs16\ql ; and\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx7975\trrh206\row}}}\pard\plain\cf1\f51\fs9\ql \~
\par\pard\plain
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8307\trrh206
\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql \u8226?\cell\pard\plain\intbl\cf1\f51\fs13\ql \~\cell\pard\plain\intbl\cf10\f51\fs16\ql repeat dosing PK that supports a 20 minute minimum re-dosing interval.\cell{
{\trowd\clvertalc\cellx756\cellx1312\cellx1420\cellx8307\trrh206\row}}}\pard\plain\sb198\cf10\f51\fs16\ql The chart below illustrates the PK profile of sublingual sufentanil NanoTab compared to IV delivery of sufentanil from one of our completed Phase 1 PK\plain\cf10\f51\fs16\ql studies.\par\qc\sb198{\*\shppict{\pict\jpegblip\picw554\pich336\picscalex75\picscaley75\bliptag-7110467716
{\*\blipuid 9028345a90a4d62d49cd33752ced7e5f}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